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Zusammenfassung
Der von Willebrand Faktor (VWF) ist ein multifunktionelles, multimeres Protein, das in der
Blutgerinnung als Mechanosensor eine bedeutende Rolle spielt. Er vernetzt sich bei Verletzun-
gen mit Thrombozyten und Kollagen, wodurch sich ein filamentöses Netzwerk ausbildet, das
das verletzte Endothelgewebe bedeckt. Seit kurzem ist bekannt, dass viele Eigenschaften des
VWF scherratenabhängig sind, insbesondere auch seine Spaltung durch die Metalloprotease
ADAMTS13. Einzelmolekülkraftmessungen konnten zeigen, dass einige VWF Domänen
Strukturen besitzen, die unter Scherspannung entfalten, wodurch neben Bindestellen auch die
Spaltstelle freigelegt wird. Da zudem vermutet wird, dass die Multimergröße für die scher-
abhängige Funktionalität wichtig ist, ist vor allem die Spaltung des VWF maßgeblich für das
Verständnis seiner mechanosensitiven Wirkung. Bislang gab es aber weder eine quantitative
Beschreibung der Größenverteilung noch einen direkten Nachweis der Kraftabhängigkeit der
ADAMTS13 Aktivität in Scherfluss. Um diese Lücke zu schließen, verwendeten wir in dieser
Arbeit Fluoreszenzkorrelationsspektroskopie (FCS), wobei die Messungen der einzelnen Pro-
jekte durch weitere Techniken und Simulationen komplementiert wurden.
Im ersten Projekt gelang es uns die VWF Größenverteilung zu quantifizieren. In Zusammen-
arbeit mit der Gruppe von Prof. Schneppenheim, die uns rekombinante VWF-eGFP Kon-
strukte zur Verfügung stellte, konnten wir mit Hilfe von FCS nachweisen, dass die Größen des
plasmatischen VWF exponentiell verteilt sind. Diese exponentielle Verteilung wurde mittels
quantitativer Gelanalysen (Prof. Budde) und Interner Totalreflexionsfluoreszenzmikroskopie
(Dr. Benoit) bestätigt. Sie ist in guter Übereinstimmung mit dem Polymerisierungsmodell
eines schrittweisen Wachstums nach Flory, weshalb wir die Größenverteilung explizit anhand
eines einzigen Parameters, dem Polymerisierungsgrad, beschreiben konnten. Tatsächlich er-
gab die Untersuchung einer VWF Mutante, dass der Polymerisierungsgrad ein Indikator für
krankhafte Veränderungen der Größenverteilung ist, wodurch er als solcher klinische Anwen-
dung finden könnte.
Mit Hilfe der nun bekannten Größenverteilung konnte daraufhin die Spaltung des VWF durch
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ADAMTS13 quantifiziert werden. Die Kombination von FCS mit einer eigens entwickelten
Scherzelle erlaubte es erstmals die Kinetik der VWF Spaltung als Funktion der Scherrate zu
bestimmen, was ein spannendes Beispiel für eine mechanosensitive, biochemische Reaktion
darstellt. Dabei entdeckten wir einen schaltähnlichen, sigmoidalen Anstieg der Enzymaktivität
bei hohen Scherraten. In Zusammenarbeit mit der Gruppe von Prof. Netz konnten wir dieses
Verhalten durch Brownsche Hydrodynamiksimulationen konsistent als scherratenabhängige
Polymerentfaltung erklären, die auf einer kritischen Kraft für das Entfalten der Spaltdomäne
als einzige Annahme aufbaute. Damit ergibt sich nun erstmals ein konsistentes Bild für das
Zusammenspiel von Scherfluss, Entfaltung der VWF Multimere, Öffnung der Spaltdomänen
und ADAMTS13 Aktivität, das notwendig ist um Vorhersagen über den Effekt von VWF
Mutationen auf Gerinnungsstörungen treffen zu können.
Als Teil der Studie zur scherinduzierten ADAMTS13 Aktivität wurde eine VWF Mutante
(G1629E) vermessen, die eine stark erhöhte Sensitivität für den ADAMTS13 Verdau aufwies.
Dies weckte unsere Aufmerksamkeit, da die gängigen ADAMTS13-Aktivitätstests eine man-
gelnde Genauigkeit und Reproduzierbarkeit bei der Diagnose lebensbedrohlicher thromboti-
scher Erkrankungen aufweisen. Wir entwickelten einen Diagnosetest, der ein rekombinantes
Fusionsprotein der hochsensitiven Mutante als Enzymsubstrat einsetzt. Mit dem Konstrukt
rVWF-G1629E-eGFP und unter Verwendung von FCS konnten wir die Sensitivität gegenüber
der bisher eingesetzten Tests um einen Faktor fünf erhöhen, was eine erhebliche Verbesserung
zur Entwicklung adequater Therapien bedeutet. In Zusammenarbeit mit der Gruppe von Prof.
Gräter, konnte die erhöhte Sensitivität der Mutante im Rahmen von Molekulardynamiksimu-
lationen mit einer destablisierten Spaltdomäne begründet werden.
FCS wurde weiterhin genutzt um molekulare Wechselwirkungen des VWF zu untersuchen.
So betrachteten wir neben der Multimerisierung auch die VWF Dimerisierung, die durch die
Bildung von Disulfidbrücken im Endoplasmatischen Retikulum (ER) stattfindet. Mittels FCS
und Thermophorese (MST) konnten wir zeigen, dass die Protein Disulfid Isomerase (PDI)
spezifisch an die für die Dimerisierung verantwortliche VWF-CK Domäne bindet (KD =
258 ± 104 nM). Ergänzend zu unseren Bindungsmessungen konnten Kolokalisierungsstu-
dien ausgewählter VWF Mutanten (Dr. Brehm) die Rolle von PDI zusätzlich auf die VWF
Dimerisierung einschränken und zeigen, dass PDI lediglich eine Nebenrolle bei der Korrektur
fehlgefalteter Mutanten im ER spielt.
Zusätzlich betrachteten wir die Bindung des Gerinnungsfaktors VIII (FVIII) an Phosphatidyl-
serin (PS)-haltige Thrombozyten, die zu einem späteren Zeitpunkt der Gerinnungskaskade
auftritt. Mit Hilfe von FCS und MST konnten wir die Bindung von FVIII an PS-haltige
Modellmembranen quantitativ beschreiben. Während für nicht-aktivierten FVIII das erwartete
Bindungsverhalten zu sehen war, zeigte aktivierter FVIII (FVIIIa) eine starke Bindungsanoma-
lie mit deutlichem Affinitätsmaximum bei dem physiologischem PS-Gehalt von Thrombozyten.
Zudem wurde die FVIIIa Bindung durch Annexin A5 beeinflusst, welches den scheinbaren
PS-Gehalt durch kompetetives Binden einstellt. Diese Studie demonstriert die regulatorische
Funktion des PS-Gehalts in der Blutgerinnung.
Summary
The multimeric von Willebrand Factor (VWF) plays a pivotal role as a mechanosensitive pro-
tein in hemostasis. In succession of injury, VWF promotes adhesion of platelets to collagen
as well as platelet aggregation, thereby forming a filamentous network, which covers the da-
maged epithelial tissue. Recently, it was discovered that most of VWF’s functions are shear-
dependent, in particular its cleavage by the protease ADAMTS13. Single-molecule force
experiments revealed that the multimer possesses structural elements that unfold under flow-
induced tension, exposing several binding and the cleavage site. Because the multimer size
seems to be an important parameter for VWF’s shear-dependent functionality, cleavage of
VWF is a significant factor in hemostasis. However, there was hitherto neither a quantita-
tive description of the size distribution of VWF nor a fundamental understanding of the effect
of shear on ADAMTS13’s activity. To close this gap, Fluorescence Correlation Spectroscopy
(FCS) was used in this work, complemented with alternative experimental approaches or simu-
lations, depending on the specific research question.
In a first study, we initially quantified the VWF size distribution. In cooperation with the
group of Prof. Schneppenheim, who provided recombinant VWF-eGFP constructs, we found
plasmatic VWF to exhibit an exponential size distribution using FCS. This finding was corro-
borated by quantitative gel analysis (Prof. Budde) and by single-molecule photo bleaching ex-
periments using total internal reflection fluorescence microscopy (Dr. Benoit). We attributed
the exponentially distributed sizes to a step-growth polymerization process during biosynthe-
sis according to Flory. This biophysical characterization allows for an explicit description
of the size distribution with a single parameter, namely the extent of polymerization, which
might be used as disease marker for clinical applications.
With the identified size distribution it was then possible to quantify ADAMTS13-mediated
cleavage of VWF in blood plasma. Combining the FCS setup with a custom-built shear cell,
we measured the effect of shear flow on VWF cleavage kinetics for the first time, which
provides a fascinating example for a mechanosensitive biochemical reaction. We found a
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Hill-type behavior with a sigmoidal increase in activity with increasing shear. In cooperation
with the group of Prof. Netz, brownian hydrodynamics simulations of polymers in shear
flow were performed, which revealed that this behavior results from shear-dependent polymer
unfolding. These results enable to draw a consistent picture of the interrelation of shear-flow,
VWF unfolding, opening of the mechanosensitive cleavage domain, and ADAMTS13 activity,
which is essential to enable predictions of hemostatic dysfunction of mutant VWF.
During these studies on shear-induced ADAMTS13 activity, we found that one VWF mu-
tant (G1629E) is extremely susceptible to proteolysis. This attracted our interest, because
reliable quantification of ADAMTS13 activity levels is important in clinical diagnostics but
remains challenging with commonly used assays. Using a recombinant fusion construct of
VWF-G1629E as enzyme substrate, we developed a highly sensitive ADAMTS13 activity as-
say. We found a five-fold increased sensitivity compared to commonly used assays, which
implies a significant improvement for adequate therapies. Molecular dynamics simulations
(Prof. Gräter) rationalized the increased sensitivity as a local structural destabilization due to
the mutation G1629E that results in an increased accessibility of the A2 cleavage domain.
We also used FCS to quantitatively characterize molecular interactions of VWF. In the context
of the multimerization study, we focused on VWF dimerization, which occurs in the endo-
plasmatic reticulum (ER) by formation of disulfide bonds. Using FCS and Microscale Ther-
mophoresis (MST), we showed that protein disulfide isomerase (PDI) binds VWF exclusively
within the VWF CK-domain, which is responsible for dimerization (KD = 258 ± 104 nM).
In addition to our binding studies, co-localization experiments of specific VWF-CK domain
mutants were performed (Dr. Brehm), which elucidated the role of PDI in the initial VWF
dimerization rather than in the repair of misfolded VWF in the ER.
Aside from studies involving VWF, we investigated the binding of the coagulation factor VIII
(FVIII) to phosphatidylserine (PS)-expressing platelets, which is another important step in the
coagulation cascade. Using FCS and MST, we established a quantitative description of FVIII
binding to PS-containing vesicles. While non-activated FVIII showed the expected binding
behavior, we found a pronounced binding anomaly for activated FVIII (FVIIIa) that is ma-
nifested in a sharp peak in binding affinity around the natural PS content of platelets. More-
over, annexin A5 effectively influenced FVIIIa binding, triggering the apparent PS content by
shielding PS lipids via competitive binding. This study demonstrates the regulatory function
of the PS content in blood coagulation.
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Introduction
Blood coagulation has evolved as the body’s own defense mechanism against bleeding. Under
physiological conditions, the coagulation system is balanced in favor of anticoagulation, but
is immediately activated in the event of vascular injury. Its exact regulation is of fundamen-
tal importance as a malfunction of the system either leads to dangerous blood loss or causes
thrombotic disorders, which may result in stroke and heart attack. To avoid both severe patho-
logical states, blood clotting has to be strictly prevented in uninjured blood vessels but has to
work extremely precise and rapid, when a vessel ruptures.
Thereby, the initiation of coagulation is particularly difficult, as will be explained in the fol-
lowing, because shear flow increases dramatically at sites of injury. Local shear rates at ves-
sel walls in the human microvasculature have been determined to be of the order of 100 to
8.000 1/s (2; 3). At vessel injuries, vasoconstriction1, or stenotic compartments2, the reduc-
tion of the vessel lumen can rise the shear rates to excessive levels above 50.000 1/s (4). At
such high shear rates, wounds need to be plugged. However, high shear flow is naturally ac-
companied by an increase of lift forces. Thus, binding is usually hindered under shear. There-
fore, well-functioning blood clotting needs a specialized mechanism to enable the required
shear-induced absorption of clotting factors to the ruptured vessel wall.
Nature meets this challenge with a polymer called von Willebrand Factor (VWF) that exhibits
an increased adhesion potential with increasing hydrodynamic shear stress (5). It initiates
coagulation mediating the binding of platelets to the ruptured vessel wall (see Figure 1.1).
More specifically, VWF is present in an inactivated state under physiological flow conditions.
When shear flow increases, it becomes activated via a shear-induced globular-stretch transi-
tion, thereby exposing numerous formerly shielded tensile binding sites. In addition to the
unfolding of the polymer chain, single force-sensing VWF domains open upon a certain shear
force. The characteristic shear rate that is needed to induce VWF’s conformational change ex-
hibits a very sensitive size dependence, as smaller multimers are more resistant to shear forces
1contraction of the muscular wall of the vessels to reduce the amount of blood loss
2abnormal narrowed parts of the vessel
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Figure 1.1: VWF in blood coagulation. Activated by shear flow, VWF (blue) binds to collagen (dark
green) and platelets (green) via binding sites in its A1 and A3 domains, which initiates coagulation.
Unfolded VWF can be cleaved in the A2 domain by the protease ADAMTS13 (purple).
than larger ones. This leads to a highly specialized regulatory potential of VWF function,
because different sizes of VWF are present in the plasma, and the appearing size distribution
can be permanently adjusted in the circulation by the enzyme ADAMTS13 (a disintegrin and
metalloproteinase with a thrombospondin type 1 motif, member 13) (6). ADAMTS13 was
shown to be the specific VWF cleaving protease in 2001 (8; 9; 10). By cleaving VWF multi-
mers at a specific cleavage site in the A2 domain, it regulates the VWF size distribution and
hence the binding capacity of VWF in the human vasculature. This A2 cleavage domain is
mechanosensitive and opens under high shear forces (11). Thus, the size regulation depends
on the shear rates in the vessel. This results in a feedback loop, which is adapted precisely to
the requirements of coagulation and prevents both clotting and bleeding (see Figure 1.2): High
shear rates increase the cleavage activity resulting in small VWF multimers. Small multimers
cannot be stretched anymore, which downregulates cleavage.
Thus, VWF’s cleavage as well as binding sites are activated by shear flow. Under shear,
initially the VWF A1 domain opens, which possesses a binding site to platelets and colla-
gen. Over time additionally the VWF A2 domain for cleavage by ADAMTS13 is activated
(11; 12). Therefore, the initiation of clot formation (via VWF platelet interaction) is preferred
over VWF inactivation (via cleavage by ADAMTS13) facilitating controlled coagulation un-
der high shear flow conditions. In conclusion, VWF shows the counterintuitive behavior of
shear-induced enhanced adhesion rates due to its multimeric and mechanosensitive structure
and can be well controlled by its environment via its distributed sizes.
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globular unfolded + ADAMTS13
Figure 1.2: Shear flow and proteolytic cleavage maintain VWF activity balanced. (I) Under low
shear conditions, inactivated VWF exists in a globular shape in the circulation (left). The A domains
A1 (red) and A2 (yellow) are shielded. Shear flow unfolds long VWF multimers and the A domains
become exposed (middle). Opening of the mechanosensitive A2 domain exposes a cleavage site for
ADAMTS13. In the presence of ADAMTS13, unfolded VWF is degraded at the A2 domain (right).
Scale bars correspond to 10 nm. (II) Height-coded atomic force microscopic images of VWF transition.
Monomers appear as yellow dots covering the surface (left). Under shear flow, VWF monomers/dimers
polymerize to a structured two-dimensional network (middle). In the presence of ADAMTS13, this
network is efficiently degraded (right). Scale bars correspond to 100 nm. (III) Immunofluorescence
images of VWF stained in green in the globular (left) and in the unfolded state (middle), in the absence
or presence (right) of ADAMTS13. Scale bars correspond to 100 µm (reprinted with permission from
(7)).
Discovery
The first hint towards the existence of VWF came from the discovery of bleeding patients who
lacked it (13; 14). Erik Adolf von Willebrand, a Finnish internal specialist, studied several
members of a family from Föglö, an island in the Åhland Archipelago in the Gulf of Both-
nia (Figure 1.3) (15). He found a so far unknown form of bleeding disorder that showed an
increased bleeding tendency but, in contrary to hemophilia3, additionally an increased blee-
ding time4. Another significant difference to hemophilia was that the symptoms were mostly
found in females. Von Willebrand called this serious bleeding tendency pseudo-hemophilia
because he was not able to determine if it was caused by a defect in platelets, blood plasma,
or the vasculature. In 1933, von Willebrand discovered further details of the disease, i.a. a re-
3clotting factor FVIII deficiency
4medical test to assess how long a person bleeds after causing a standardized cut in its forearm
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A B
Figure 1.3: Discovery of von Willebrand disease. A Erik von Willebrand, a Finnish internal spe-
cialist, described the von Willebrand disease for the first time (adapted from (17)). B Von Willebrand
studied the clinical picture of family Sundblom. Four girls of the family died from bleeding before the
age of six (with courtesy of Reinhard Schneppenheim).
duced agglutination tendency of the thrombocytes, in cooperation with the German physician
Rudolf Jürgens. From thereon, it was called von-Willebrand-Jürgens syndrom (16). Today,
the international denotation ”von Willebrand disease” (VWD) is used.
In the 1950s, an association between increased bleeding times and decreased levels of FVIII
was found in patients with VWD and a bleeding time-correcting plasma factor was defined
(18; 19; 20). In 1971, the factor was purified for the first time and called FVIII-related antigen
(21). When it was shown that it is the product of a different gene on a different chromosome
than FVIII, it was finally renamed in ”von Willebrand Factor”. The complete sequence of
VWF was reported by several groups in 1985 (22).
VWF research
The last decades have seen considerable progress in understanding VWF assembly, the struc-
tural requirements for its function, and the molecular basis of VWD. However, the dependency
of VWF’s functionality on shear stress remained unexplored for a long time. Because the in-
vestigation of the effect of shear is crucial when examining our circulatory system, shear flow
regulation of hemostasis recently came to the fore of research with the ultimate goal to bridge
the gap between nanomechanics and clinical presentation. Focusing on the force sensing abi-
lity of VWF finally shifted VWF research to the field of biophysics. Using a rotating disk
system combined with Atomic Force Microscopy (AFM), Siedlecki et al. observed in 1996
for the first time that VWF undergoes a shear-induced conformational transition from a glo-
bular to a stretched state (23). In 2007, Schneider et al. directly visualized this conformational
change using fluorescently labeled VWF molecules, which were sheared by a SAW (surface
acoustic waves)-driven flow chip (5). Moreover, they identified the shear-induced increase in
binding affinity of VWF to collagen coated channels, unraveling this effective self-regulating
repair mechanism of our body for the first time. In a recent work of Zhang et al., force was ap-
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plied directly to single A2 cleavage domains using optical tweezers. This enabled to measure
both the A2 domain opening force and the dependence of the catalytic rate on ADAMTS13
concentration (24).
These studies clearly elucidated the importance of conformational changes for the function
of VWF. However, the exact dependence of VWF functionality on shear is still poorly under-
stood. Yet, it is of eminent interest for the wider field of force sensing mechanisms in biology,
since mechanosensitive polymers under flow conditions are hitherto rarely explored. Simul-
taneous measurements of hydrodynamic flow-induced unfolding at the single molecule level
and the concomitant alteration of VWF’s functionality, such as binding or enzymatic activi-
ty, remain difficult to access and have not been studied quantitatively. Above all, there is a
need to perform measurements under blood plasma conditions, since VWF may easily alter its
properties in an artificial environment. Nevertheless, most studies of VWF so far have been
performed in buffer.
Technical challenges
The experimental realization of such studies, however, is challenging due to VWF’s extremely
heterogeneous size distribution, which includes orders of magnitudes in multimer size, and,
moreover, due to its dependency on shear flow. As the latter results in both unfolding of the
multimer and opening of single force-sensing domains, VWF research has to focus both on
the multimer and on the domain level.
Studies under blood plasma conditions exclude the usage of a wide range of experimen-
tal techniques. Several techniques based on fluorescence microscopy can be used, though.
Amongst others, Total Internal Reflection Fluorescence Microscopy (TIRFM), Laser Scan-
ning Microscopy (LSM), Fluorescence Correlation Spectroscopy (FCS), Microscale Ther-
mophoresis (MST), Förster resonance energy transfer (FRET), and Fluorescence Recovery
After Photobleaching (FRAP) work well in bulk media (25; 26; 27; 28; 29; 30).
The need to study the dynamics of multimeric VWF on a molecular level, limits the number
of potential approaches for VWF research considerably. In order to induce conformational
changes, force has to be applied on the multimer. On the one hand, this can be done by directly
using optical and magnetic tweezers, or AFM (31; 32; 33). On the other hand, shear flow can
be applied. Although the former approaches are very well suited to study intramolecular forces
and molecular stability, as well as conformational architecture and organization, the so applied
forces are homogenous along the polymer chain and constant during application. However,
simulations of VWF unfolding under shear flow reveal that the intramolecular forces in VWF
are inhomogeneous and fluctuating (34; 35). Thus, it is expected that in VWF multimers under
shear flow more and less susceptible intramolecular regions may exist, which in addition show
a size dependent probability to appear. This cannot be imitated using techniques that apply
forces directly. Therefore, shear flow is needed for studies of VWF in its natural environment.
There are several fluorescent techniques working well under flow conditions, e.g. FRET (36),
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FCS (37), and MST (38). Accordingly, all these techniques come into consideration for VWF
studies in a physiological environment. As FRET depends on very specific labeling, the ana-
lysis is limited to well defined two-component interactions or intramolecular studies. Experi-
ments with the whole range of VWF sizes would highly increase the intricacy of a correspon-
ding study. In particular, the observation of collective phenomena seems nearly impossible.
However, MST averages over all molecules in the sample and is well suited for ensemble
measurements. Thus, it can be used for all studies that are independent of VWF size. MST
cannot resolve the single multimers within the solution, though.
Fluorescence Correlation Spectroscopy (FCS) allows for an accurate determination of macro-
molecular dynamics (39; 40; 41; 42; 43; 44). In particular, the diffusion coefficient, structural
relaxation and interactions between different species can be measured (45). Moreover, since
the required sample size is very small, FCS studies can easily be combined with microfluidic
devices (37; 46). Because FCS is based on confocal microscopy and uses concentrations in
the nanomolar regime, it achieves few molecule resolution, which allows for the distinction
between molecules with different brightnesses and sizes. Therefore, it is suitable to study size
dependent-functions using the full-length VWF distribution. Moreover, it is sensitive for VWF
fragments consisting of single domains only. Thus, we chose FCS as the best suited technique
for the VWF research questions addressed in this work. For some projects, complementary
techniques were applied to strengthen the results obtained with FCS.
This work
The work presented in this thesis is motivated by the idea to quantitative measure VWF un-
der blood plasma conditions and shear flow. It involves four VWF-related projects, namely
VWF size distribution analysis (chapter 4), shear-induced VWF cleavage (chapter 5), an
ADAMTS13 activity assay (chapter 6), and the interaction of Protein Disulfide Isomerase
(PDI) with VWF (chapter 7). The first project provides a characterization of plasmatic full-
length VWF samples. This paved the way for quantitative studies under shear with the full-
length multimer. For experiments under shear flow, a microfluidic shear cell was built that was
used in the second project to relate cleavage rates to VWF’s shear dependent conformation.
Based on this study, we developed a diagnostic approach to determine ADAMTS13 levels in
patient’s plasma in the third project. Finally, binding studies were performed, which eluci-
dated the role of Protein Disulfide Isomerase (PDI) on VWF dimerization. We introduced
both MST and FCS to this study and adapted the multicomponent FCS data analysis to quan-
tify full-length VWF binding studies. Furthermore, a project focusing on a later step in the
coagulation cascade is presented that investigates the mechanism of FVIII binding to platelets
(chapter 8).
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In summery, we introduced FCS as a promising method for VWF research and proved it to be
well suited for investigations of VWF under shear and blood plasma conditions. We showed
that it can be used as diagnostic approach for both quantitative defects in the VWF size distri-
bution and ADAMTS13 deficiencies. Above all, we obtained a more precise picture of VWF
as a force-sensing polymer by quantifying, for the first time, the shear-induced ADAMTS13
activity, which we explained consistently with the biophysical theory of polymer unfolding.

2
ExperimentalMethods
Fluorescence Correlation Spectroscopy (FCS) allows for accurate determination of molecu-
lar dynamics in bulk fluids and under flow conditions. It this work, FCS was employed for
quantitative studies of VWF and its function in its natural environment, i.e. in blood plasma
and under shear flow. In the first part of this chapter, the basic principles of FCS (2.1.1), its
expansion to heterogeneous multimer samples (2.1.2), and the used instrumentation (2.1.3)
are discussed in detail. For the size distribution analysis presented in chapter 4, quantitative
gel analysis and Total Internal Reflection Fluorescence Microscopy (TIRFM) were used in
addition to FCS. These techniques are briefly introduced in section 2.2 and 2.3. For studies
of VWF under shear flow, a specialized setup was established, which had to generate constant
shear flow in small sample volumes and to be combinable with the FCS setup. The properties
of the built shear cell are discussed in section 2.4. As a complementary technique to FCS,
Microscale Thermophoresis (MST) was used in chapters 7 and 8 for biomolecular interac-
tion studies. In the last section of this chapter 2.5, the theory of MST and its experimental
realization are described.
2.1 Fluorescence Correlation Spectroscopy (FCS)
2.1.1 Principle
FCS is an experimental technique with single-molecule sensitivity, which detects the dyna-
mics of fluorescent molecules in solution (39; 40; 41). In particular, diffusion coefficients,
structural relaxation and interactions between different species can be measured. FCS follows
the intensity time trace I(t) of fluorescent molecules in a detection volume and gains informa-
tion from temporal intensity fluctuations. The fluctuations result from changes in the particle
number and/or alterations of the particle brightness (Figure 2.1 A,B), caused by their motion
such as diffusion, rotation, and active transport, by enzymatic activity, and/or by photophysical
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Figure 2.1: Conceptual basics of FCS. A A confocal microscope detects changes in fluorescence due
to transport of fluorescent molecules into the confocal volume by flow, diffusion, or transitions of the
molecules to different fluorescent states. B The resulting fluctuations in the fluorescence intensity I(t)
are autocorrelated using G(τ). C The autocorrelation curve contains information about photophysical
effects such as triplet kinetics, diffusion properties, and the number of fluorescent molecules in the
detection volume.
or photochemical reactions, each of them appearing at a characteristic timescale (45).
The autocorrelation curve G(τ), derived from the intensity fluctuations, is used to extract these
characteristics from the measurement signal. In particular, G(τ) is a measure of the self-
similarity of the signal after a lag time τ. It represents the conditional probability to find a
molecule in the confocal volume at a later time τ, given it was there at a time t (47). The
normalized autocorrelation function is defined as:
G(τ) =
〈I(t) · I(t + τ)〉
〈I(t)2〉
(2.1)
where 〈〉 denotes the time average. For the systems studied in this thesis, photophysical effects
due to triplet kinetics as well as diffusion dynamics of the fluorescent particles contribute to
the autocorrelation function:
G(τ) = 1 + Gtrip ·Gdi f f (2.2)
The first term, Gtrip, considers the relatively high probability of fluorophores to enter a triplet
state at the excitation intensities typically used for FCS. The resulting temporary dark states
appear in the autocorrelation curve as an additional slope at timescales that are significantly
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shorter than diffusion (Figure 2.1 C). This slope is described by an exponential decay (48):
Gtrip(τ) =
(
1 +
ftrip
1 − ftrip
)
e−
τ
τtrip (2.3)
with fraction of molecules in the triplet state ftrip and triplet decay time τtrip. Although triplet
kinetics had to be included into the fitting routine, Gtrip was not the subject of the studies
presented here but rather used to obtain reliable results for Gdi f f .
Gdi f f accounts for the dynamics of the fluorescent particles diffusing through the detection vo-
lume and can be fitted by diffusion models to obtain parameters such as the diffusion constant
or the particle concentration. For free diffusion of molecules in a three-dimensional Gaussian
probe volume with radial dimension ωr and axial dimension ωz, Gdi f f is given by:
Gdi f f (τ) =
1
N
·
1
1 + τ
τD
·
1√
1 + τS 2·τD
(2.4)
where N denotes the average number of particles in the focus volume and the diffusion time
τD the time, at which the autocorrelation function has decayed to one-half of its value. The
structure parameter S is a measure for the ratio between the focus radii in axial and radial
dimension, ωz and ωr, and depends on the optical properties of the setup and the sample
solution: S = ωz/ωr. It is calibrated with a well-known fluorescent molecule before every
experiment and kept fixed for data analysis. This leaves two fitting parameters describing the
fluorescent sample: τD and N. The latter is used to determine the concentration of fluorescent
particles c:
c =
N
Vc f · NA
(2.5)
with Avogadro constant NA and confocal detection volume Vc f , which amounts typically to
about 0.2 fl. The diffusion time τD characterizes the average time that the molecules need to
cross the focal width and allows for the determination of the diffusion coefficient D:
D =
ω2r
4 · τd
(2.6)
As τD depends on the size of the detection volume, the diffusion coefficient D is better suited
to describe the characteristic diffusion properties of a molecule in a given solvent. D is a
measure for the mobility of a particle and depends on its size, the viscosity of the fluid η,
and the temperature T . For a perfectly spherical particle, the hydrodynamic radius rhyd can be
deduced from the Stokes-Einstein relation as follows:
D =
kBT
6πηrhyd
(2.7)
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with Boltzmann constant kB. For a particle with cylindrical shape, D is given by:
D = A ·
kBT
3πηL
(2.8)
with cylinder length L, cylinder diameter d, and correction factor A:
A = ln(L/d) + 0.312 + 0.565/(L/d) − 0.1/(L/d)2 (2.9)
2.1.2 Multicomponent Analysis
For measurements of an n-component mixture of non-interacting fluorescent particles, the
overall autocorrelation function is a weighted sum of the autocorrelation functions Gi(τ/τi) of
all components (49):
G(τ) =
∑n
i=1 q
2
i NiGi(τ/τDi)(∑n
i=1 qiNi
)2 (2.10)
where qi denotes the brightness, Ni the number, and τDi the diffusion time of molecules of
species i. For the heterogeneous VWF sample, multicomponent analysis was used. The adap-
tion of equation 2.10 to the individual projects is described in the following.
Size Distribution
In this thesis, a novel size distribution analysis approach, based on equation 2.10, was in-
troduced to determine the size distribution of VWF multimer samples (see chapter 4). VWF
multimers are organized as long linear chains consisting of a certain number of dimers i, which
serve as the building block of the multimer. For known brightnesses qi and diffusion times τDi,
the size distribution Ni can be fitted with equation 2.10. In this work, a VWF-eGFP fusion
construct was used, where each monomer is labeled with one eGFP molecule at the dimeri-
zation site of the multimer. Therefore, the brightness qi scales with the number of dimers i.
Quenching might occur for dimers with respect to monomers due to the binding site of eGFP.
However, it is not expected for multimers among each other because there is no label at the
multimerization site. As the brightness was counted dimer-wise, quenching was neglected for
VWF and qi = i was used for analysis.
There exist several models for the diffusion times τDi of polymers consisting of i subunits.
The simplest one is the Rouse model (50), which describes the conformational dynamics of an
ideal chain consisting of i beads connected by harmonic springs. This model neglects excluded
volume interactions between the beads, and each bead is subjected to a random thermal force
as well as a drag force. This results in a diffusion coefficient Di = D/i and diffusion times
τDi,Rouse = τD · i. Zimm extended this model by the inclusion of hydrodynamic interactions
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Figure 2.2: Illustration of the effect of cleavage and binding on G(τ). A Increasing concentration of
fluorescent particles leads to lower amplitudes of the autocorrelation curve G(0). This effect is used to
detect VWF cleavage. B Binding shifts the autocorrelation curves towards longer diffusion times due
to increasing effective particle sizes.
among the beads due to forces that are caused by the motion of the solution itself (51). The
Zimm model predicts a diffusion coefficient Di = D/
√
i and a diffusion time τDi,Zimm = τD ·
√
i.
The diffusion time of a stiff cylinder lies in between these two models as shown in equation
2.8. As there is little known about the persistence length of the VWF polymer and its exact
shape in the used buffer containing 1.5 M urea, we used the simple Rouse model, which
worked sufficiently well for fitting.
Cleavage
The amplitude of the autocorrelation curve G(0) is a measure for the particle concentration
(Figure 2.2 A). For the concentration detection of a system with multiple species, the ampli-
tude of the autocorrelation function is given by:
G(0) =
∑n
i=1 q
2
i Ni(∑n
i=1 qiNi
) (2.11)
with number Ni and brightness qi of molecules of species i. For species with varying bright-
nesses qi, weighting with the brightness results in a systematic underestimation of the number
of molecules in the detection volume. This underestimation can be analytically derived using
equation 2.11. Thus, knowing both the size distribution and the brightness of the different
species, allows to obtain quantitative results. In chapter 5, the equation was adapted to quan-
tify the cleavage of VWF multimers. This was possible because recombinant VWF-eGFP
molecules were used, where each monomer was labeled with one eGFP molecule. Thus,
cleavage resulted in an increase in fluorescent molecules. For the VWF size distribution
N(i) = (p − 1)pi−1 with p = 0.64 (see chapter 4), the underestimation due to distinct bright-
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nesses of the molecules was calculated to:
G(0)
G(0) −G(0)FCS
= 40.4% (2.12)
We showed that the data correction C = CFCS · 1.4 is valid also for the cleaved sample within
the used measurement times (for details see supplement B).
Binding
With multicomponent analysis, also binding events can be analyzed assuming a two compo-
nent mixture of free and bound fluorescent receptor molecules. Due to the increase in apparent
size, binding to another molecule shifts the autocorrelation curves towards longer diffusion
times (see Figure 2.2 B). If binding does not alter the brightness of the receptor molecule, i.e.
qbound = q f ree, equation 2.10 can be simplified to:
G(τ) =
1
N
[
(1 − f ) ·G(τ/τ f ree) + f ·G(τ/τbound)
]
(2.13)
with the fraction of bound receptor molecules f and the total number of receptor molecules N.
This form of the autocorrelation function allows for the analysis and discrimination of differen-
ces in the diffusion characteristics and can be applied to quantitatively determine the binding
of small fluorescent particles to particles of larger sizes. For data analysis, the autocorrelation
functions of both components, G(τ/τ f ree) and G(τ/τbound), are determined separately and kept
as fixed parameters. This proceeding reduces artifacts, leaving the number of particles and the
fractions of bound and unbound particles as the only free fit parameters.
Measurements of binding to a multimer containing several binding sites poses the challenge
that the brightness of the multimer depends on the number of bound fluorescent receptor
molecules fi. Furthermore, if the multimers are present in different sizes, as it is the case
for the VWF multimers used in this work, the number of binding sites scales with the size of
the multimer Ni. Thus, the brightness changes due to binding according to qi = fiNi. For this
scenario, we developed the following fitting formula, which is used in chapter 7:
G(τ) =
1
N
[
(1 − f ) ·G(τ/τ f ree) + f 3 · īG(τ̄)
]
(2.14)
with average multimer size ī and average multimer diffusion time τ̄ (for details see chapter 7).
2.1.3 Instrumentation
FCS measurements were performed on an Axiovert 200 microscope with a ConfoCor 2 unit
(Carl Zeiss, Jena, Germany) equipped with a 40x (NA = 1.2) water immersion apochromat
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Figure 2.3: Quantitative Gel Analysis. A Multimer pattern of a VWF sample shows a ladder of mul-
timers. Densitogram intensity is plotted versus multimer size and integrated over area A. B Intensities
are normalized with the size of the multimer in the respective band, which provides the distribution of
multimer sizes.
objective (Carl Zeiss, Jena, Germany). An argon laser (488 nm) and a HeNe-laser (633 nm)
were used for illumination. Samples were measured in eight well LabTek I chamber slides
(Nunc, Rochester, NY), except for measurements under shear flow, which were performed in
a self-built sample holder (see section 2.4.1). For experiments at 37◦C, either a heating stage
(ibidi GmbH, Martinsried, Germany) or a water bath (Julabo GmbH, Seelbach, Germany;
shear experiments) was used. Correlation was performed with the ConfoCor 2 software. For
FCS data analysis of the VWF size distribution and VWF binding, Labview routines were
implemented. Fitting procedures were carried out using IgorPro.
2.2 Quantitative Gel Analysis
For the quantification of VWF size distributions, gels were analyzed in this thesis in addi-
tion to FCS measurements (see chapter 4). Although gel analysis is the most frequently used
technique for VWF multimer analysis (52; 53; 54), gels have usually been compared qual-
itatively in the past. In order to quantitatively interpret gels in terms of size distributions,
we introduced a new analysis method, which was applied to recombinant VWF samples as
well as blood samples of patients. Therefore, sodium dodecyl sulfate agarose gels were pro-
vided by the group of Prof. Budde (Medilys Coagulation Laboratory Asklepios Klinic Altona,
Hamburg). After separation of the multimers via gel electrophoresis, they were visualized
by detecting their luminescent signal (see Figure 2.3). Thereby, proteins were labeled with
horseradish peroxidase-conjugated antibodies that cleave a chemiluminescent agent causing
luminescence that is proportional to the amount of protein. The gels were evaluated using lu-
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Figure 2.4: Total Internal Reflection Fluorescence Microscopy (TIRFM). A Schematic illustration
of the used objective-type TIRFM. The laser beam (green) is focused on the periphery of the objective’s
back focal plane such that it reachs the glass-water interface under a total reflection angle, generating
an evanescent field. B TIRFM image of VWF multimers immobilized on a glass surface. C Bleaching
steps of the intensity time traces are used to determine the multimer size [B and C modified from (55)].
minescent immunoblotting, implying that the measured signal intensities in each band reflect
the number of antibody labels (see Figure 2.3 A). As the number of antibody labels scales with
the size of the multimers, the signal A was normalized by the number of dimers i, correspond-
ing to the size of the multimers in the respective band (see Figure 2.3 B). The normalized
intensities correspond to the molecular weights of the multimers. Thus, plotting A/i versus i
directly illustrates the distribution of the multimer sizes N(i).
2.3 Total Internal Reflection FluorescenceMicroscopy
Total Internal Reflection Fluorescence Microscopy (TIRFM) is used for imaging fluorescent
molecules on a transparent substrate with single molecule resolution (25; 56). Instead of direct
illumination, the evanescent field of a totally internal reflected laser beam provides selective
illumination of the sample (see Figure 2.4 A). The critical angle necessary for total reflection
and the generation of a evanescent field is given by αc = arcsin
(
n2
n1
)
with refraction indices
n2 < n1. The resulting evanescent field decays exponentially with increasing distance to the
interface:
I(z) = I0 · exp
(
−
z
d
)
(2.15)
with the depth of penetration:
d =
λt
4π
√
n21sin
2α − n22
(2.16)
Thus, only fluorophores within typically 100 nm above the substrate surface are excited. This
restriction of the sample illumination to a very thin layer ensures a high signal-to-noise ratio
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Figure 2.5: Geometries of rotary viscometers. A Plate-and-plate design built of two coaxial circular
plates. Shear rates increase with increasing distance to the center. B Cone-and-plate design with a
rotating cone above a static plate. Produces homogenous shear rates. C Couette-cell consisting of two
coaxial cylinders. For narrow gaps between the cylinders, homogenous shear rates are generated.
of the detected fluorescence.
In this thesis, TIRFM was used to analyze the size distribution of fluorescent recombinant
VWF-eGFP (see chapter 4). Under continuous excitation, the fluorescence signal of the sam-
ple was observed to decrease in discrete steps over time (see Figure 2.4 B). As these bleaching
steps can be taken as a measure for the number of eGFP-tagged VWF monomers (57), coun-
ting the bleaching steps provided a means for analyzing the VWF size distribution (see Figure
2.4 C).
2.4 Microfluidic Shear Cell
In order to study VWF under defined shear flow, a shear cell was designed with the experi-
mental requirement that it had to be combinable with the FCS setup and constantly produce
homogenous shear rates over several hours. Rotary viscometers fulfill the second requirement
of long-term studies as the rotational movement sustains the generated flow. In such devices,
the fluid between two surfaces is sheared due to the rotation of one component. The resulting
shear rates depend on the geometry of the components and can be adjusted via the rotational
speed. The most frequently used geometries can be divided into three groups: plate-and-plate,
cone-and-plate, and concentric cylindrical, also known as Couette-cell (Figure 2.5). The first
consists of two coaxial circular plates, one of which is static and the other rotating (Figure
2.5 A). In this geometry, the resulting shear rates increase with increasing distance to the
center. The cone and plate viscometer uses a cone of very shallow angle, which rotates at a
short distance above a flat plate (Figure 2.5 B). With this design, homogenous shear rates are
achieved throughout the whole sample volume. The Couette cell is built of two coaxial cylin-
ders, which rotate relatively to each other (Figure 2.5 C). For very small distances between the
two cylinders, the shear rates within this gap can be considered as homogeneous. We chose a
combination of the latter ones.
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Figure 2.6: Mooney-type shear cell. A A combination of cone-and-plate and concentric cylindrical
geometry was used to obtain constant shear rates within the whole sample volume. B A sample holder
containing three wells serves as static outer cylinder. The rotating inner cylinder is connected to a
brushless motor and generates shear rates from 10 to 10.000/s.
2.4.1 Design
In this work, a Mooney-type shear cell was built (58). It consists of a combination of the
cone-and-plate and the concentric cylindrical geometry and was designed in a way so that
constant shear rates were provided within the whole sample volume (Figure 2.6). It is made
of a stainless steel sample holder containing wells with radii ro = 6.5 mm, serving as static
outer cylinders. Before the experiments, a coverslip (Carl Roth, Karlsruhe, Germany) is fixed
with nail varnish to the bottom of the sample holder. The rotating inner cylinder (radius
ri = 6.1 mm) is connected to a brushless motor with integrated controller (Faulhaber GmbH,
Schönaich, Germany) and generates shear rates from 10 − 10.000/s. The angle φ between
cover glass and cone tip measures φ = arctan((ro − ri)/ro) = 3.74◦. The sample volume is
approximately 150 µl.
The value of the generated shear rates can be calculated based on the design parameters of the
device. If the constriction ri/ro > 0.97 holds for a shear cell with radius ri of the rotating inner
and radius ro of the static outer cylinder, the shear rate γ̇ is given by:
γ̇ =
∣∣∣∣∣∆v∆r
∣∣∣∣∣ = v(ri) − v(ro)ro − ri = ωi · riro − ri (2.17)
with surface velocity v and angular velocity ω. As both manufacture and alignment of such
a narrow gap between inner and outer cylinder was technically not feasible (ri/ra = 0.94), a
more elaborated formula had to be used. For power-law fluids with flow behavior index n, the
shear rate is described by (59):
γ̇ =
ωi · (2/n) · ε2/n
ε2/n − 1
(2.18)
2.5. MICROSCALE THERMOPHORESIS (MST) 19
where ε = ro/ri. For Newtonian fluids (n = 1) equation 2.18 can be simplified to:
γ̇ =
ωi · 2 · ε2
ε2 − 1
(2.19)
For shear-thinning fluids like blood, n is less than 1. As n strongly depends on patient-specific
parameters such as hematocrit and cholesterol concentration, values for n in whole blood in
literature range from 0.6 to 0.7 (60; 61). Here, for measurements in blood plasma (i.e. blood
without cells), n = 0.8 was assumed.
2.4.2 Experiments under shear flow
Since FCS measurements rely on diffusion, shearing and FCS data sampling needed to be run
in an alternating mode, where the solution was sheared for a certain time period, which was
directly followed by a 15 minute long FCS detection period without shear. This approach
allows to detect events that are stable in the absence of shear, such that the sample is not
expected to change during the detection period. This was the case for the shear-induced VWF
cleavage presented in chapter 5.
For measurements with VWF, both cylinders had to be coated to avoid sticking of VWF to the
surface. Therefore, the shear cell was incubated for half an hour with ultra heat treated (UHT)
milk and thereafter washed with buffer for at least ten times.
2.5 Microscale Thermophoresis (MST)
MST is a technology that measures the directed movement of molecules in a temperature
gradient. Analyzing this phenomenon called thermophoresis allows for studies on binding
affinities and kinetics of biomolecules (28; 62; 63).
2.5.1 Principle
In fluids, molecules with thermophoretic mobility DT move in a temperature gradient ∆T
with the velocity v = DT · ∆T (64). The thermophoretic movement induces differences in
concentration c, which leads to diffusion. This results in a total flow density of:
j = jD + jDT = −∆c · D − c · ∆T · DT (2.20)
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Figure 2.7: Microscale Thermophoresis (MST). A Fluorescence is detected from molecules in a
probe chamber. After switching on a focused infrared-laser, a temperature gradient establishes, which
generates directed motion of the molecules. This thermophoretic movement produces a concentration
gradient inside the capillary. The concentration increases with increasing distance from the laser focus.
B Detection of fluorescence over time monitors the thermophoretic movement. I. Cold fluorescence
Fcold is detected, before the laser is switched on. II. After switching the laser on, a temperature jump is
observed in fluorescence because of the temperature dependence of the fluorescent dyes. It is followed
by the charateristic thermophoretic movement. Fhot is extracted from this fluorescence time course. III.
After switching off the laser, backdiffusion starts.
with D being the diffusive mobility of the molecules. In equilibrium, thermophoresis is ba-
lanced by ordinary diffusion (j = 0):
dc
c
= −
DT
D
· dT (2.21)
leading to an equilibrium concentration distribution of:
c(x)
c0
= exp[−(DT/D) · (T (x) − T (x0))] (2.22)
where c0 denotes the concentration at position x0. The ratio of the diffusive mobilities DT/D
is defined as Soret coefficient S T and a measure for the strength of thermodiffusion in the
steady state. For small, quasi-constant temperature steps, the concentration distribution due
to thermophoretic movement may also be interrelated with a local change in the Gibbs free
energy G using a Boltzmann distribution (65):
c(T1)
c(T2)
= exp
[
−
G(T1) −G(T2)
kBT
]
(2.23)
with Boltzmann constant kB. Equation 2.22 and 2.23 directly relate the Soret coefficient to the
overall entropy S :
S T · kBT =
∆G
∆T
= −S (2.24)
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For single particles at constant pressure, S denotes the local negative entropy of the particle-
solvent system. In water, the particle entropy is dominated by the entropy of ionic shielding
and the entropy of hydration. This leads to:
S T =
A
kBT
−shyd + βσ2e f f4εε0T · λDH
 (2.25)
with the hydration shell shyd per surface area A, the effective surface charge density σe f f , the
Debye screening length λDH, the dielectric constant ε, and the electric constant ε0. β gives the
relative change of the solvent’s dieletric constant ε(T ) with temperature.
2.5.2 Soret Analysis
As depicted in equation 2.25, the Soret coefficient depends on size, conformation, charge,
and solvation entropy of a particle. Binding to other molecules may alter all or some of
these properties, which is used in MST to quantify the interaction of biomolecules because S T
determines the change in concentration in steady state:
c = c0 · exp(−S T · ∆T ) (2.26)
with the temperature rise ∆T = T − T0 at the respective spot. In MST experiments, a low
power infrared laser generates a temperature gradient inside a probe filled chamber, e.g. a
capillary with solved molecules. Using fluorescent molecules allows for the visualization
of the thermophoretic movement as a shift in the detected fluorescence intensity (see Figure
2.7 A). The thermophoretic depletion is thereby given by the ratio Fhot/Fcold of the average
fluorescence intensity determined in the time periods when the laser is switched on (Fhot) and
off (Fcold) (see Figure 2.7 B). In a typical experiment, the amount of unlabeled binding partners
(called receptor in the following) is varied. Directly plotting the detected thermophoretic
depletion against the receptor concentration results in a binding isotherm.
The binding isotherm can be analyzed applying the law of mass action. In a bimolecular
binding process of binder molecule B and receptor molecule R, the complex RB associates
with the rate kon and dissociates with the rate ko f f :
c f reeR + c
f ree
B 
 cRB (2.27)
The affinity between ligand and binder molecules is quantified by the dissociation constant
KD:
KD =
ko f f
kon
=
c f reeR · c
f ree
B
cRB
=
(cR − cRB)(cB − cRB)
cRB
(2.28)
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Figure 2.8: Soret Analysis. A The thermophoretic movement changes upon binding. B This results
in differences in the fluorescence time traces. C Binding isotherms are obtained directly from the
thermophoretic depletion. Fitting with equation 2.29 is indicated as dotted line.
with cR = c
f ree
R + cRB and cB = c
f ree
B + cRB. Rearrangement of equation 2.28, leads to the
expression used for data analysis:
cRB
cB
=
cR + cB + KD −
√
(cR + cB + KD)2 − 4cRcB
2cB
(2.29)
where cRB/cB denotes the fraction of occupied binding molecules, which is measured as ther-
mophoretic depletion in the MST experiments (see Figure 2.8).
3
VWF: aMechanosensitive Polymeric Blood Protein
The multimeric blood protein VWF is a key factor in primary hemostasis as it initiates coagu-
lation by the promotion of platelet adhesion at sites of vascular injury. Remarkably, VWF
possesses a shear-flow sensitive structure, and binding of various enzymes and coagulation
factors, interacting with VWF, is activated by shear stress. Moreover, its function in primary
hemostasis correlates with its size. The work presented in this thesis focuses on VWF as a
multimeric, mechanosensitive protein, and on the shear-induced regulation of its functiona-
lity. Underlying medical and biological basics are presented in this chapter. Starting with a
general overview of hemostasis (3.1), the biosynthesis of VWF (3.2), and its structure-function
relationship (3.3) as well as the VWF-associated disease Thrombotic Thrombocytopenic Pur-
pura (3.4) are discussed in detail. Finally, the protocol to produce recombinant fluorescent
VWF-eGFP, as was used in this thesis, is described (3.5).
3.1 Hemostasis
Hemostasis is a complex pivotal process that stops bleeding at ruptured vessel walls. It can be
divided into two steps: During the primary hemostasis, vasoconstriction along with the forma-
tion of a platelet plug initially occlude the vascular lesion. During the subsequent secondary
hemostasis, the formation of fibrin clots ensures the final blood coagulation. Strict regulation
of both parts is essential to prevent both heavy blood loss and clogged blood vessels (66).
Primary hemostasis has to be rapid, reliable, precise, and, moreover, effectively operating un-
der high shear stress, which arises where injury occurs. It is initiated by constriction of the
damaged blood vessel, minimizing the amount of blood that can be lost. Meanwhile, thrombo-
cytes adhere to the exposed sub-endothelium collagen fibers. This adhesion is mediated by the
blood protein VWF, which possesses binding sites for both collagen and the platelet receptor
GPIb. Subsequent to adhesion, the thrombocytes are activated; they start to secret coagulation
factors, undergo conformational changes, and form aggregates. The thereby evolved platelet
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plug temporarily closes the rupture in the vessel wall.
In secondary hemostasis, the formed thrombus has to be stabilized. This is ensured by the
interplay of various coagulation factors (termed Fx) and called blood coagulation cascade
(66). Most of the coagulation factors are proteolytic enzymes, which exist in the plasma in
an inactive form. Secondary hemostasis consists of three phases: the activation phase, which
leads to the conversion of prothrombin to thrombin, the coagulation phase, where soluble fibrin
monomers are built out of fibrinogen, and finally the retraction phase, where the thrombus is
stabilized and contracted via fibronectin and thrombosthenin (67). When this stable, platelet-
and fibrin-containing plot is built, repairing of the damaged vessel sets in.
The activation phase of the coagulation cascade consists of two pathways. Both result in
activation of FX, which in turn initiates the formation of thrombin. The extrinsinc pathway
uses a complex consisting of membrane-activated FVII, membrane-bound tissue factor, and
calcium to do so. The intrinsic pathway works 50-fold more efficiently, and a dysfunction of
this pathway leads to severe bleeding disorders. It is completed by a membrane-bound tenase
complex that is built from activated FVIII and FIX. Hemophilia, the second most prevalent
coagulation disorder, results from the absence or inactivity of either FVIII (hemophilia A,
85%) or FIX (hemophilia B) (67).
Within this complex network that was established as a defense mechanism against bleeding,
one glycoprotein, the VWF, cannot be substituted. Deficiency or dysfunction of VWF, called
von Willebrand disease, is the most common inherited bleeding disease (13). In addition to its
essential role in primary hemostasis, VWF acts as carrier protein for FVIII, which is rapidly
removed from the circulation in the absence of VWF. Consequently, patients who lack VWF
suffer from severe bleeding disorders due to profound defects both in blood clotting and in the
formation of platelet plugs at sites of vascular injury.
3.2 VWF: Biosynthesis and Secretion
VWF is a large, multimeric glycoprotein present in blood plasma, platelet α-granules, and
subendothelial connective tissue. Its biosynthesis is a highly sophisticated process, leading to
a molecular heterogeneity, which reaches from 500 kDa dimers to 40.000 kDa high molecular
weight multimers (HMWM) (Figure 3.1). Synthesis starts in the cytoplasm by production of
pre-pro-monomers, which are translocated to the endoplasmatic reticulum (ER). Here, glyco-
sylation occurs, and dimers form via intermonomer disulfide bonds in the carboxy-terminal
domain. Dimers with a molecular mass of 500 kDa represent the repeating unit of the VWF
multimer. They are transported from the ER (pH = 7.4) to the Golgi apparatus (pH = 6.2).
There, pH-dependent multimerization occurs by formation of linear multimers via interchain
disulfide bonds at the amino-terminal, resulting in multimeric VWF (31; 68; 69). The VWF
propeptide, which acts as an oxidoreductase to promote VWF multimerization, is then furin-
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Figure 3.1: Schematic representation of plasma VWF biosynthesis and post-secretional size con-
trol. (I) VWF is synthesized in the cytoplasm, and originates from 360 kDa pre-pro-monomers. (II)
Monomeric VWF is transported to the endoplasmic reticulum, where it is dimerized through inter-
monomer disulfide bonds. (III) Multimerization takes place in the Golgi apparatus, where the dimers
form multimers, which are then secreted to the blood plasma. (IV) Size control in plasma is provided
by the protease ADAMTS13. No further multimerization occurs after secretion to the plasma (modified
from (55)).
cleaved for separate secretion (70; 71). The VWF multimers are either stored in Weibel-Palade
bodies until release upon thrombotic stimuli or secreted constitutively to the plasma (72). Af-
ter secretion to the blood plasma, no further multimerization takes place. VWF multimers are
cleared with a halflife of about 12 h. The plasma concentration averages 10 µg/ml.
3.3 VWF: Biological Activities and Structure-Function
Relationship
VWF possesses a multi-domain structure, which enables its versatile role in blood coagulation
(Figure 3.2). The individual domains carry several binding sites, and VWF performs its hemo-
static functions through binding to coagulation factor VIII (FVIII), platelets, and collagen. For
FVIII, VWF acts as a transporter protein, preventing degradation of this important player of
the coagulation cascade in the blood vessel. Initiating primary hemostasis, VWF furthermore
mediates accelerated binding of platelets to collagen that is exposed at ruptured vessel walls,
and to one another. While there are no binding sites for collagen present on platelets, there are
two binding sites designed for VWF: Non-activated platelets bind VWF’s A1-domain via the
receptor GPIb, which is characterized by a fast association rate. After activation, binding to
GPIb is followed by binding of the integrin GPIIb/IIIa to VWF’s RGD binding sequence. Be-
sides, VWF might facilitate platelet aggregation by forming networks via VWF intermolecular
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Figure 3.2: Multidomain structure of the VWF monomer and attributed binding sites (with courtesy
modified from C. Baldauf).
binding (73). Moreover, there is a reasonable suspicion that unspecific interactions of VWF
with endothelial cells exist (74; 75).
Due to its multimeric structure, there exists a wide range of mutations in the VWF coding
gene causing von Willebrand disease (VWD), an inherited bleeding disorder. VWD is charac-
terized by a prolonged bleeding time, which stems from quantitative and/or functional deficits
of VWF. It is classified into three types: VWD type 1 and 3 are quantitative defects with
depressed levels of VWF, either with regular functionality (type 1), or with almost complete
absence of VWF (type 3). In contrast, VWD type 2 includes a wide variety of structural and/or
functional defects of VWF, resulting from mutations in distinct domains of the molecule. The
impact of these mutations are diverse, involving dimerization and multimerization defects,
mechanical instabilities of individual domains, altered binding affinities, and modified proteo-
lysis kinetics (76).
Remarkably, all VWF interactions, besides FVIII binding, are known to strongly depend on
VWF’s conformation and size (Figure 3.3) (5; 24; 77; 78). This represents a highly specialized
regulation of VWF’s functionality, which is particularly important in the arterial and micro-
circulation: In this environment, VWF is exposed to high shear forces with hydrodynamic
shear rates ranging over several orders of magnitude from 10−1 to 105 1/s, which explains why
VWF requires a specific mechanism to enable platelet adhesion and aggregation. This specific
mechanism consists of two features: a multimeric structure and a force-sensing domain. At
low shear rate, VWF exists in the blood in a globular form and performs a globular-stretch
transition at a critical shear rate (5). In addition to this polymeric unfolding, VWF’s A2 do-
main possesses a mechanosensitive structure, which opens at a critical force (24). Within
this force-sensing A2 domain lies the cleavage site for ADAMTS13 (a disintegrin and me-
talloproteinase with a thrombospondin type 1 motif, member 13). The metalloproteinase was
found to be the specific plasma protease, regulating the size of VWF, in 2001 (8; 9; 10).
Because smaller multimers are more resistant to shear forces than larger ones, VWF func-
tionality strongly depends on its size, and its shear-induced degradation by ADAMTS13 is a
determining factor in hemostasis. Thereby, the size regulation by ADAMTS13 establishes, in
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Figure 3.3: VWF in the blood vessel and during coagulation. Differently sized VWF multimers
persist at low shear rates in an inactivated globular state. Shear stress elongates VWF, and binding sites
are exposed. The metalloprotease ADAMTS13 regulates the VWF size distribution by shear-dependent
proteolysis. VWF binds to endothelial cells, platelets, and collagen. VWF and platelets form networks
during hemostasis, which cover the damaged epithelial tissue.
combination with shear flow, a unique feedback loop of VWF’s activity: The higher the shear
rate, the faster ADAMTS13 cleaves the polymer. The shorter the polymers, the less they are
stretched, reducing ADAMTS13 cleavage potential.
3.4 Thrombotic Thrombocytopenic Purpura (TTP)
The hematological disorder thrombotic thrombocytopenic purpura (TTP) is a severe, occlu-
sive, microvascular thrombotic microangiopathy. It is associated with acquired or conge-
nital deficiency of the VWF cleaving protease ADAMTS13. In TTP, absence of functional
ADAMTS13 leads to unusually large VWF multimers, which are hemostatically more active.
This results in life-threatening depositions of thrombi in the microvasculature that consist
of platelets and ultralarge VWF, leading to thrombocytopenia and bleeding episodes (79).
Most cases of TTP in adults are caused by acquired autoantibodies that inhibit ADAMTS13
(80). Interestingly, the ADAMTS13 concentration fluctuates over a wide regime and pa-
tients with more than 10% of the physiological ADAMTS13 level can live without symptoms.
Severely deficient ADAMTS13 activity occurs at ADAMTS13 levels of 5% and below (81).
Although plasma exchange therapies are widely used to remove autoantibodies and reple-
nish ADAMTS13, TTP still leads to a high morbidity rate and significant mortality (14). The
detection of such low ADAMTS13 concentrations around 100 pM and below is technically
challenging. Thus, measurements of ADAMTS13 activity in TTP and other pathological con-
ditions remain in the focus of substantial clinical research effort.
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3.5 Expression of recombinant VWF-eGFP
For the used measurement techniques based on fluorescence microscopy (see chapter 2), a
recombinant fluorescent VWF-enhanced green fluorescent protein (eGFP) fusion construct
was produced. For cloning of the wild-type VWF-eGFP plasmid, the stop codon was elimi-
nated from the plasmid pIRESneo2-vWF (Takara Bio Europe/Clontech, Saint- Germain-en-
Laye, France) and an EcoRI restriction site was introduced. The eGFP sequence was cut out
from the plasmid pEGFP-N2 (Takara Bio Europe/Clontech) by the restriction endonucleases
EcoRI and NotI and inserted into the plasmid pIRESneo2 by using its EcoRI/NotI restric-
tion sites (pIRESneo2-EGFP). Subsequently, VWF-cDNA from plasmid pIRESneo2-VWF,
lacking the stop codon, was cut out by EcoRI and cloned into pIRESneo2-EGFP (pIRESneo2-
VWF-EGFP).
Several mutations of the full-length recombinant VWF were used in this work. Plasmids of
these mutants were produced as following:
rVWF-eGFP dimer: The pIRESneo2-vWF-delPro-EGFP was modified such that the signal
peptide sequence plus the first three codons of the VWF propeptide were retained, while the
rest of the propeptide, corresponding to codons 26-763 (delT26-R763), was cut out. There-
fore, the VWF multimerization site was missing, and expression of this construct resulted in
VWF monomers that assembled into carboxy-terminal dimers but could not multimerize at
the amino-terminal.
rVWF-eGFP monomer: The plasmid pIRESneo2-vWF-delPro/C2771R-EGFP was produced
by in vitro-mutagenesis of the VWF-delPro construct, producing VWF-eGFP dimers. The
cystein codon 2771 was exchanged for arginine (p.C2771R), which presents a naturally oc-
curring mutation. This mutation causes a severe dimerization defect in addition to the mul-
timerization defect of the VWF-delPro construct. Thus, expression resulted in rVWF-eGFP
monomers.
rVWF-eGFP-IIC: In the wild-type plasmid pIRESneo2-VWF-EGFP, the codon 1099 for cys-
teine was exchanged for tyrosine (p.C1099Y), which corresponds to another mutation found in
patients. Expression of the plasmid PIRESneo2-vWF-C1099Y-EGFP did not result in quan-
titative defects in the expression of VWF. However, it generated a deficiency in large and
medium-sized VWF multimers. In patients, this mutation is characterized as VWD type 2A,
phenotype IIC.
rVWF-eGFP-G1629E: This construct carries a mutation in the mechanosensitive A2 domain
that strongly destabilizes the domain. The plasmid of wild-type pIRESneo2-VWF-eGFP was
modified by exchanging in codon 1629 glycine for glutamine (p.G1629E). Due to this mu-
tation, the VWF cleavage site becomes permanently accessible, leading to highly increased
cleavage rates and absence of long VWF multimers.
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Human Embryonic Kidney (HEK) 293 cells were transiently transfected with full-length mVWF
or wtVWF cDNA by liposomal transfer (Lipofectamine 2000; Invitrogen). 48 h after transfec-
tion, cells were trypsinized and grown until confluence in Dulbeccos modified Eagle medium,
containing 10% fetal bovine serum and G418 at 500 mg/ml for selection. After further growth
of an aliquot of the stable cell line until 70−80% confluence, cell culture medium was ex-
changed by OPTIPRO-SFM medium for serum-free expression. Cell culture medium was
harvested after 72 h and concentrated by Amicon Ultrafree, MWCO 100.000 (Merck Milli-
pore, Darmstadt, Germany).

4
Size Distribution Analysis of VWF
This chapter presents a study on the size distribution of the plasmatic polymer VWF. In pri-
mary hemostasis, the function of VWF is determined by its shear-flow sensitive structure and
correlates with its size. From a polymer physics point of view, this size dependent functio-
nality is of eminent interest, because the distribution of VWF sizes represents an important
regulator of the influence of shear flow on its activity. Although it was well known that VWF
forms multimers before being secreted to the blood plasma, there was hitherto no quantitative
description on the size distribution.
We found exponentially distributed sizes using multiple experimental approaches, involving
FCS, Quantitative Gel Analysis (Prof. Budde), and TIRFM (Dr. Benoit). Recombinant VWF
constructs were provided by the group of Prof. Schneppenheim. We attributed the resulting
size distribution to a step-growth polymerization process during VWF biosynthesis. As a
consequence, the size distribution can be explicitly described by a single parameter, namely
the extent of polymerization, which we found to be reduced for a disease-related VWF mutant.
Using FCS, we measured shifts in the VWF sizes due to ADAMTS13-induced proteolysis and
showed that the decreasing average VWF size is in agreement with the expected evolution of
an exponential distribution under random cleavage. The quantitative assessment of the VWF
size distribution in terms of an exponential might prove to be useful both as a valuable biophy-
sical characterization and as a possible disease marker for clinical applications. Moreover, it
allows for quantitative studies of full-length VWF rendering experiments with isolated VWF
domains instead of the multimers unnecessary.
The experimental data and the resulting conclusions are presented in the following publication:
S. Lippok, T. Obser, J.P. Müller, V.K. Stierle, M. Benoit, U. Budde, R. Schneppenheim, J.O.
Rädler. 2013. ”Exponential Size Distribution of von Willebrand Factor.” Biophysical Journal
105:1208-1216.
Reprinted with permission from ref. (55). Copyright 2013 Biophysical Society.
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ABSTRACT VonWillebrand Factor (VWF) is a multimeric protein crucial for hemostasis. Under shear flow, it acts as a mecha-
nosensor responding with a size-dependent globule-stretch transition to increasing shear rates. Here, we quantify for the first
time, to our knowledge, the size distribution of recombinant VWF and VWF-eGFP using a multilateral approach that involves
quantitative gel analysis, fluorescence correlation spectroscopy, and total internal reflection fluorescence microscopy. We
find an exponentially decaying size distribution of multimers for recombinant VWF as well as for VWF derived from blood
samples in accordance with the notion of a step-growth polymerization process during VWF biosynthesis. The distribution is
solely described by the extent of polymerization, which was found to be reduced in the case of the pathologically relevant mutant
VWF-IIC. The VWF-specific protease ADAMTS13 systematically shifts the VWF size distribution toward smaller sizes.
This dynamic evolution is monitored using fluorescence correlation spectroscopy and compared to a computer simulation of
a random cleavage process relating ADAMTS13 concentration to the degree of VWF breakdown. Quantitative assessment
of VWF size distribution in terms of an exponential might prove to be useful both as a valuable biophysical characterization
and as a possible disease indicator for clinical applications.
INTRODUCTION
The large plasma glycoprotein von Willebrand Factor
(VWF) is essential for the initiation of blood coagulation
as it promotes adhesion of platelets to the injured vessel
wall as well as platelet aggregation (1,2). It is present in
human blood and the secretory granules of endothelial cells
and platelets. Plasma VWF plays a crucial role in early
hemostasis as it binds rapidly and tightly to collagen when-
ever blood is exposed to injured tissues (3). Remarkably,
VWF is a multimer that consists of several identical subunits
and its function in primary hemostasis strictly correlates
with its multimer size. Even though much research is being
done on its size-dependent functionality, only little is known
about the exact size distribution and its origin. Quantitative
deficiency of plasma VWF causes von Willebrand disease
(VWD) type 1, the most common congenital bleeding disor-
der (1). Although VWD is often caused by a lack of long
multimers, an aberrantly increased activity of VWF due to
larger than normal multimers is assumed to be a pathogenic
factor in thrombotic thrombocytopenic purpura (2,4). The
size-dependent functionality relates to the shear flow-sensi-
tive structure of VWF, which responds to shear by expan-
sion to an elongated form, thereby exposing binding sites
for collagen and the platelet receptor GPIb (5). This process
highly depends on the extent of multimerization of VWF
because smaller multimers are more resistant to shear forces
than larger ones and subsequently binding sites for their
ligands are not as readily exposed (6,7). Consequently, the
size of the multimeric VWF is a critical factor for VWF’s
functionality and the question arises, which size distribution
is produced by VWF biosynthesis and how it is controlled in
homeostasis. In polymer science, the problem of polymer
size distribution has been addressed by the seminal work
of Paul Flory in 1936, in which he calculated the exact
size distribution of polymers based on the model of step-
growth polymerization reaction (8). He showed that a
theoretical prediction of a multimer size distribution is
possible if the mechanism and the kinetics of the synthesis
reaction are known. Vice versa, the size distribution pro-
vides clues with respect to the polymerization mechanism.
VWF is expressed as a proprotein (Fig. 1 A), which is
translocated into the endoplasmatic reticulum, where it
dimerizes via intermonomer disulfide bonds in the
C-terminal domain (Fig. 1 B). The dimers with a molecular
mass of 500 kDa represent the repeating unit of the VWF
multimer. They are transported from the endoplasmatic
reticulum (pH z 7.4) to the Golgi (pH z 6.2). This is the
place where multimerization occurs by formation of linear
multimers via interchain disulfide bonds at the N-terminal
resulting in multimeric VWF with molecular masses of up
to > 40.000 kDa (Fig. 1 C) (9–11). In this process, VWF
propeptide acts as an oxidoreductase to promote VWF
multimerization (12–14). The propeptide is then cleaved
for separate secretion (15,16). After multimerization,
VWF is either secreted constitutively to the plasma or stored
in Weibel-Palade bodies and released upon certain stimuli
(e.g., thrombin, plasmin, fibrin) without further multimeri-
zation taking place in the plasma (17). For a postsecretion
size regulation, circulating VWF undergoes cleavage by
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the specific metalloprotease ADAMTS13, a disintegrin and
metalloproteinase with a thrombospondin type 1 motif,
member 13 (Fig. 1 D) (18). As known from bleeding disor-
ders, defects in VWF multimer synthesis or size regulation
have fundamental implications in hemostasis and exhibit
defined patterns in VWF gel electrophoresis. Yet, the size
distribution of VWF and its molecular causation has not
been quantitatively studied so far.
Here, we investigate the size distribution of VWF using
fluorescence correlation spectroscopy (FCS), quantitative
gel analysis, and total internal reflection fluorescence
microscopy (TIRFM). TIRFM allows for direct imaging
of recombinant VWF-eGFP multimers including the assess-
ment of VWF size by intensity analysis. Gel analysis is
widely accepted in VWF diagnostics for screening patient
samples for diseases. FCS measures the hydrodynamic
size of fluorescently labeled species in solution. In contrast
to gel analysis and TIRFM, FCS allows for measurements of
fluorescent VWF-eGFP in blood plasma and is therefore
well suited for VWF analysis in its native environment.
We compare the size distribution of recombinant VWF
and VWF-eGFP and its disease-related mutant VWF 2A
(IIC), which is characterized by an increased concentration
of dimers (19,20). We show that after secretion from VWF
producing cells, VWF has an exponential size distribution in
both healthy and pathologic form. The physiological and
pathological distributions are distinct in the extent of
polymerization characterizing the distribution. We also
show that proteolytic cleavage by ADAMTS13 leads to non-
exponential distributions that shift with time allowing for
in situ monitoring of VWF cleavage under blood plasma
conditions.
MATERIALS AND METHODS
Production of recombinant VWF
The recombinant fusion protein rVWF-eGFP was expressed and purified
separately in its monomer, dimer, and multimer form as described in detail
in the following:
Cloning of a VWF-enhanced green fluorescent protein
(EGFP) Plasmid
From the plasmid pIRESneo2-vWF (Takara Bio Europe/Clontech, Saint-
Germain-en-Laye, France) the stop codon was eliminated and an EcoRI
restriction site was introduced. The EGFP sequence was cut out from the
plasmid pEGFP-N2 (Takara Bio Europe/Clontech) by EcoRI and NotI
and inserted into plasmid pIRESneo2 by using its EcoRI/NotI restriction
sites (pIRESneo2-EGFP). Subsequently, VWF-cDNA from plasmid
pIRESneo2-VWF lacking the stop codon was cut out by EcoRI and cloned
into pIRESneo2-EGFP (pIRESneo2-VWF-EGFP).
pIRESneo2-VWF-EGFP was then used to produce three mutant
constructs:
1) pIRESneo2-vWF-delPro-EGFP with the retained signal peptide
sequence and the first three codons of the VWF propeptide but lacking
the rest of the propeptide corresponding to codons 26–763 (delT26-
R763). Expression of this construct will result in VWF monomers that
assemble into carboxy-terminal dimers but not into larger multimers.
2) pIRESneo2-vWF-delPro/C2771R-EGFP, which was produced by
in vitro-mutagenesis of construct 1), by exchanging codon 2771
for cysteine against the naturally occurring mutation to arginine
(p.C2771R). Expression of this construct results in VWF monomers
only, because p.C2771R causes a severe dimerization defect (R. Schnep-
penheim, unpublished) in addition to the multimerization defect of the
VWF-delPro construct 1.
3) PIRESneo2-vWF-C1099Y-EGFP, which was produced by in vitro-muta-
genesis of wild-type pIRESneo2-VWF-EGFP, by exchanging codon
1099 for cysteine against the naturally occurring mutation to tyrosine
(p.C1099Y). Expression of this mutant results in near normal quantita-
tive expression of mutant VWF, however, lacking large and medium
sized VWF multimers as in the phenotype IIC of VWD type 2A.
Generation of stable cell lines constitutively secreting VWF
Transfection of 293 cells was carried out as described previously (21). 48 h
after transfection cells were trypsinized and grown until confluence in
Dulbecco’s modified Eagle’s medium buffer containing 10% fetal bovine
serum and G418 at 500 mg/ml for selection. After further propagation of
an aliquot of the stable cell line until 70–80% confluence, cell culture
medium was changed to OPTIPRO-SFM medium for serum-free expres-
sion. Cell culture medium was harvested after 72 h and concentrated by
Amicon Ultrafree (MWCO 100000 DA) if necessary.
FIGURE 1 Schematic representation of plasma VWF size regulation. (A)
VWF is synthesized by endothelial cells and megakaryocytes and originates
from a 360 kDa monomer. (B) Monomeric VWF is transported to the endo-
plasmic reticulum where it is dimerized through intermonomer disulfide
bonds. (C) Multimerization takes place in the Golgi apparatus, where the
dimers form multimers with sizes ranging from 500 to 40.000 kDa, which
are then secreted to the blood plasma. (D) Size control in plasma is provided
by the protease ADAMTS13. No further multimerization occurs after
secretion to the plasma.
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Blood samples
The patient samples were sent to our laboratory for the evaluation of VWF
multimers and subtyping of the already known VWD. Informed consent
was obtained from all subjects.
Quantitative gel analysis
VWF multimer analysis was carried out in sodium dodecyl sulfate agarose
gels combined with immunoblotting and luminescence visualization. The
luminescent blot was stored on electronic media using photo imaging
(FluorChem8000; Alpha Innotech, San Leandro, CA) (22). VWFmultimers
were separated via gel electrophoresis and visualized by detecting their
luminescent signal. Electrophoretic bands were visualized by means of
luminescent immunoblotting. Thereby, intensities were obtained by
labeling the proteins with horseradish peroxidase-conjugated antibodies
that cleave a chemiluminescent agent producing luminescence that is
proportional to the amount of protein (23).
The multimer patterns of rVWF and rVWF-eGFP are taken from
different gels, which were recorded on different days. Therefore, the run
times vary from sample to sample. As the run times are not used for data
analysis this does not have any influence on the analyzed data.
FCS
FCS detects the dynamics of fluorescently labeled molecules diffusing in
and out of a confocal volume (24–28) and can be applied to multicom-
ponent systems with different fluorescent species (29). It can be used for
measurements in crowded media like blood plasma, thus enabling the study
of molecules in their native environment (30). This ensures that the inves-
tigated molecules keep their natural properties, because these often change
in bulk fluids acting as solvents and thereby reducing effects such as
aggregation. FCS data analysis is described in detail in the Supporting
Material.
For FCS measurements, an Axiovert 200 microscope with a ConfoCor 2
unit (Carl Zeiss, Jena, Germany) equipped with a 40 (NA ¼ 1.2) water
immersion apochromat objective (Carl Zeiss) was used. An argon laser
(488 nm) was used for illumination. Samples were measured in eight-
well LabTek I chamber slides (Nunc, Rochester, NY). All measurements
were performed in 5 mM Tris-HCl, pH 8.0 with 1.5 M urea at a temperature
of 37C controlled by an ibidi heating stage (ibidi GmbH, Martinsried,
Germany). At this urea concentration, VWF can be conceived as a semi-
flexible polymer as urea stretches it without affecting its basic structure.
These conditions are widely used for VWF analysis if measurements
with the stretched polymer have to be performed without shear flow
(4,31). eGFP functionality was proved to be functional under this buffer
condition in agreement with Alkaabi et al. (32). Measurements were per-
formed for 10  60 s (eGFP, monomer and dimer) and 20  6 min
(rVWF; rVWF-IIC). To ensure optimal fluctuation detection for multicom-
ponent analysis, we chose long measurement times to obtain sufficient
statistics while keeping concentrations low (20 nM for all samples).
Correlation was performed using ConfoCor 2 software. For FCS data anal-
ysis, a Labview routine was implemented.
TIRFM
TIRFM is a suitable technique for imaging fluorescent molecules on a trans-
parent substrate with single molecule resolution (33,34). The technique
uses the evanescent field of a totally internal reflected laser beam exciting
only fluorophores above the substrate surface within typically 100 nm. This
provides a high signal/noise ratio of the collected fluorescence and is
therefore well suited for direct imaging of fluorescent molecules.
For TIRFM measurements, rVWF was immobilized on epoxy silane-
coated glass slides and imaged using the TIRFM setup presented in (35).
For excitation in the total internal reflection mode, a 473 nm laser (iBeam
smart, TOPTICA, Gräfelfing, Germany) was used at a power of 0.4 mW.
The corresponding filter set consisted of a Chroma z 470/10, a Chroma z
470 RDC, and a Chroma HQ 525/50 (Chroma Technology GmbH, Olching,
Germany). The emitted light signal was detected by a back-illuminated
EMCCD camera (DU-860D, Andor, Belfast, Ireland). The EMCCD chip
was operated at a temperature of 90C and the electron multiplication
gain was set to 300-fold. 3000 frames (21  21 mm2) were taken per image
sequence with a recording rate of 10 frames/s. All measurements were
carried out in phosphate buffered saline. To minimize eGFP bleaching
before the actual measurement, all adjustment procedures were carried
out at low laser power (0.1 mW).
Data analysis was obtained with a step detection algorithm. As the
routine cannot distinguish between on- and off-steps and fails in detecting
steps that occur within a very short time slot, the obtained step number was
corrected by eye for blinking and missed steps.
Proteolysis of full-length rVWF by ADAMTS13
Cleavage of recombinant VWF-eGFP by ADAMTS13 was achieved as
reported in Pruss et al. (36). Cleaved samples were stored at 80C until
multimer analysis was performed.
RESULTS
Quantitative gel analysis of rVWF
Gel analysis is the most frequently used technique for VWF
multimer analysis (22,23,36). By quantitative analysis of the
intensity profiles obtained by antibody staining in gels
(Fig. 2, A,B and C,D, respectively) we yield the size distri-
bution of VWF, which in a semilogarithmic plot shows good
agreement with an exponential (Fig. 2, E and F). Hereby we
assume that antibody staining is proportional to the number
of dimers in the VWF multimer. The gels were evaluated
using luminescent immunoblotting implying that the
measured luminescent signal intensities in each band reflect
the number of antibody labels (Fig. 2, C and D). The signal
was normalized by the number of dimers i corresponding to
the size of the multimers in the respective band. These
normalized intensities correspond to the molar distribution
function and were plotted in a semilogarithmic diagram
versus the multimer size given in number of dimers i
(Fig. 2, E and F). We took gel data from both wild-type
rVWF and rVWF-IIC and their eGFP fusion analogs
(Fig. 2 A) as well as from VWF of normal plasma VWF-
NP and patient plasma VWF-IIC (Fig. 2 B). For rVWF,
clearly an exponential decay is found. One possible mecha-
nistic explanation for such an exponential decay is the Flory
theory of linear condensation polymers (8) that describes a
step-growth polymerization process taking place in an
enclosed reactor by the intermolecular reaction of bifunc-
tional compounds (for details, see the Supporting Material).
It predicts an exponential size distribution for step-growth
polymerization resulting in a molar fraction of i-mers
containing i subunits (8)
Ni
N
¼ ð1 pÞpi1: (1)
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Here, Ni and N represent the number of i-mers and the total
number of VWF molecules, respectively. p indicates the
extent of polymerization, i.e., the number of polymerized
subunits to the total number of subunits, N. We assume
that VWF multimerization complies with the step-growth
polymerization model insofar as the formation of disulfide
bonds can be assumed to be independent of size and the re-
action volume is finite, which is a reasonable assumption
considering the fact that multimerization occurs in the Golgi
Apparatus only. Fitting the measured size distribution by the
exponential function N(i) ¼ N1pi-1 yields an extent of poly-
merization of p ¼ 0.70 5 0.02 for rVWF. N1 is a constant
fitting parameter that contains information about the number
of dimers available for polymerization (for details, see the
Supporting Material). p describes the slope of the size distri-
bution: high values of p indicate a slowly decaying size dis-
tribution with long multimers being more abundant,
whereas small values of p indicate a steep decay with only
a small amount of long multimers. The same exponential
decay as for rVWF is found for rVWF-eGFP (black
squares), showing that the shape of the distribution does
not change significantly when fusing eGFP to VWF. The
recombinant VWF-eGFP construct is therefore well suited
for further studies employing fluorescence microscopy.
The pathological rVWF-IIC appears only in a few bands
of short sizes due to its lack of large multimers. Fitting
yields an exponential, as for physiological VWF, yet with
an extent of polymerization p ¼ 0.36 5 0.01 for rVWF-
IIC (dark green) and p ¼ 0.22 5 0.01 for rVWF-IIC-
eGFP (green).
Physiological VWF derived from blood samples also
exhibits an exponential decrease (Fig. 2 F) with an extent
of polymerization p ¼ 0.78 5 0.02 for normal patients.
However, the distribution function seems to exhibit a slight,
but systematic deviation underrepresenting the larger frac-
tion. This deviation can be attributed to ADAMTS13-
induced cleavage that occurs in plasma and is depicted in
the gels by the two satellite bands flanking the main bands
that are known to be the products of proteolysis. Patholog-
ical VWF-IIC from plasma of patients suffering from von
Willebrand disease type IIC shows an extent of polymeriza-
tion p ¼ 0.66 5 0.01.
FCS single-component analysis of rVWF
FCS allows for size measurements of fluorescently labeled
VWF in solution and is in principle capable to resolve mul-
tiple species with varying diffusion properties. We find that
the measured FCS autocorrelation functions of recombinant
VWF-eGFP are consistent with an exponential size distribu-
tion. First, we investigate recombinant VWF-eGFP (rVWF)
monomer and dimer. A single-component analysis provides
diffusion times (diffusion coefficients) of tD ¼ 322 ms (D ¼
31.9 mm2/s) for the monomer and tD ¼ 447 ms (D ¼
19.5 mm2/s) for the dimer (Fig. 3 A). Fig. 3 A also shows
purified eGFP as a control. The eGFP diffusion time of
tD ¼ 90 ms is in agreement with previous results (37).
Because VWF is a rather elongated protein (11) a crude
approximation of the VWF monomer and the VWF dimer
as cylinders with the same diameter and twice the length
for the dimer is reasonable. With these assumptions, the
measured diffusion coefficients correspond to a cylinder
3 nm in diameter and 85.3 nm (dimer) and 42.7 nm
(monomer) in length (for details, see the Supporting
Material). This is in accordance with experiments per-
formed by tapping mode atomic force microscopy (38)
and electron microscopy measurements (11).
The single-component analysis can also be used as a first
approximation of the full VWF distribution. Because it
averages over all the species within the sample, it cannot
FIGURE 2 Quantitative gel analysis of recombinant and blood plasma
VWF. (A) Multimer patterns of recombinant VWF distributions showing
a ladder of multimers. (B) Multimer patterns of VWF distribution of normal
plasma and of a patient with von Willebrand disease type IIC. (C and D)
Densitogram intensity is plotted versus multimer size in terms of dimer
number i. (E) Fits of normalized data show no significant difference in
size distribution between rVWF (gray squares) and fluorescent rVWF-
eGFP (black squares), stressing that the recombinant distribution with fused
eGFP exhibits a normal multimerization behavior. Best fits to the gel data
are obtained using an exponential function N(i) ¼ N1pi-1 with an extent
of polymerization of p ¼ 0.70 (black dotted line). For pathological
rVWF-IIC (green triangles), a reduced extent of polymerization of p ¼
0.36 (dark green dotted line) for rVWF-IIC and p ¼ 0.22 (green dotted
line) for rVWF-IIC-eGFP is obtained. (F) Both plasma samples show like-
wise an exponential decay with a decreased p ¼ 0.66 for pathological
VWF-IIC (VWF-NP: p ¼ 0.78). We observe a small, systematic deviation
for large multimer sizes due to enzymatic cleavage in the plasma.
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reflect the different species within the VWF size distribu-
tion. Thus, single-component analysis is not able to provide
the actual size distribution N(i). However, it provides an
average VWF size and is suited to rapidly pinpoint differ-
ences between the physiological distribution of rVWF and
of the pathological distribution rVWF-IIC (Fig. 3 B)
showing an average diffusion time of tD ¼ 2244 5
515 ms (black line) for physiological and tD ¼ 712 5 22
ms (green line) for pathological rVWF. For rVWF, the diffu-
sion time is in good agreement with measurements per-
formed by Torres et al. (39) who detected an average
diffusion time of 2.0–3.5 ms for VWF-NP bound to fluores-
cently labeled antibodies. For rVWF-IIC, the lack of large
multimers explains the shift to shorter diffusion times in
our measurements. Although this single-component anal-
ysis does not contain quantitative information about the
size distribution of VWF, it is clearly sufficient to distin-
guish between the physiological and the investigated patho-
logical VWF distribution (Fig. 3 B).
FCS multicomponent analysis of rVWF
To examine the nature of the VWF size distribution a
multimer analysis was applied (Fig. 4) and found to be
consistent with the exponential size distribution measured
with quantitative gel analysis. The multimer analysis allows
to compare the autocorrelation function expected for a given
size distribution N(i) with the experimental autocorrelation
curve (see the Supporting Material, S1). Several distribution
functions were tested forN(i). Best results are achieved using
an exponential function N(i) ¼ N1pi-1 in agreement with the
data obtained with quantitative gel analysis. The base is
found to be p ¼ 0.64 for physiological rVWF (Fig. 4 A)
and p ¼ 0.18 for pathological rVWF-IIC (Fig. 4 B).
The best fit to the exponential distribution shows a small
improvement over the initial single component analysis
(Fig. 4). The fact that the multicomponent analysis is
close to a single component fit is explained by the fact
that the FCS autocorrelation function weights each mole-
cule with its squared brightness (see the Supporting Mate-
rial). For rVWF-eGFP the brightness scales with the
number of dimers i, the resulting weighted size distribution
FIGURE 3 FCS measurements of recombinant VWF distributions and
their building blocks. (A) Single-component fits of eGFP (light blue),
rVWF monomer (dark blue), and rVWF dimer (purple) give correlation
times tD of 90 ms, 322 ms, and 447 ms. Assuming a cylindrical shape for
the dimer, the corresponding diffusion coefficient D¼ 19.5 mm2/s character-
izes a cylinder with length l ¼ 85.3 nm and d ¼ 3 nm. A clear shift toward
longer diffusion times can be seen for the multimer distribution rVWF
(black). (B) Single-component analysis was used as a first estimate of the
autocorrelation function of physiological rVWF (black). A clear shift can
be seen for pathological rVWF-IIC (green) that allows distinguishing
between normal and abnormal conditions. Average diffusion times of tD ¼
22445 515 ms (rVWF) and tD ¼ 7125 22 ms (rVWF-IIC) are obtained.
FIGURE 4 Multimer analysis of rVWF using FCS. (A) Multicomponent
fit (red dotted line) of the autocorrelation function of physiological rVWF
(black line) leads to a size distribution that decays with the base p ¼ 0.64.
Furthermore, the single-component analysis (gray dashed line) fits the
distribution well, yielding an average multimer size of i ¼ 6.3 5 1.4
dimers. (B) With the multicomponent fit (red dotted line) for the patholog-
ical distribution rVWF-IIC (green line), the base is determined to be p ¼
0.18, indicating the lack of large VWF multimers. Single-component fit
(gray dashed line) infers an average multimer size of i ¼ 2.05 0.1 dimers.
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is N0(i) ¼ i2 N(i), which exhibits a sharp maximum at the
average multimer size i ¼ 4.7. Due to the narrow weighted
distribution function, the multicomponent fit appears to be
close to the fit of a single species. The average multimer
size is in good agreement with the average multimer size ob-
tained with single-component analysis that yields i ¼ 6.35
1.3 for rVWF (for details see the Supporting Material S1).
For the mutant rVWF-IIC with p ¼ 0.18, an average multi-
mer size of i ¼ 1.5 is calculated compared to i ¼ 2.0 5 0.1
measured with the single-component fit. However, it is
important to note that the proper multicomponent analysis
using the proposed exponential size distribution N(i) de-
scribes the measured autocorrelation function the best
within the experimental accuracy.
Direct imaging of VWF with TIRFM
The data presented so far reveals an exponential size distri-
bution of VWF. Using TIRFM, we confirmed these results
by direct imaging. Under continuous excitation, the fluores-
cence signal of rVWF-eGFP was observed to decrease in
discrete steps over time. As described in (40) and explained
in detail in the Supporting Material S3, the number of
bleaching steps can be taken as a measure for the number
of eGFP-tagged VWF monomers. Counting bleaching steps
therefore provides a means for analyzing the VWF size
distribution. Measurements of an rVWF dimer sample
proved that this analysis method is indeed suitable for our
samples (see the Supporting Material S3).
For localizing the rVWF multimers, an average image of
the first 100 frames was calculated (Fig. 5 A) and regions of
interest were selected. Bleaching steps in the intensity-time
traces of these regions were identified with the step detec-
tion algorithm described in (41) (Fig. 5, B and C). The rela-
tive frequency for detecting a certain number of steps was
plotted versus the number of steps (Fig. 5 D) and each
step number was assigned to a certain multimer size. As
we count the multimer size in number of dimers i but the
bleaching steps scale with the number of monomers, two
bleaching steps add up to an increase of one in the multimer
size. Odd numbers of bleaching steps were round up to the
next even number. The thereby obtained size distribution
N(i) was plotted versus the multimer size in number of
dimers i. Fitting yields an exponentially decaying size distri-
bution N(i) ¼ N1pi-1 with a base p ¼ 0.29 (Fig. 5 D),
convincingly confirming the findings from quantitative gel
analysis and FCS.
Effect of ADAMTS13 cleavage on VWF size
distribution
The VWF size distribution is after secretion into the blood
plasma dynamically controlled by the protease ADAMTS13
(Fig. 1 D) with defects in ADAMTS13 activity resulting in
unusually large VWF that cause thrombotic thrombocyto-
penic purpura. We investigated this time-dependent evolu-
tion of the VWF size distribution with FCS and found
systematic shifts to smaller multimer sizes that are no
longer exponentially distributed. Various concentrations of
ADAMTS13 were used to visualize different cleavage
states. rVWF concentrated to 65% of normal plasma con-
centration (0.65 units/ml) was digested by 0.12, 0.25, and
1.00 units/ml ADAMTS13. As expected, the cleavage due
to ADAMTS13 shifts the autocorrelation curves to higher
particle numbers (lower amplitude) and shorter diffusion
times (steeper decay). It is not possible to describe these
autocorrelation curves with a multicomponent analysis
with an exponentially decaying size distribution N(i), indi-
cating that the cleavage changes the shape of the distribu-
tion. Yet, using single-component analysis it is possible to
extract average diffusion times of tD ¼ 1045 ms, 813 ms,
and 617 ms (0.12, 0.25 and 1.00 units/ml ADAMTS13)
(Fig. 6 A). We find an exponential dependence of the
average multimer size in terms of dimer number i on the
FIGURE 5 Direct imaging of rVWF using TIRFM. (A) TIRFM image of
VWFmultimers immobilized on a glass surface. The multimer size is deter-
mined by counting eGFP bleaching steps as each rVWFmonomer is labeled
with one eGFP. The intensity-time traces of the two highlighted molecules
represent an 8-mer (B) and a dimer (C). The positions of the counted steps
are indicated with arrows. (D) The relative frequency for detecting a certain
number of steps in the intensity trace is shown as a bar chart. Size distribu-
tion analysis of N(i) (black squares) yields, in good agreement with the
results from quantitative gel analysis and FCS, an exponentially decaying
size distribution N(i) ¼ N1pi-1 (red dots) with the base p ¼ 0.29.
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ADAMTS13 concentration with i ¼ 4.5, 2.6, and 1.2, corre-
sponding to 0.12, 0.25, and 1.00 units/ml concentration of
ADAMTS13 (Fig. 6 B).
To get an estimate of the size distribution in the presence
of ADAMTS13, the cleavage process was simulated based
on a model that assumes random cleavage sites combined
with equal cleavage probability for all multimer sizes
(Fig. 6 C). Starting with the measured exponentially shaped
multimer distribution, each iteration cuts each multimer
once at a random site. For each iteration, the average multi-
mer size of the generated size distribution is calculated and
plotted against the number of cleavage steps (Fig. 6 D).
Comparison of experiment and simulation (Fig. 6, C and
D), shows that the average multimer size scales exponen-
tially with the number of cleavages of each molecule, with
~0.1 units/ml ADAMTS13 and one cleavage step resulting
in the same average multimer size. This means that a 0.1
units/ml ADAMTS13 concentration is necessary to cleave
each molecule of a 0.65 units/ml VWF concentration once
within 5 h.
DISCUSSION
In this article, we found independent evidence that the size
of recombinant VWF is exponentially distributed. First
quantitative gel analysis of VWF based on antibody staining
indicates an exponential size distribution, second a FCS
multicomponent analysis of recombinant VWF-eGFP
proves consistent with the proposed distribution function,
and finally the frequency distribution obtained from direct
single molecule fluorescence imaging yields an exponential
dependence for the first five VWF-eGFP multimer sizes. An
exponential size distribution as such is not unexpected and
well known for both equilibrium polymers (42) and linear
condensation polymers (8). An equilibrium polymer forms
by reversible association of subunits with mutual binding
constant affinity. Prominent examples for equilibrium poly-
mers are actin, microtubulin, and other cytoskeleton fila-
ments (43). Linear condensation polymers are formed by
irreversible growth mechanisms. It is well established that
VWF is a covalently linked multimer as the VWF multime-
rization occurs via formation of disulfide bonds. Further-
more, it is understood that the VWF multimerization takes
place in the Golgi, where the propeptide of VWF itself
acts as oxidoreductase, thereby facilitating disulfide bond
formation that allows VWF to polymerize in this compart-
ment (12–14). An exponential size distribution results if
the reactivity of subunits is independent of the segment
size and takes place in a finite compartment. In this case,
the molar fraction of segments containing i subunits is given
by Eq. 1. The distribution is fully determined by a single
parameter, the extent of polymerization, p. This extent of
polymerization is limited both by the reaction rate of the
VWF molecules to each other and by the reaction time,
which is determined by the time the VWF remains in the
Golgi. We find that the fraction of polymerized dimers is
prVWF ¼ 0.70 5 0.02 for rVWF and prVWF-IIC ¼ 0.22 5
0.01 in case of the pathological form rVWF-IIC. It is note-
worthy that for the disease mutant VWF-IIC, the exponen-
tially decaying size distribution is maintained indicating
that the mechanism of biosynthesis is the same. As
aberrances in the size distribution of VWF-IIC are caused
by mutations in the VWF propeptide that prevent multime-
rization in the Golgi (44), a decreased reaction rate can be
assumed and explains the lower extent of polymerization.
The fact that the exponential VWF size distribution is in
accordance with a step-growth reaction mechanism allows
the quantification of a VWF distribution by a single param-
eter. Knowing the extent of polymerization p yields the
entire range of multimers. An interesting finding is the
fact that the extent of polymerization is in general fairly
low with far less long multimers being formed than hitherto
expected. For the physiological distribution rVWF, 30% of
VWF dimers remain as non-polymeric species. Multimers
consisting of five or more dimers account for only 24% of
the total number of VWF molecules whereas multimers
containing 10 or more dimers represent just 4%. Hence,
the polymeric form of VWF that is supposed to be the one
most relevant for VWF function is a minority species
of VWF. Secondly, as characteristic for the base of an
FIGURE 6 Multimer analysis after ADAMTS13-induced proteolytic
cleavage. (A) Varying concentrations of ADAMTS13 are used to visualize
different cleavage states. Correlation curves of rVWF distribution are
shifted toward lower correlation times and higher particle concentrations
(lower G(0)) with increasing protease concentration. (B) Single-component
analysis indicates an exponential decay of the average multimer sizes
with increasing ADAMTS13 concentration. (C) Simulation of a random
cleavage process shows the changes in the size distribution due to
ADAMTS13 cleavage. (D) Average multimer sizes decrease exponentially
with an increasing number of cleavage steps per molecule. Comparing the
decay constant in (B) and (D), ~0.1 units/ml ADAMTS13 and one cleavage
step per molecule lead to a similar effect on the average multimer size.
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exponential function, already small changes in p have a
strong leverage on the multimer distribution and conse-
quently a detrimental impact on the physiological state. A
loss of 25% in the extent of polymerization reduces the
number of 10mers by a factor of 100.
The size distribution of VWF is changed upon secretion
to the blood plasma by ADAMTS13-induced cleavage.
We used rVWF to mimic this cleavage process. Varied
cleavage states represented by different concentrations of
ADAMTS13 can be clearly distinguished from uncleaved
rVWF. The exponentially shaped size distribution is not
maintained during cleavage. Simulation of a random cleav-
age process allows us to relate the ADAMTS13 concentra-
tion to a certain number of cleavage steps. We show that
cleavage with 0.1 units/ml ADAMTS13 concentration under
partly denaturing condition in urea has the same effect on
the average multimer size as cutting each VWF molecule
once at a random site. In blood plasma, ADAMTS13-
induced cleavage is assumed to require shear-induced
stretching of VWF. We find that the size distribution of
healthy patients exhibits almost the same exponential size
dependence as recombinantly expressed VWF. Small devia-
tions at larger size fractions could be indicative of extracel-
lular ADAMTS13 activity in blood flow. Interestingly, the
size distribution of patients exhibiting von Willebrand
disease type IIC showed less deviation from the normal
case as predicted from the recombinant expressed VWF-
IIC. It must be assumed that the deficiency in the extent
of polymerization is partly compensated, possibly by
VWF expelled from Weibel-Palade bodies. Plasma VWF
is essential for the initiation of blood coagulation but is
immediately joined by VWF stored in the granules of endo-
thelium cells (Weibel-Palade bodies) at the beginning of
hemostasis so that long VWF multimers can be provided
whenever needed.
From a measurement technique point of view, we showed
that FCS is capable of following the evolution of VWF size
distribution under blood plasma conditions. This opens up
the possibility to use recombinant VWF-eGFP in combina-
tion with FCS as a diagnostic assay for ADAMTS13 activity
in hematology. Moreover, FCS has the capability to use
shear forces during measurement. Therefore, experiments
with urea as a stretcher could become redundant and be
replaced by measurements under shear flow in situ.
CONCLUSION
In this work, we reported on the exponential size distribu-
tion of recombinant and physiological VWF multimers.
We found evidence that the exponential distribution is the
generic outcome of VWF biosynthesis as disease-related
VWF mutant VWF-IIC also exhibits an exponential size
distribution, albeit with a smaller extent of polymerization.
In light of this finding, we hypothesize that the disease-
related mutation type IIC affects the polymerization reac-
tion. We show that FCS allows for monitoring the change
in VWF-eGFP size distribution under blood plasma condi-
tions over time. In particular, ADAMTS13 activity was
measured and it was shown that the decreasing average
VWF size is in agreement with the expected evolution of
an exponential distribution under random cleavage. We
believe that the extent of polymerization, describing the
size distribution of VWF, provides a valuable indicator in
VWF-related disease diagnostics and that FCS proves
valuable as a quantitative tool to follow the evolution of
VWF size distribution in vitro over time.
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Shear-Induced Cleavage of VWF
In this chapter, a study on full-length VWF cleavage under shear flow is presented. Due to the
size dependent functionality of VWF, its degradation by the metalloprotease ADAMTS13 is
a determining factor in hemostasis. ADAMTS13 cleaves VWF within the mechanosensitive
A2 domain, which is believed to open under shear flow. Quantifying the effect of shear is
essential in order to enable predictions of hemostatic dysfunctions of mutant VWF. Therefore,
the interrelation of shear-flow, VWF unfolding, opening of the mechanosensitive A2 domain,
and ADAMTS13 activity is currently a highly debated topic. Yet, the enzymatic activity of
ADAMTS13 on full-length VWF had not been measured under flow conditions.
Here, FCS was used in combination with a custom-built microfluidic shear cell to investi-
gate ADAMTS13-mediated cleavage of full-length VWF as a function of shear rate. This
novel approach allowed, for the first time, to quantify the effects of shear on the kinetics of
VWF cleavage in blood plasma. The presented measurements reveal a remarkable Hill-type
behavior with a sigmoidal increase in activity with increasing shear. The data are in good
agreement with Brownian hydrodynamics simulations of shear-dependent polymer unfolding,
which were performed by the group of Prof. Netz. Besides, a strong increase in ADAMTS13
activity under blood plasma conditions was observed, suggesting the involvement of hitherto
unknown accessory factors in the blood plasma. This study combined a novel biophysical
methodology with theoretical simulations and clinically relevant VWF mutations to quantify
VWF cleavage. In addition, the findings represent a significant contribution to the general
understanding of shear-induced unfolding of multimeric proteins, with important implications
for ADAMTS13 and VWF-related hemostatic dysfunctions.
The experimental data and the resulting conclusions are presented in the following manuscript:
S. Lippok, M. Radtke, T. Obser, L. Kleemeier, R. Schneppenheim, R.R. Netz, J.O. Rädler.
”Shear dependency of ADAMTS13-mediated cleavage measured on full-length VWF under
blood plasma conditions.” PNAS, under review
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ABSTRACT 
Proteolysis of the multimeric hemostatic protein von Willebrand Factor (VWF) by 
ADAMTS13 is crucial for prevention of microvascular thrombosis. ADAMTS13 cleaves 
VWF within the mechanosensitive A2 domain, which is believed to open under shear flow. 
Yet, the enzymatic activity of ADAMTS13 on full-length VWF has not been measured under 
flow conditions. Here, we combine Fluorescence Correlation Spectroscopy (FCS) and a 
microfluidic shear cell to monitor real-time kinetics of full-length VWF proteolysis as a 
function of shear stress. Without shear, ADAMTS13 cleaves wild-type VWF with Michaelis-
Menten type activity (KM = 171 ± 85 nM) only under partially denaturing conditions (1.5 M 
urea), while cleavage of the pathological mutant VWF-G1629E occurs in the absence of 
denaturants. Under shear, ADAMTS13 activity on wild-type VWF exhibits a sigmoidal 
increase with half-maximum shear rate 21γ& = 5360/s and cooperativeness coefficient n = 5. 
Brownian hydrodynamics simulations quantitatively reproduce the observed shear 
dependence in terms of the shear-induced tension profile along VWF multimers. Experiments 
under physiological conditions show five-fold increas d cleavage rates in comparison to 
buffer, while cleavage is inhibited in patient blood containing anti-ADAMTS13 antibodies. 
Our findings for the first time quantify the flow-rate dependence of ADAMTS13 activity in 
blood plasma, which, in case of mutant forms of VWF, is relevant to the prediction of 
hemostatic dysfunction.  
 
SIGNIFICANCE  
 
Mechanosensitive degradation of multimeric von Willebrand Factor (VWF) by ADAMTS13 
is crucial for hemostasis. Hydrodynamic shear is thought to make its A2 domain susceptible 
to proteolysis. Quantification of this effect in wild-type VWF in combination with biophysical 
modeling is essential to enable prediction of hemostatic dysfunction of mutant VWF. We 
report the first characterization of full-length VWF cleavage by ADAMTS13 as a function of 
shear rate, including the Michaelis-Menten constant i  buffer and blood plasma. The shear-
dependence is rationalized by hydrodynamic modeling of shear-dependent polymer unfolding. 
As well as providing the first quantitative evidenc for dependence of proteolysis on shear-
induced opening of VWF, the work represents a methodological advance, which will facilitate 
future studies on VWF mutations in coagulation disorders.  
INTRODUCTION  
In the event of vascular injury, the multimeric plasma protein von Willebrand Factor (VWF) 
mediates platelet adhesion, aggregation and crosslinking to maintain hemostasis [1,2]. VWF 
is either constitutively secreted into the circulation or is stored in Weibel-Palade bodies and 
released in the form of ultralarge multimers in response to physiological and 
pathophysiological stimuli [3]. A carefully controlled balance of VWF binding and 
crosslinking, and VWF degradation and cleavage by ADAMTS13 (a disintegrin and 
metalloprotease with thrombospondin type 1 motif, member 13) [4-6], is required for 
hemostasis. Here, fluid shear stress plays a key rol : It initially activates the binding of the 
VWF A1 domain to platelets, and regulates over time additionally VWF degradation by 
opening the A2 domain, exposing the cleavage site for ADAMTS13 [7,8]. Hence, force-
controlled activation and cleavage of VWF is part of a feedback loop that balances 
hemostasis. Absence of ADAMTS13 causes the life-thratening disease thrombotic 
thrombocytopenic purpura (TTP), which is characterized by uncontrolled microvascular 
thrombosis [5,9]. ADAMTS13 may also control the size distribution of VWF in the 
circulation, since the effect of shear stress depends on the hydrodynamic drag and hence on 
the size of VWF multimers [10]. 
The mechanism of shear-induced unfolding of VWF has been explored in several studies in 
the recent past [11,12]. VWF is cleaved by breakage of the Tyr1605-Met1606 bond in its A2 
domain, which is a deeply buried cleavage site [13,14]. The interaction of immobilized VWF 
or VWF fragments with ADAMTS13 fragments or variants has been characterized in buffer 
using ELISAs [7,15]. Recognition of recombinant VWF fragments by recombinant 
ADAMTS13 has been examined under both denaturing [16] and non-denaturing conditions 
[17]. In a seminal study by Zhang et al. using laser tweezers, force was applied directly to 
single A2 domains in buffer and the dependence of the catalytic rate on the enzyme 
concentration was measured [14]. Pulling at the ends of polymeric molecules results in a 
homogenous force profile along the polymer chain under equilibrium conditions. However, 
simulations of unfolding under shear flow reveal that the intramolecular forces in VWF are 
inhomogenous and fluctuating [18,19]. Therefore, clavage probabilities under shear flow are 
expected to show a size dependence and more and less susceptible intramolecular regions may 
exist. In particular, ADAMTS13 is not expected to act on the full-length protein in the same 
fashion as on isolated fragments. 
 
We have recently shown that Fluorescence Correlation Spectroscopy (FCS) allows one to 
measure the size distribution of VWF [20]. In addition, FCS can be used to monitor binding in 
complex fluids such as blood plasma [21] and provides information on macromolecular 
dynamics [22-24]. This is of particular interest for studies of VWF, since it is assumed that 
unidentified enhancers of ADAMTS13 activity are present in plasma, whose effects cannot be 
mimicked in experiments performed in buffer [25]. Moreover, since the sample size required 
is very small, FCS studies can easily be combined with microfluidic devices [26,27]. 
 
In this paper, we study the cleavage of VWF by ADAMTS13 under shear flow in aqueous 
buffer and in blood plasma. Using FCS, we detect the breakdown of VWF-eGFP by 
measuring the increase in VWF number concentration. A specially designed shear cell, 
combined with an FCS setup, allows us to monitor the cleavage of recombinant full-length 
VWF-eGFP as a function of shear flow. With this approach, we analyzed VWF cleavage 
under denaturing conditions as a reference and the obs rved Michaelis Menten constant was 
compared with that obtained for the disease-related mutant VWF-G1629E, which is 
abnormally sensitive to proteolysis [17]. We showed that cleavage of rVWF under shear flow 
in blood plasma can be followed over time. In normal pl sma, enhanced proteolytic activity 
was found, presumably due to hitherto unknown accessory factors. We then determined 
cleavage rates as a function of shear rate. In agreement with Brownian hydrodynamics 
simulations, the shear dependence exhibited a Hill-type sigmoidal with a half-maximum shear 
rate 21γ& = 5360/s and a cooperativeness coefficient of n = 5. Theoretical modeling enabled us 
to calculate the degree of flow-induced polymer unfolding and extract the probability of 
opening of the A2 domain from the distribution of tension along the coarse-grained polymer 
model of VWF. 
 
RESULTS 
Cleavage of full-length rVWF follows Michaelis-Menten kinetics. In this study, we 
adopted a novel approach to study VWF proteolysis, ba ed on the use of recombinant VWF-
eGFP (rVWF) fusion as substrate. Each VWF monomer is thus labeled with a single eGFP 
unit, and therefore cleavage of the rVWF-eGFP multiers results in an increase in the number 
of fluorescent molecules. We monitor this increase u ing the amplitude of the fluorescence 
correlation signal, G(0), which is inversely proporti nal to the average particle number N in 
the detection volume (see Figure 1 and Supporting Information S1). To test this concept, we 
performed cleavage experiments in denaturing buffer that unfolds VWF (Figure 2). Figure 2A 
displays the decrease in G(0) with cleavage over time, which reflects an increase in the molar 
concentration of rVWF (CVWF). The rVWF concentration increased linearly, with the cleavage 
rate dCVWF/dt depending on the ADAMTS13 concentration used (Figure 2B). For constant 
amounts of ADAMTS13, the cleavage rates increased hyperbolically as a function of the 
VWF concentration (Figure 2C). We fitted the curves with Michaelis-Menten kinetics 
dCVWF/dt = vmaxCVWF/(CVWF+KM) imposing the constraint that the KM value does not depend 
on the enzyme concentration. With this global fitting, we obtain KM = 171 ± 85 nM and 
vmax = 358 ± 118 pM/min for the physiological ADAMTS13 concentration (1 µg/ml), 
designated here as 1 U/ml. A tenfold increase in protease concentration (10 U/ml) resulted in 
a doubling of the maximum cleavage rate (vmax = 584 ±193 pM/min). The goodness of fit for 
vmax is, however, limited, and this might explain the lower than expected increase in this 
parameter at the higher ADAMTS13 concentrations. Autoproteolysis of ADAMTS13 at high 
concentrations may also play a role.  
Shear-induced rVWF cleavage. A shear cell was built that could be mounted on a 
microscope stage in combination with an FCS setup. We chose a Mooney-type design for the 
shear cell, consisting of a cylindrical container and  rotating inner cylinder with a conical tip, 
which generates constant shear rates throughout the sample volume of 150µl (see Figure 3A). 
This device allowed us to monitor enzyme activity under shear flow with shear rates up to 
10.000/s. Since FCS measurements rely on diffusion, hearing and FCS data sampling had to 
be run in an alternating mode: The solution was sheared and VWF cleaved for 15 min, and 
this was followed by a 15-min FCS detection period in the absence of shear, during which the 
VWF concentration was determined (Figure 3A). A typical experiment consisted of 16 such 
cycles. At zero shear rate,  = 0/s, cleavage rates w re very low, less than 2pM/min. 
However, higher shear rates did indeed results in increasing rVWF concentrations 
(Figure 3B). The full shear rate dependence was studied for cleavage of 10 nM rVWF at two 
different ADAMTS13 concentrations in buffer, with applied shear rates ranging from 0/s to 
10.000/s (Figure 3C,D). The data show negligible enzymatic activity at low shear rates, with 
cleavage rates equivalent to that at zero shear, which is at the limit of resolution of the 
experiment. Significantly lower cleavage rates were detected for 1 U/ml ADAMTS13 
compared to 10 U/ml. The increase in ADAMTS13 activity with shear could be described by 
an exponential ( )γγαγ ~/exp)(/ &&& =dtdC , in which case a characteristic shear rate γ~&
= 1090 ± 44 s-1 is obtained (Figure 3C,D dashed lines). However, btter agreement with data 
is found when fitting a power law nadtdC γγ && =)(/  with exponents nU1 = 2.7 and nU10 = 3.6 
(see bold dotted lines in Figure 3C,D). At even higher shear rates, above 5000/s, a new regime 
appears, where FCS correlation curves detect aggregation of the VWF multimers. This 
process appears to be irreversible and the aggregates impede determination of reliable 
cleavage rates. Details of the course of aggregation, which might be due to shear-induced 
opening of intermolecular binding sites, are given in Supporting Information S2. 
Cleavage of the mutant rVWF-G1629E. Next, we asked whether ADAMTS13 cleaves 
disease-related VWF mutants with altered kinetics. We studied VWF-G1629E, which carries 
a mutation within the A2 domain near the site cleaved by ADAMTS13, as schematically 
depicted in Figure 4A. The G1629E mutation is believ d to keep the domain permanently 
unfolded [17]. In agreement with this assumption, strong ADAMTS13 activity was detected 
even at zero shear. In order to compare the cleavag rates with those for wild-type rVWF, we 
plotted the mutant data together with the ADAMTS13 activity previously measured under 
denaturing conditions. Strikingly, although the enzyme concentration used in the mutant case 
is 200-fold lower (0.05 instead of 10 U/ml), the rates are comparable (Figure 4B). This 
confirms that the mutant VWF is far more susceptible to proteolysis than the wild type, 
leading to the loss of large multimers and ultimately o the significant bleeding symptoms 
seen in patients with the mutation G1629E.  
Hydrodynamic Computer Simulations. Our experiments show that rates of cleavage by 
ADAMTS13 in the regime of elevated shear rates very s nsitively depend on the precise shear 
rate and that, in agreement with the general belief, mutations in the A2 domain can 
dramatically lower the shear rate at which cleavage becomes significant. In order to 
corroborate the concept of shear-induced opening of the A2 cleavage domain, we compared 
the measured shear-dependent cleavage rates with simulations of the tension profile in 
unfolded VWF. To this end, we modeled the VWF polymer as a chain of weakly aggregating 
beads connected by stiff springs and performed Brownian dynamics simulations including 
hydrodynamic interactions [18,28,29]. In our simulation model, spherical beads of radius a 
represent VWF's repeating units (dimers), which interact with a cohesive strength ε. Rescaled 
shear rates γτ  were used, with the characteristic diffusion time of a single bead being given 
γ&
by τ=6πηa3/kT. Thus, the simulation results apply to arbitrary values of radius and 
viscosity. In order to obtain physical units, we chose to set a=45nm and  η=1.2x10-3 Pas. The 
remaining free parameter is the cohesive strength ε, which strongly influences the shear rate at 
which unfolding sets in. This parameter was set at 1.2 kT, such that, in the absence of shear 
flow, the polymer is collapsed, and the unfolding transition occurs at a shear rate close to the 
experimental data. A different choice for the radius would shift the unfolding transition to 
different shear rates and the cohesive strength could be altered to reproduce the 
experimentally observed data. We calculated tension pr files along the chain of beads under 
shear flow as a function of polymer size and shear rate (Figure 5). Figure 5A shows the 
profile of the average tension along the VWF polymer for a representative polymer size of 20 
beads (tension profiles of 10mer and 30mer are depicted in Supporting Information S3). The 
distribution exhibits a flattened profile with minimal tension at the ends and its curvature 
increases with increasing shear rate. Strong fluctuations are indicated by the high standard 
deviation σ shown for γ&  = 15.000/s. Typical snapshots of the 20mer unfolded by shear flow 
are illustrated in Figure 5B. In order to connect the ension profile with the cleavage activity, 
we make the key assumption that there exists a critical tension, above which a single subunit 
opens and becomes accessible for cleavage by ADAMTS13. To illustrate this point, the 
normalized tension distribution P(f) of a single bead (i=10) in a 20mer is shown in the inset of 
Figure 5C. With increasing shear, the tension distribution broadens and shifts toward higher 
tension. The opening probability for a single bead is obtained by calculating the fraction 
Pi(f>fc) that exceeds a critical force fc. We define the opening probability for the whole 
multimer as the probability that at least one cleavage site is accessible, 
( )∏ >−−=
N
ciopen ffPP
1
(11)(γ&  , and plot the results for different VWF sizes N in Figure 5C. 
The shear dependence of the open fraction is well described by a Hill-type sigmoidal 
( ) nP −+= 211
1
)(
γγ
γ
&&
&  (Figure 5C, dotted lines). Here, 2/1γ&  denotes the half-maximum shear 
rate, at which half of the polymers are open and n the cooperativeness coefficient. We obtain 
increasing values for 2/1γ&  with decreasing polymer size N (2/1γ& (N=10) = 4.3⋅ 104 s-1, 2/1γ&
(N=20) = 2.4⋅ 104  s-1, 2/1γ& (N=30) = 2.0⋅ 104  s-1) and cooperativeness coefficients n10 = 4.9, 
n20 = 5.3, and n30 = 6.1. In the simulation, a critical opening force of fc = 2.9 pN was chosen to 
ensure that a vanishing opening probability of well b low 1% is obtained for low shear rates. 
A lower critical force leads to higher opening probabilities at low shear but does not affect the 
characteristic increase for high shear rates (see Supporting Information S4).  
 
Shear-induced cleavage in blood plasma. We were particularly interested in characterizing 
the shear dependence of VWF proteolysis in blood plasma (Figure 6). Therefore, rVWF-eGFP 
was added to patient's blood plasma and studied in the FCS-shear cell. In this case, no 
ADAMTS13 is added, since normal plasma contains natural ADAMTS13. In this setting, 
both the recombinant VWF as well as the endogenous unlabeled VWF serve as substrates for 
ADAMTS13. For data analysis, we estimate the concentration of unlabeled VWF to be 3 nM 
(see Supporting Information S1). Figure 6A shows the cleavage rate as a function of VWF 
concentration under denaturing conditions in 25% normal plasma (NP) (0.25 U/ml 
ADAMTS13). For comparison, the plot also shows the data for (1 U/ml) ADAMTS13 in 
buffer (taken from Figure 2C). Straight lines indicate fits with the same KM = 171 nM value, 
but different vmax = 505 ± 37 pM/min (NP) and vmax = 358 ± 118 pM/min (buffer), 
respectively. The patient's plasma used in Figure 6B contained anti-ADAMTS13 
autoantibodies (AB plasma) and cleavage rates are considerably reduced (3.13 ± 1.5 pM/min 
instead of 18.24 ± 2.0 pM/min). Figure 6C shows the cleavage rate as a function of shear. 
Importantly, we did not find any evidence for VWF aggregation in experiments with blood 
plasma. We were therefore able to measure VWF cleavage in blood plasma up to 
 = 10.000/s. In order to exclude the possibility that VWF concentration might increase under 
high shear over time due to solvent evaporation, we carried out a control experiment on pure 
eGFP protein, which shows only a small concentration increase of 6% in buffer subjected to a 
shear rate of  = 8400/s over 2.5h. Under shear, rVWF in 50% NP exhibits, as predicted by 
the simulation, a Hill-type sigmoidal increase with increasing shear rates. For the 50% AB 
plasma with reduced ADAMTS13 activity, we find the same sigmoidal dependence on shear, 
but overall reduced cleavage rates. The experimentally determined dependence on shear rate 
is in good agreement with the hydrodynamic model. Assuming that the cleavage rate kCR is 
proportional to the shear-dependent unfolding probability: )(max γ&openCR Pkk ⋅= , the straight 
lines in Figure 6C are best fits with optimized prefactors kmax,NP = 243 ± 20 pM/min and 
kmax,AB = 101 ± 26 pM/min, respectively. Using a Hill-type function for )(γ&openP  as before, we 
obtain the half maximum shear rate 2/1γ& = 5358 ± 41 s
-1 and cooperativeness coefficient n 
= 4.8 ± 0.2 s-1. The opening probability is calculated based on the Brownian hydrodynamic 
model using a fixed parameter set (a = 90 nm, fc = 2.9 pN). Here, we average Popen over three 
different sizes N, as shown in Figure5C, and weight according to the size distribution ~pN-1 
with p=0.64 [20].The fact that the shear dependence of cleavage in both NP and AB plasma 
has the same shape is a strong indication that VWF unfolding is the determining mechanism, 
while the concentration of available ADAMTS13 just sets the prefactor. 
 
DISCUSSION: 
Using FCS and recombinant rVWF-eGFP, we have measurd the ADAMTS13 activity in 
real-time. In denaturing buffer, we observed Michaelis-Menten kinetics with 
KM
VWF = 171 nM. At first glance, this value seems rather low by comparison with those 
obtained in recent experiments performed with VWF fragments: Zanardelli et al. measured 
KM = 1.61 µM by high pressure liquid chromatography for cleavage of a 16.9 kDa fragment 
of the VWF A2 domain [30]. In experiments using gel analysis and ELISA, Gao et al. 
obtained KM = 1.7 µM for cleavage of an A2 domain fragment consisting of amino acid 
residues Asp1596-Arg1668 [7]. Both values seem to reflect lower proteolytic a tivities than 
found in our work. However, our data, for the first time, yield rates of full-length VWF 
cleavage. Consequently, our KM is expressed in terms of the molar concentration of 
multimeric VWF. If converted into molar concentration of VWF cleavage sites, using an 
average number of 12.6 monomers per VWF molecule [20], we obtain an effective monomer 
Michaelis-Menten constant KM
mono = 2.1 µM, in good agreement with the results for VWF 
fragments. 
γ&
γ&
 
The unfolding of VWF under shear is known as a globu ar-stretch transition and it has long 
been speculated that its susceptibility to proteolysis is modulated by force-induced extension. 
We find that the shear dependence in experiment is accurately described by Brownian 
dynamics simulations. Experiment and theory both exhibit an Hill-type sigmoidal dependence 
on shear with half maximum shear rate 2/1γ&  = 5358/s and cooperativeness coefficient n = 4.8. 
These findings are in line with earlier observation of abrupt onset of VWF unfolding as a 
function of shear rate using fluorescence microscopy and small-angle neutron scattering 
[11,12]. The relationship between VWF unfolding and cleavage activity can be accounted for 
by assuming that the A2 domain opens when the force exerted on it exceeds a critical value. 
Using Brownian hydrodynamics simulations, we determined the tension induced by shear 
flow along the backbone of unfolded VWF multimers. By comparison with the cleavage data, 
we yield a critical force fc = 2.9 pN for the opening of the A2 domain. This parameter has also 
been calculated by molecular dynamics (MD) simulations [8] and independently measured 
with optical tweezers [14]. The former yielded values of up to 1000 pN, and are likely to be 
significantly overestimated, owing to the short (nanosecond) time-scale of MD simulations. In 
contrast, the unfolding forces measured with optical weezers are in the same range (5-20 pN) 
as those presented here. However, optical tweezers apply homogenous forces to VWF, while 
shear flow leads to an inhomogeneous force distribution with strong fluctuations. Since 
mutations in VWF’s A2 domain are known to affect the opening force, a model of shear-
induced-opening might be constructed, which could relate mutations directly to hemostatic 
dysfunction. Future work may thus close the gap betwe n the atomistic models and the 
coarse-grained hydrodynamic model used in this work. 
Measurement of ADAMTS13 activity in its natural environment, namely blood plasma, is of 
clinical importance, and fluorescence-based assays h ve the advantage of being readily 
applicable to body fluids. In this work, we determined the kinetics of rVWF-eGFP cleavage in 
25% normal blood plasma and found that the rate of pr teolysis is increased more than five-
fold relative to experiments performed in buffer. This finding corroborates a previous 
hypothesis, which suggested that certain components found in blood, such as coagulation 
factor VIII,  increase VWF's susceptibility to cleavage [31]. The enhancement of proteolysis 
is attributed, inter alia, to the conformational change induced in VWF by the binding of factor 
VIII [32]. Other cofactors and their effects on VWF have not yet been studied, but might 
provide novel therapeutic targets. FCS-based measurments of rVWF-eGFP cleavage may 
also have diagnostic potential. Determination of leve s of ADAMTS13 activity in plasma is, 
for example, required for differential diagnostics n microangiopathies. The sensitivity of the 
conventionally used assays is hitherto limited, especially at clinically relevant, pathologically 
low ADAMTS13 levels. FCS combined with recombinant VWF-eGFP added to patient 
samples permits detection of extremely low levels of ADAMTS13 activity. Even higher 
detection limits, well below 5%, can be achieved, if the extremely proteolysis-sensitive 
rVWF-G1629E is employed as a substrate. However, as indicated by the mechanism of shear-
induced unfolding and opening, ADAMTS13 concentration is only one determinant of 
pathology, while mutant forms of VWF itself are likely to make a much greater contribution 
to hemostatic dysfunctions. FCS can help to quantify the effect of mutations and assess the 
impact of potential drugs. In this context, the ability to measure specific cleavage activity on 
VWF in native blood samples constitutes a valuable extension of available methods, as it 
provides insight into the dynamics of the hemostatic network.  
MATERIALS AND METHODS 
Protein expression: The recombinant fusion protein rVWF-eGFP was expressed and purified 
as described in detail before [20]. For the mutant VWF-G1629E, the plasmid PIRESneo2-
VWF-G1629E-eGFP was used, which was produced by in vitro mutagenesis of wild-type 
pIRESneo2-VWF-eGFP by replacing wild-type codon 1629 for glycine with the naturally 
occurring mutant codon specifying glutamic acid (p.Gly1629Glu). Wild type rhuADAMTS13 
used was produced as described in [17]. 
Plasma samples were taken from normal volunteer donors and collected in S-monovettes, 
coagulation sodium citrate (Sarstedt, Germany), incubated at room temperature (30 min), and 
centrifuged (10 min, 2300 rpm). The supernatant was aliquoted and stored at −80°C until use. 
Informed consent was obtained from all subjects. 
Fluorescent Correlation Spectroscopy (FCS) measurements were performed on an Axiovert 
200 microscope with a ConfoCor 2 unit (Carl Zeiss, Jena, Germany), equipped with a 40x 
(NA = 1.2) water-immersion Apochromat objective (Carl Zeiss). A 488 nm argon laser was 
used for illumination. For calibration, eGFP was measured for 20x60 s in the corresponding 
buffer. Experiments without shear flow were carried out in eight-well LabTek I chamber 
slides (Nunc, Rochester, NY) on rVWF for 20x15 min and on rVWF-G1629E for 20x9 min, 
(owing to its higher sensitivity to proteolysis). Correlation analysis was performed using the 
ConfoCor 2 software. The FCS data analysis is described in detail in Supporting Information 
S1. 
Shear cell: A custom-made shear cell was used to apply shear forces consisting of a 
combined cone-and-plate and concentric cylindrical design, called Mooney system [33]. A 
coverslip (Carl Roth, Karlsruhe, Germany) was fixed with nail varnish to a stainless steel 
sample holder containing wells of radii ro = 6.5 mm, serving as outer cylinders. The inner 
rotating cylinder (radius ri = 6.1 mm) was connected to a brushless motor with integrated 
controller (Faulhaber GmbH, Schönaich, Germany). Before use, both cylinders were first 
incubated for 30 min with UHT milk to avoid sticking of the sample to the surface, and then 
washed with buffer for at least ten times. For shear-flow measurements, periods of applied 
shear stress (15 min) without FCS recording alternad with measuring periods (5x3 min) 
without shear flow. 
Cleavage protocol: Measurements were conducted in either buffer or bl od plasma. The 
cleavage buffer contained 5 mM Tris-HCl (pH 8.0) with 10 mM BaCl2 for ADAMTS13 
activation [34,35]. For measurements without shear flow, 1.5 M urea was added to partially 
denature VWF based on the commonly used protocol [30,34,36]. For measurements in blood 
plasma, the plasma was diluted to the desired concentration with 5 mM Tris-HCl (pH 8.0). 
For all measurements, the temperature was set to 37°C (without shear: heating stage, ibidi 
GmbH, Martinsried, Germany; with shear: water bath, Julabo GmbH, Seelbach, Germany). 
Simulation methods: Brownian dynamics simulations were performed using a discretized 
Langevin equation, where hydrodynamic interactions are taken into account via the Rotne-
Prager tensor [37] (for details, see Supporting Information S3). The VWF was modeled as a 
homopolymer consisting of N beads, which interact via Lennard-Jones potentials of depth 
, and are connected in a linear chain by harmonic bonds with a rescaled 
spring constant . Tensile forces acting along each bond  
are recorded during the course of simulation. To compare the dimensionless quantities used in 
the simulation to physical values (marked by the tilde), we use the dimer radius a = 45nm, the 
viscosity η = 1.2x10-3Pas, and the temperature T = 310K. 
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Figure 1 
 
 
Figure 1: FCS analysis of the kinetics of VWF proteolysis. The correlation curve G(τ) at time 
0 is proportional to the reciprocal of the number of fluorescent molecules in the detection 
volume N = 1/G(0), i.e. the molar concentration of VWF. For multimeric rVWF-eGFP with 
one eGFP molecule attached to each VWF monomer, cleavag  by ADAMTS13 results in an 
increase in the number of fluorescent molecules. This increase in N concomitantly reduces the 
value of G(0) and can be detected in real-time. 
 
  
Figure 2 
 
 
Figure 2: Cleavage of full-length rVWF in buffer follows Michaelis-Menten kinetics. A 
Representative autocorrelation curves showing that pro eolysis of VWF is reflected in a 
progressive decrease in amplitude G(0) with time. B Molar concentration of rVWF molecules 
increases linearly over time and the cleavage rates depend on ADAMTS13 concentration. C 
The hyperbolic dependence of cleavage rate on VWF concentration was fitted with the 
Michaelis-Menten equation (dotted lines). Constraining a Michaelis-Menten constant 
independent of the enzyme concentration, we obtained KM = 171±85 nM, 
vmax = 358±118 pM/min (1 U/ml ADAMTS13), and vmax =584 ±193 nM (10 U/ml 
ADAMTS13). 
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Figure 3: Shear-induced cleavage of rVWF. A Cartoon illustrating VWF proteolysis under 
shear flow. The shear cell generates constant shear rates throughout the whole sample volume. 
Above a certain threshold, VWF unfolds, the A2 domains open and cleavage sites for 
ADAMTS13 are exposed. B Molar VWF concentrations at the end of each shear p riod are 
plotted as a function of the total duration of shear as shown here for  = 0/s and 5000/s. C 
rVWF cleavage rates (1 U/ml ADAMTS13) as a function of applied shear rates. D Use of a 
tenfold higher protease concentration (10 U/ml) signif cantly increases cleavage rates. 
Exponential (dashed lines) and power law (bold dotted lines) fits are plotted; better agreement 
is found for the power law. For shear rates > 5000/s, VWF aggregation becomes dominant 
over VWF cleavage. 
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Figure 4: Proteolysis of the disease-related mutant rVWF-G1629E. A Schematic drawing of 
the multidomain structure of a VWF monomer. The G1629E mutation is located close to the 
site cleaved by ADAMTS13 and results in constitutive opening of the A2 domain. B Kinetics 
of mutant cleavage in the absence of shear. In buffer without urea, the mutant exhibits 
significantly increased susceptibility to proteolysis as compared to rVWF in denaturing 
buffer. Note that cleavage rates in both cases are comparable, even though a 200-fold lower 
ADAMTS13 concentration (0.05 U/ml) was used in case of the mutant. Best Michaelis-
Menten kinetic fits are shown as dotted lines. 
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Figure 5: Results of hydrodynamic simulations of polymer response to shear flow. A The 
average tension <f> is plotted as a function of bead position i along a polymer of size N = 20. 
The tension exhibits a flat profile with a decrease t ach end of the chain and increases with 
increasing shear rate γ& . The standard deviation σ, plotted at the bottom for γ&= 15.000/s, 
indicates a broad distribution of the tensile forces. B Snapshots of typical polymer 
configurations obtained at different shear rates as indicated. C Opening probability Popen as a 
function of shear rate, obtained from the tension distribution P(f) of individual beads. P(f) for 
a single bead is shown in the inset (with increasing shear from dark to light). The opening 
probability of a single bead is defined as the probability that tension exceeds a critical value 
(fc) of 2.9 pN (indicated by a red dashed vertical line i  the inset). The opening probability 
Popen for the multimer is the probability that at least one cleavage site is accessible. It exhibits 
a Hill-type sigmoidal increase with increasing shear rates (sigmoidal fit: dotted lines). 
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Figure 6: VWF proteolysis in blood plasma. A Kinetic analysis of rVWF cleavage in 25% 
NP (0.25 U/ml ADAMTS13) yields vmax = 505 ± 37 nM at a fixed KM = 171 nM (Michealis-
Menten fit: blue dotted line). For comparison, the (lower) enzyme activity in buffer (1 U/ml 
ADAMTS13) is shown (grey). B Protease activity in normal versus patient's AB plasma. The 
patient's plasma exhibited a six-fold reduced protease activity under denaturing conditions. C 
Shear-flow induced cleavage in blood plasma. For both NP and AB plasma, cleavage rate 
increases following a Hill-type sigmoidal with increasing shear ( 2/1γ& = 5358/s, n = 4.8, 
sigmoidal fit: dotted lines). Decreased proteolytic activity was found for AB plasma. This is 
in good agreement with the hydrodynamic simulation model assuming that the cleavage rate 
kCR is proportional to the shear-dependent probability of opening:  (open 
markers) with enzyme activity dependent kmax = 243 pM/min (NP) and kmax = 101 pM/min 
(AB). 
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6
Destabilized recombinant VWF as Substrate for
ADAMTS13 Activity Assays
ADAMTS13 activity assays are the key laboratory finding in TTP diagnostics. In these assays,
the enzymatic activity is indirectly detected via the cleavage of substrate VWF. However, this
poses the challenge that the A2 cleavage domain of full-length VWF needs to be open to
provide access for ADAMTS13, as demonstrated in the previous chapter. Thus, either VWF
fragments or denaturing buffers are commonly used. Under these constraints, standard coagu-
lation tests for the detection of ADAMTS13 activity are still limited by reproducibility and
insufficient sensitivity for ADAMTS13 concentrations of less than 5 % of the physiological
plasma level. Yet, these low concentrations are known to result in TTP. Thus, exact quantifi-
cation is needed for adequate therapies.
We established an assay that applies a recombinant fusion protein of the destabilized mutant
VWF-G1629E as enzyme substrate. We analyzed the increased sensitivity in terms of enzyme
kinetics and found cooperative Hill-type behavior in addition to a highly increased affinity
to ADAMTS13 compared to VWF-wt. Using the mutant enabled us to detect ADAMTS13
activity levels down to 0.5 %, which is 5- to 10-fold more sensitive than commonly used as-
says. Molecular Dynamics Simulations (Prof. Gräter/ Dr. Baldauf) identified local structural
changes in the mutated A2 cleavage domain that induce destabilization, which presumably
keeps the cleavage site accessible even in the absence of shear. The increased sensitivity of
rVWF-G1629E-eGFP as an ADAMTS13 substrate provides a significant improvement both
in analytical sensitivity and in accuracy that might enhance TTP diagnostics. Moreover, re-
combinant fluorescent proteins as substrates allow for fast and cost-efficient read-out. Further
specialized VWF mutants might be used to enhance coagulation diagnostics.
The experimental data and the resulting conclusions are presented in the following manuscript:
S. Lippok, C. Aponte-Santamarı́a, T. Obser, R. Schneppenheim, C. Baldauf, F. Gräter, U.
Budde, J.O. Rädler. ”Destabilized recombinant VWF as substrate for highly sensitive
ADAMTS13 activity assays.” to be submitted to Journal of Thrombosis and Haemostasis
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ABSTRACT 
The protease ADAMTS13 plays an essential role in haemostasis as it cleaves the large 
multimeric glycoprotein von Willebrand Factor (VWF). Deficiency of ADAMTS13 with 
plasma activity levels of 5 % and below leads to the severe coagulation disorder thrombotic 
thrombocytopenic purpura (TTP). Reliable quantification of the ADAMTS13 activity levels 
in patient's blood is important in clinical diagnostic , but remains challenging with commonly 
used assays. Because the ADAMTS13 activity is detected via breakdown of substrate VWF, 
limitations arise partly from the fact that the cleavage site of VWF is only accessible upon 
opening at high shear rates or under denaturing conditi s. Here, we show that a fast and 
sensitive ADAMTS13 assay can be set up employing the recombinant mutant VWF-G1629E-
eGFP as a fluorescent enzyme substrate. Using Fluorescence Correlation Spectroscopy (FCS), 
we followed online the ADAMTS13-meditated breakdown of the fluorescent substrate both in 
vitro and in patient's blood samples. We obtained a 5-fold improved detection limit than that 
achieved with commonly used assays. In vitro data affirm cooperative enzyme kinetics with 
Hill coefficient n = 2.3 as well as a linear rate response to ADAMTS13. Molecular dynamics 
simulations (MDS) suggest that the enhanced responsive ess to ADAMTS13 arises from a 
local structural destabilization of the mutation G1629E that results in an increased 
accessibility of the A2 cleavage domain. The elevated signal-to-noise ratio achieved with the 
mutant provides a significant improvement both in analytical sensitivity and in accuracy in 
laboratory tests that facilitates diagnosis of TTP as well as difficult to detect mild 
ADAMTS13 deficiencies. 
 
INTRODUCTION 
The multimeric protein von Willebrand Factor (VWF) is essential for the initiation of blood 
coagulation as it promotes the binding of platelets to ruptured vessel walls [1,2]. The size 
distribution of VWF is regulated by the protease ADAMTS13 (a disintegrin and 
metalloprotease with thrombospondin type 1 motif, memb r 13). The enzymatic cleavage by 
ADAMTS13 represents a crucial control mechanism in hemostasis [3]. A severe deficient 
ADAMTS13 activity (5 % of that in normal plasma) leads to increased amounts of ultralarge, 
highly-active VWF multimers that cause a thrombotic mi roangiopathy, which is commonly 
referred to as thrombotic thrombocytopenic purpura (TTP) [4-6]. TTP is caused either by 
mutations of the ADAMTS13 gene or by acquired autoantibodies that inhibit ADAMTS13 
activity [7]. The ADAMTS13 specific cleavage site is located at the peptide bond Tyr1605-
Met1606 and deeply buried in the VWF A2 domain [8,9]. This domain has been shown to be 
mechanosensitive and its opening in vivo is induced by shear flow, for instance arising at 
ruptured vessel walls. Only the opened A2 domain allows access to its cleavage site [10,11]. 
Moreover, we showed recently that the opening mechanism of the A2 domain has a huge 
impact on the resulting cleavage rates [Lippok et al., 2014, submitted]. 
The quantification of ADAMTS13 activities below 5 % is the key laboratory finding to 
diagnose TTP [12]. Although numerous activity assays lready exist, there are hitherto 
limitations in sensitivity and reproducibility [12,13]. In particular, the extremely low disease-
related ADAMTS13 activity levels are difficult to measure. A critical impediment is that 
assays using full-length VWF as substrate rely on the opening of the A2 domain. Therefore, in 
many cases only VWF fragments are used [13-15], or cleavage is conducted in denaturing 
buffer containing 1.5 M urea [16-19]. This makes it difficult to identify whether the detected 
amount of ADAMTS13 is functional in circulation. Moreover, denaturing substances only 
partly destabilize the VWF multimer, which decreases the detected cleavage rates and 
considerably reduces the achieved signal-to-noise ratio. 
There are several naturally occurring mutations in the A2 domain, which induce increased 
VWF proteolysis in patients. In a broad study, Hassenpflug et al. investigated the impact of 13 
different VWD type 2A mutations on ADAMTS13-dependent proteolysis [20]. 11 of them 
showed increased specific proteolysis compared to VWF wild-type (VWF-wt). For four 
mutants, this holded true even in the absence of urea. In particular one mutant, namely VWF-
G1629E, was found to result in very strongly increased nsitivity to proteolysis under 
nondenaturing conditions. Moreover, this mutant showed no quantitative defects in the 
expression and exhibited the physiological VWF size distribution. 
Here, we use the mutant VWF-G1629E as enzyme substrate to measure the ADAMTS13 
activity in patient's plasma. As shown recently, Fluorescence Correlation Spectroscopy (FCS) 
is capable to detect full-length VWF cleavage on-line under blood plasma conditions using 
recombinant VWF-eGFP fusion proteins [Lippok et al., 2014, submitted]. FCS collects 
intensity fluctuations that arise from fluorescent proteins diffusing through a laser focus to 
assess the number density of detected molecules. Using FCS and the fluorescent fusion 
protein rVWF-G1629E-eGFP, we quantified ADAMTS13 activity levels down to 0.5 % in 
buffer, i.e. with a 5- to 10-fold higher detection limit than most commercially available 
assays. Moreover, we investigated the elevated cleavage rates of the mutant by enzyme 
kinetics in 0.5 % normal plasma (NP) and found a cooperative behaviour with Hill coefficient 
n = 2.3 in contrast to non-cooperative Michaelis-Menten type kinetics published recently for 
denatured wild-type VWF [Lippok et al., 2014, submitted]. In particular, we show that 
cleavage rates of the mutant were 20-fold increased compared to cleavage with denatured 
VWF-wt. The elevated sensitivity of rVWF-G1629E is supported by Molecular Dynamics 
Simulations (MDS) showing a destabilization of the mutated A2 domain, which suggests a 
facilitated access to the cleavage site. We discuss po ible applications of the mutant rVWF-
G1629E as enzyme substrate for standard coagulation tests in clinical laboratories. 
 
MATERIALS AND METHODS 
Protein expression: Recombinant fusion proteins were produced as describd in [21]. Full-
length ADAMTS13 cDNA was cloned into the expression vector pIRES neo2 for stable 
transfection of HEK 293 cells by liposomal transfer under selective pressure 48h after 
transfection [20]. Wild-type rhuADAMTS13, secreted to the medium, was used for cleavage 
experiments. 
Plasma samples were collected from normal volunteer donors in S-monovettes, coagulation 
sodium citrate (Sarstedt, Germany). After incubation at room temperature for 30 min, samples 
were centrifuged (10 min, 2300 rpm). The supernatant was stored at -80°C until further use. 
Informed consent was obtained from all subjects. 
FCS measurements were run on an Axiovert 200 microscope with a ConfoCor 2 unit (Carl 
Zeiss, Jena, Germany), equipped with a 40x (NA = 1.2) water-immersion Apochromat 
objective (Carl Zeiss) and a 488 nm argon laser for illumination. Experiments were carried 
out in 8-well LabTek I chamber slides (Nunc, Rochester, NY) in 5 mM Tris-HCl (pH 8.0) 
containing 10 mM BaCl2 for 10x6 min on rVWF-G1629E and for 20x9 min on rVWF (owing 
to the decreased cleavage). For measurements in blood p asma, the plasma was diluted to the 
desired concentration with Tris-HCl buffer. For wild-type rVWF, 1.5 M urea was added, 
based on the commonly used protocol [3,14,22]. The setup was calibrated measuring eGFP 
for 20x60 s in the corresponding buffer. The temperature was set to 37°C (heating stage, ibidi 
GmbH, Martinsried, Germany). Correlation analysis was performed using the ConfoCor 2 
software. FCS data was analyzed as described in detail before [Lippok et al., 2014, 
submitted]. 
MDS were carried out starting from the solvated conformation of the VWF A2 domain (taken 
from its X-ray structure PDB ids. 3GXB [23]). Simulations were carried out with the 
GROMACS package [24-26] (4.5.5 version) following the procedure described in [27], both 
for the wild type domain (5 runs of 200 ns each for 1 µs concatenated simulated time) and for 
the mutant G1629E (4 runs of 200 ns each for 0.8 µs concatenated simulated time). The 
PyMOL software was used [28]. 
A PCA was carried out to identify changes in the conformational dynamics of the domain 
induced by the mutation G1629E. It consists in the calculation and diagonalization of the 
covariance matrix of the atomic positions of the backbone atoms [29]. Concatenated 
trajectories of both wt and mutant domains were used for the PCA calculation. The RMSF of 
the atomic positions was computed by concatenating separately the simulations of the wt and 
the mutant domain. An FDA analysis [30] was performed to monitor changes in the internal 
stress of the protein upon mutation. Time-averaged pair-wise forces <Fij> were computed for 
all residue pairs (i,j) of the A2 domain, in its wild-type (<Fij(wt)>) and mutated 
(<Fij(G1629E)>) forms. The absolute value of the difference ∆Fij=|<Fij(wt)>-<Fij(G1629E)>| 
was subsequently calculated as a measure of the change in internal stress after mutation. | | 
denotes absolute values. 
 
RESULTS 
FCS measurements of rVWF-G1629E cleavage. We established an assay to investigate 
ADAMTS13-mediated cleavage of mutant VWF-G1629E (Figure 1A). The mutant was 
provided as recombinant VWF-G1629E-eGFP fusion protein (rVWF-G1629E) in buffer and 
added to the blood plasma (Figure 1B). In this construct, one eGFP molecule is bound to each 
VWF monomer. Thus, cleavage of one rVWF-G1629E protein r sults in two fluorescent 
molecules. FCS detects the increasing protein number on-line by means of the amplitude of 
the autocorrelation curve G(0), which is inversely proportional to the number of fluorescent 
molecules in the confocal volume, G(0) 1/N [31].  
Figure 2A illustrates cleavage of 6 nM rVWF-G1629E by ADAMTS13 at a concentration of 
0.3 U/ml, which corresponds to 30 % of the physiological ADAMTS13 amount in normal 
plasma (NP). The graph depicts the shift of the autocorrelation curves towards lower 
amplitudes during cleavage over time. Note, that neither denaturing substances nor shear flow 
were applied for these experiments. Nevertheless, a decrease in the amplitude is clearly 
visible over time. The corresponding increase in particle number is plotted in the inset of 
Figure 2A. The steepness of this curve defines the cleavage rate dC/dt, which is the increase 
in molar VWF concentration over time. The cleavage rate depends on the applied enzyme 
concentration and is used as a measure for the ADAMTS13 activity. 
Enzyme kinetics of rVWF-G1629E. To quantify the sensitivity of the mutant to cleavage, 
we investigated the enzyme kinetics of ADAMTS13-mediated cleavage at 0.5% NP (Figure 
2B). We find a cooperative Hill-type behaviour. Fitting with dC/dt = vmax/(1+(KA/C)
n) yields 
a cooperativity coefficient n = 2.3 ± 0.2, a maximu cleavage rate 
vmax = 143.2 ± 0.4 pM/min, and a VWF-G1629E concentration producing half maximum 
cleavage KA = 11.5 ± 0.5 nM. For cleavage of denatured VWF-wt, non-cooperative 
Michaelis-Menten kinetics were observed [Lippok et al., 2014, submitted]. Moreover, a 15-
fold reduced KM was found compared to the KA value for rVWF-G1629E cleavage.  
Linear rate response to ADAMTS13 concentration. Figure 3A shows the cleavage rates for 
a constant rVWF-G1629E concentration (6 nM) as a functio  of ADAMTS13 concentration 
in buffer. We used this substrate concentration, because it is in the most sensitive 
concentration regime for FCS measurements. We detect th  expected linear response within 
the entire investigated ADAMTS13 concentration regime. ADAMTS13 concentrations in the 
range of 5 to 30 % are easily detectable with commonly used assays. Fitting this concentration 
range with a linear fit, we get an increase of the cleavage rate with ADAMTS13 concentration 
of 1.61 ± 0.08 nM/min (red dotted line). Fitting only the low concentration range as depicted 
in the inset (0.5 - 5 %), which is hardly accessible with commonly used diagnostic assays, we 
achieve 1.50 ± 0.04 nM/min. This demonstrates that t e assay is highly sensitive for rVWF-
G1629E cleavage by ADAMTS13 at activities down to 0.5 % of the physiological level. 
Hence, we gain a resolution limit that is significantly lower than that of most commonly used 
assays, which lies between 2.5 and 5 % [32,33]. 
Accuracy of rVWF-G1629E cleavage detection in plasma samples. Next, we performed 
FCS measurements under blood plasma conditions to tes  th  accuracy of our assay (see 
Figure 3B). For diagnostics, direct measurements in blood plasma are an essential 
requirement in order to avoid purification steps. Therefore, recombinant rVWF-G1629E was 
added to varying concentrations of normal plasma (NP) of a healthy volunteer (Figure 3A). 
ADAMTS13 activity was quantified in highly diluted plasma samples, containing only 1-5 % 
NP. We show that adding a higher amount of rVWF-G1629E (24 nM instead of 6 nM) 
increased the cleavage rates, so that we achieved a significantly better signal-to-noise ratio. 
The resulting cleavage rate at 1 % NP (400 pM/min) is well above the detection limit (about 
2 pM/min). This demonstrates that the assay has not yet reached its detection limit at the 
applied ADAMTS13 concentrations. Moreover, for both rVWF-G1629E concentrations, the 
expected linear increase in the cleavage rate with increasing ADAMTS13 concentration is 
visible. Thus, the mutant allows for highly accurate measurements under blood plasma 
conditions. 
Comparison of rVWF-G1629E and rVWF-wt. To quantify the increase in accuracy, we 
compared the sensitivity of the mutant to proteolysis with that of rVWF-wt as shown in 
Figure 3B. For rVWF-wt, a denaturing buffer had to be us d to partially denature the rVWF-
eGFP fusion protein. Otherwise, the cleavage site would not be accessible for ADAMTS13 
and cleavage activity could not be detected [Lippok et al., 2014, submitted]. Moreover, 
threefold prolonged measurement times were needed for the wild-type compared to those of 
the mutant to achieve a reliable signal-to-noise ratio. With these requirements, we were able 
to detect ADAMTS13 concentrations down to 1 % NP. However, w  found that the cleavage 
rates are more than 20-fold reduced for rVWF-wt, which results in a considerable loss in 
accuracy. This is probably due to the fact that theur a-containing buffer only partly 
destabilizes VWF and does not completely open the A2 cleavage domain [34]. To verify this, 
we measured the diffusion coefficients of rVWF-wt dimer in nondenaturing and denaturing 
buffer, and rVWF-G1629E dimer (data not shown). We obtained DDimer,wt = 20.1 µm
2/s 
(nondenaturing conditions), DDimer,wt = 19.5 µm
2/s (denaturing conditions), and 
DDimer,mutant = 18.9 µm
2/s. These data confirm the conception of only partly opening due to 
urea, while the mutation induces an increased destabilization, which we measure in terms of 
increased cleavage rates.  
Altogether, using the mutant instead of wild-type VWF as substrate offers the possibility to 
detect more than 20-fold lower ADAMTS13 plasma levels without losing accuracy. In 
addition, measurement times are significantly reduc and the experiments can be performed 
without adding denaturing agents, which might alter th  studied reactions.  
Molecular Dynamics Simulations of the VWF A2 domain with and without mutation 
G1629E. To monitor the conformational changes induced by the G1629E mutation, which 
provide the increased cleavage rates, we performed MD simulations (Figure 4). MDS allow to 
ellucidate changes on the structure, dynamics and mechanical stability of proteins. We 
performed simulations of the wt and mutant VWF A2 domain for hundreds of nanoseconds. 
Within this time regime, the A2 domain remained folded in both its wild type and its mutant 
form, maintaining its globular shape, which keeps the ADAMTS13 cleavage site Y1605-
M1606 shielded. This suggests that larger conformation l changes, which increase the 
mutant's cleavage, occur on a longer time scale than the simulated time. 
However, the simulations allowed us to capture local distabilizations, which may make the 
domain more prone to unfold in a shorter time when mutated. By performing principal 
component analysis (PCA), we identified two collective motions of the domain that covered 
31% of the total positional fluctuations of the protein. We found that the wild type domain 
sampled two main region in the subspace consituted by these two vectors (Figure 4A). The 
mutated domain did not only populate these two but also further regions. This indicates that 
the mutated domain adopted a broader range of conformations than the wt domain, depicting 
higher conformational dynamics. 
To further identify the parts of the domain that display the largest conformational changes 
upon mutation, we computed the round mean square fluctuations (RMSF) of the A2 domain 
(Figure 4B). We observe a broader conformational variability for the mutant due to local 
fluctuations at the helix H5 and the loop L3-4. The former is positioned near the residue 
G1629. Interestingly, the loop L3-4, which connects the helix H3 with the strand B4, is not in 
direct contact with the G1629 residue, but also presented an increment in the RMSF. In 
contrast, the knotted C-terminal part of the protein (residues < 1580) presented small RMSF 
both for the wild type and the mutant. This implies a high structural stability for this region 
and is in concordance with previous computational studies [11]. In terms of RMSF, no affects 
were seen for the cleavage site located at the strand B4.  
Finally, we analyzed whether the mechanical integrity of the protein was changed upon 
mutation. To this end, we performed a FDA analysis to compute the internal stress of the 
protein in wt and mutant. We observed that the mutation induced drastic changes in many of 
the residue pair-wise forces, which provide a measure of the internal stress. (Figure 4C). 
These changes were not only observed locally at the mutation site, but also extended to other 
distant parts of the protein including the ones hiding the ADAMTS13 cleavage site. In 
addition, pairs that are not involved in the mutation site also showed alterations, presumably 
to counteract for the perturbation imparted by the mutation to maintain the overall mechanical 
stability of the protein.  
These data strengthens the theory of a destabilized structure that leads to a highly increased 
proteolysis, a reduced number of long multimers and finally to significant bleeding symptoms 
in patients with the mutation G1629E. Although we could not observe full unfolding of the 
domain due to the simulated time scale of merely hundreds of ns, we identified local 
structural changes and a wide-spread change in the iternal stress of the protein. Such changes 
may act as destabilization factors that make the mutated A2 domain more prone to unfold.  
 
DISCUSSION 
We studied the fluorescent VWF mutant rVWF-G1629E as a new substrate for fast and 
accurate laboratory tests of ADAMTS13 activity in patien  samples. Using FCS, we 
investigated the increased sensitivity of the mutant with enzyme kinetic studies that exhibited 
strongly increased cleavage rates and a cooperative Hill-type behaviour. Cooperativeness was 
not observed for cleavage of denatured VWF-wt [Lippok et al., 2014, submitted]. Due to the 
destabilized structure of the mutant, several binding sites might be accessible at the same 
time, which may lead to cooperative binding of the protease with prolonged dwell times at 
each of the multimers. 
We showed that using rVWF-G1629E as substrate allows to de ect ADAMTS13 activities 
down to 0.5 % of the physiological level, which is 5-fold more sensitive than most commonly 
used assays. MDS showed that the G1629E mutation induced local structural variations of the 
A2 domain, hence corroborating the hypothesis that te mutated regions allows facilitated 
access to the cleavage site.  In addition to its high sensitivity, the application of the mutant 
renders shear flow as well as denaturing agents unnecessary, while still allowing for 
measurements with full-length VWF.  
Recently, Lotta et al. presented a similarly sensitive assay based on SELDI-TOF mass 
spectroscopy [13]. Instead of full-length VWF, they used a VWF fragment (VWF73) as 
substrate, which was fixed to a surface, to measure the residual plasmatic activity of 
ADAMTS13 in TTP patients. The cleavage reaction was performed for 16 hours. Further 
frequently used, well-established diagnostic ADAMTS assay , rely on either denaturing VWF 
substrate or on subsequent labeling via antibodies against VWF [12]. In contrast, the assay 
presented here does not require surface immobilization, which minimizes possible sources of 
error. Moreover, subsequent treatments such as washing, purification, or labeling are 
unnecessary, and the assay merely runs for an hour. 
The use of a recombinant fluorescent substrate is advantageous in many ways. Recombinant 
proteins are applicable as a reliable standard for activity tests, which in principle might also 
allow absolute calibration of ADAMTS13 level. Moreover, the self-fluorescence of the 
substrate allows for fast read-out of the full blood assay without additional labeling or 
purification steps, which may strongly accelerate currently used approaches, while avoiding 
possible sources of error. This includes the possibility of fluorescent read-out of quantitative 
gel electrophoresis, which renders the use of expensiv  fluorescent antibodies for detection 
unnecessary.  
We presented here one VWF mutant that is suited for ADAMTS13 detection due to its 
increased sensitivity to ADAMTS13. However, there are much more naturally occurring 
mutations known to be sensitive for distinct VWF functions and binding partners. While these 
mutants lead to diseases in patients, they might provide opportunities to increase sensitivity 
and specificity in diagnostics. This may open a wide f eld of enhancements not only for the 
diagnostics of TTP. 
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FIGURES 
 
 
Figure 1: ADAMTS13 activity assay using enzyme substrate rVWF-G1629E and 
FCS. A The mutant rVWF-G1629E exhibits a mutation close to the ADAMTS13 
specific cleavage site that facilitates opening of the VWF A2 domain. B FCS measures 
the number density of eGFP labeled rVWF-G1629E added to pa ient plasma samples 
containing ADAMTS13 and hence allows for on-line monitring the cleavage mediated 
by ADAMTS13. 
 
 
Figure 2: FCS-based assay for rVWF-G1629E cleavage detection. A Cleavage 
detection via FCS. The amplitude of the autocorrelation curve G(0) is inversely 
proportional to the number of fluorescent molecules N in the detection volume and 
decreases during cleavage according to G(0)∝ N. Inset: The increase in particle 
concentration is plotted over cleavage time. The slope of the curve defines the cleavage 
rate dC/dt. B Enzyme kinetics of rVWF-G1629E in 0.5% NP. We measured Hill-type 
activity with cooperativity coefficient n = 2.3. A half maximum cleavage rate at 11.5 nM 
rVWF-G1629E indicates strongly increased cleavage compared to VWF-wt. 
 
 
 
Figure 3: Linear rate response to ADAMTS13 concentration. A ADAMTS13 activity 
in buffer. Cleavage rates increase linearly with ADAMTS13 concentration, depicted in % 
of the level in normal plasma. The assay quantifies cl avage rates down to ADAMTS13 
concentrations of 0.5 %, as highlighted in the inset. B Cleavage of rVWF-G1629E and 
rVWF-wt in normal plasma. rVWF-G1629E cleavage is clearly quantifiable down to 1 % 
NP concentration (green). For a 4-fold increased substrate concentration of 24 nM (green 
triangles), the signal-to-noise ratio is considerably increased and the measured cleavage 
rate at 1% NP is well above the detection limit of about 2 pM/min. Cleavage of wild-type 
rVWF results in more than 20-fold decreased cleavage r t s (grey and black), which 
significantly reduces the signal-to-noise ratio at disease-related low ADAMTS13 
concentrations. Additionally, for cleavage of wild-type rVWF, increased measurement 
times and denaturing buffer conditions had to be used. Fits are indicated as dotted lines. 
 
 
Figure 4: MD simulations reveal structural and mechanical changes in the VWF A2 
domain upon G1629E mutation. A PCA analysis of the A2 domain yielded two main 
collective eigenvectors. Populated regions of the subspace constituted by these two 
vectors are shown for wt (left) and mutant (middle). Differences in population density are 
depicted according to the color scales. Regions in red correspond to areas only visited by 
the wt and regions in blue visited by the mutant domain. The mutation induced a broader 
range of conformations than measured for the wt. B Left RMSF of each residue of wt 
(black) and mutant (red). The secondary structure of the A2 domain is indicated at the 
upper part, highlighting the N- and C-terminus (Nt and Ct, respectively), the strands 
(B1...B6), the helices (H1...H6), and the loop connectig H3 with B4 (L3-4). The RMSF 
for G1629 is highlighted in blue, the one for the ADAMTS13 cleavage site Y1605-
M1606 (YM) in green. For the mutant, a broader conformational variability due to local 
fluctuations is observed at the helix H5 and the loop L3-4 (accentuated in red). Right 
Structure of the A2 domain (ribbon representation). The YM cleavage site (green) and 
residue G1629 (blue) are highlighted as spheres. Various representative conformations 
are shown for the regions with increased RMSF for the mutant compared to the wild type 
domain (L3-4 and B5, tubes). C Changes in the internal stress of the protein upon 
G1629E mutation recovered by FDA. The secondary structure of the protein is spanned 
around the circle. Each point of the circle corresponds to a residue, ranging from the N-
terminus at 0 degree to the C-terminus at 360 degree. The cleavage site is highlighted in 
green and G1629 in blue. Each line connecting two points of the circle corresponds to the 
difference ∆f ij for the residue pair (i,j). Here, ∆f ij=|<Fij(wt)>-<Fij(G1629E)>|, with 
<Fij(wt)> the time-averaged pair-wise force of the residue pair (i,j) in its wild type form 
and <Fij(wt)> in its mutated form. ∆f ij is displayed according to the color scale at the 
bottom, varying from no change (white) to substantial change (black) in the internal 
stress. The mutation perturbed the internal stress, both locally at the mutation site and  at 
distant parts, see e.g. lines connecting the region near G1629 with structure elements L4, 
B5, H5 and H1. 
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Binding of PDI to VWF and its Role on Dimerization
The biosynthesis of VWF multimers is a highly sophisticated process that is organized by
spatial separation of each step in different cellular compartments due to varying pH value
requirements. It is known that VWF dimerization occurs in the endoplasmatic reticulum (ER),
where intermolecular disulfide bonds in the VWF CK domains are formed. However, the
identity of the enzyme facilitating this disulfide bond formation had not yet been identified.
While investigating the localization of VWF mutants within the ER, our cooperation partners
recently observed co-localization of VWF with protein disulfide isomerase (PDI), an essential
catalyst and chaperone for protein folding within the ER (82). Thus, we hypothesized that
PDI might be involved in VWF dimerization.
To confirm this hypothesis, we performed binding studies with FCS and MST and measured
specific binding of PDI to VWF wildtype with KD = 236 ± 66 nM. We showed that PDI
binds VWF exclusively within the CK-domain since binding of PDI to the isolated CK do-
main exhibits a similar KD value (258 ± 104 nM). Together with immunofluorescence data of
VWF with selected CK-domain mutations (Dr. Brehm), we found that the PDI binding site
is located N-terminally of Cys2773. Co-localization measurements of pathologically relevant
CK-domain mutants, which were performed in the group of Prof. Schneppenheim, showed
that an additional ER polymerase, namely ERp57, is a key player in the repair of misfolded
VWF mutants. This indicates the role of PDI in VWF dimerization rather than in the repair
of misfolded VWF. Altogether, our findings show for the first time a direct binding of VWF
and PDI. Moreover, we shed light on the mechanism of VWF dimerization both in VWF wt
and in CK-domain mutants. This might help to answer open questions in the context of the
physiological relevance of PDI in hemostasis that are currently debated.
The experimental data and the resulting conclusions are presented in the following manuscript:
S. Lippok, G. König, T. Obser, R. Schneppenheim, J.O. Rädler, M.A. Brehm. ”The (patho)-
physiological Relevance of Protein Disulfide Isomerase Binding to von Willebrand Factor.” to
be submitted to Journal of biological chemistry
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ABSTRACT 
Multimeric von Willebrand factor (VWF) plays a pivotal role in primary hemostasis 
mediating binding of platelets to the ruptured vessel wall. Its biosynthesis occurs in spatially 
separated steps due to varying pH value requirements. The dimerization takes place at neutral 
pH in the endoplasmatic reticulum (ER) by the formation of three intermolecular disulfide 
bonds between the CK-domains of two VWF monomers. Here, we investigated the role of 
protein disulfide isomerase (PDI), an essential catalyst and chaperone of protein folding 
within the ER, in VWF dimerization. Binding studies based on Fluorescence Correlation 
Spectroscopy (FCS) and Microscale Thermophoresis (MST) identified specific binding of 
PDI to wildtype (wt) VWF with a dissociation constant of KD = 236 ± 66 nM. The interaction 
of PDI and the isolated VWF CK-domain exhibited a similar KD value (258 ± 104 nM) 
indicating that PDI binds solely to the CK domain where dimerization occurs. Moreover, our 
immunofluorescence studies revealed that VWF CK-domain mutants are associated with von 
Willebrand disease (VWD) type 2A/IID through two mechanisms: either inhibition of PDI-
catalyzed disulfide bond formation, or inhibition of PDI binding due to misfolding. The here 
described direct binding of PDI to VWF indicates PDI as the VWF dimerizing enzyme, and 
sheds new light on the mechanism of dimerization and the pathophysiological consequences 
of its inhibition by genetic alterations.  
 
 
INTRODUCTION 
 
Von Willebrand factor (VWF) is an essential glycoprotein for platelet-dependent primary 
hemostasis. The shear-induced transition between a globular and a stretched conformation of 
VWF high molecular weight multimers (HMWM) leads to exposition of binding sites for 
VWF partners and thus the initiation of platelet adhesion and aggregation. Because smaller 
multimers are more resistant to shear forces than larger ones, VWF’s shear flow-activated 
functions are dependent on its multimeric structure.  
 
The biosynthesis of VWF-HMWM’s is a highly sophisticaed multistep process, which 
involves spatial separation of each step in order to optimize for distinct pH value conditions. 
It is initiated in the cytoplasm by the translation f the VWF pre-pro-monomers. N-
glycosylation and quantitative dimerization occur in the endoplasmic reticulum (ER). 
Processing of high mannose glycans and sulfation as well as O-glycosylation, 
multimerization, pro-peptide cleavage, and tubulation ake place in the Golgi apparatus. Until 
stimulated release, the HMWM’s are stored in Weibel-Palade bodies [1-3]. 
 
Multimerization as well as dimerization are established by the formation of intermolecular 
disulfide bonds. The C-terminal cysteine knot (CK) domain contains 11 cysteines [4]. 
Recently, crystal structure analysis revealed that eight of these cysteines form intra-chain 
disulfide bonds, while three, namely, Cys2771, Cys2773, and Cys2811, mediate the inter-
chain connections for dimerization [5]. The latter are encased in the intra-chain cysteine knots 
resulting in a rigid structure that is resistant to he high shear forces, which affect VWF in the 
circulation. Mutations of the cysteines present in the CK-domain can lead to the bleeding 
disorder von Willebrand disease (VWD) type 2A/IID. C-terminal dimerization is strongly 
disturbed in these mostly heterozygous patients leading to odd-numbered multimers by 
attachment of mutant monomers to wildtype multimers by N-terminal disulfide bond 
formation [6]. 
 
The assembly of mature VWF-HMWM by multimerization is well understood [7]. It occurs in 
the acidic environment of the trans-Golgi network where dimers are multimerized by 
formation of interchain disulfide bonds between the D’-D3 domains of VWF dimers. The 
formation of these N-terminal disulfide bonds is facilitated by the VWF pro-peptide that 
contains two D domains that both harbor a CGLC protein disulfide isomerase consensus 
sequence, which have been shown to be essential for multimerization. The activation of this 
intrinsic isomerase is strongly pH-dependent. Enabled y the lower pH of the Golgi apparatus, 
it is activated by protonation of histidine residues adjacent to the CGLC sequence. 
Interestingly, mutations within the CGLC sequences in the propeptide inhibit multimerization 
but do not affect dimerization [8,9]. The relevance of a third CGLC consensus sequence in the 
D4 domain has not been elucidated yet. However, genetic alterations within this sequence 
neither influence multimerization nor dimerization [unpublished data R. Schneppenheim and 
U. Budde]. Therefore, dimerization does not seem to be performed by an intrinsic protein 
disulfide isomerase activity within VWF. To date it is not known, though, which protein 
catalyzes the highly complex formation of these bonds. Since dimerization occurs within the 
ER, it requires an ER-localized protein disulfide isomerase. Allen et al. showed that calnexin 
and ERp57, two proteins specialized in glycoprotein folding, weekly co-localize with VWF 
and are involved in VWF processing. Moreover, mutations within the VWF propeptide 
prolong ER localization and increase interaction with calnexin and ERp57 [10]. These data 
indicate that calnexin and ERp57 are involved in the initial folding of VWF and the correction 
of VWF misfolding. Protein disulfide isomerase (PDI) is one of the few members of the PDI 
family that is known to catalyze both disulfide formation as well as isomerization. Although it 
is an essential folding catalyst and chaperone of the ER [11-14], the role of PDI in VWF 
dimerization has not yet been investigated.   
 
Since it has previously been described that VWF co-lo alizes with PDI, merely, to prove 
VWF ER-localization, we further investigated if PDI is the required protein for VWF 
dimerization. We performed extensive binding studies employing immunoprecipitation, 
Microscale Thermophoresis (MST), and Fluorescence Correlation Spectroscopy (FCS) and 
showed that PDI directly binds to VWF. Using Immunoflurescence studies, we investigated 
co-localization of selected VWF CK-domain mutants and PDI or ERp57. Our data indicate 
the role of PDI rather in VWF dimerization than in the repair of misfolded VWF. 
  
MATERIALS AND METHODS 
Cell culture and expression of wtVWF and VWF mutants in HEK293 cells. HEK293 
cells were cultured in Dulbecco Modified Eagle Medium (DMEM, Invitrogen) with 10 % 
[v/v] fetal bovine serum (Invitrogen) and 1 % penicillin/streptavidin (Invitrogen) at 37°C and 
5 % CO2. For immunofluorescence, HEK293 cells were seeded in Ibidi treat 8-well µ-slides 
(Ibidi, Martinsried, Germany) 24h prior transfection with Lipofectamine LTX (Invitrogen) 
and VWF-plasmid-constructs in vector pcDNA3 [15]. 
 
Immunofluorescence was performed as previously described [16] 48h post transfection. 
Antibodies used were: rabbit anti-VWF (DAKO; 1:1,000), mouse anti-PDI (abcam, 1:100), 
mouse anti-ERp57 (Santa Cruz, 1:100) goat anti-rabbit AF488 (Invitrogen, 1:5,000), goat 
anti-mouse AF 546 (Invitrogen, 1:5,000). Images were captured at RT with a confocal 
microscope (LSM 510; Carl Zeiss, Jena, Germany) using a Plan Apochromat 63×/1.4 oil DIC 
objective, ZEN 2009 software (Carl Zeiss), and the following settings: image size of 1776 × 
1776 and 8 bit, laser power of the 543 and 488 lasers was set to 100 % and 24 %, respectively. 
After image capturing, the original LSM files were converted into TIFF files with the LSM 
Image browser software (Carl Zeiss). 
 
Co-Immunoprecipitation. Lysates were prepared from HEK293 cells in M-PER Mammalian 
Protein Extraction Reagent (Thermo Fisher Scientific Inc., Rockford, IL, USA) supplemented 
with Complete Protease Inhibitor cocktail (Roche, Penzb rg, Germany) according to the 
manufacturer’s instructions. To reduce background caused by nonspecific adsorption of 
proteins, 50 µl of protein G-agarose suspension (Roche, Penzberg, Germany) was added per 
1 ml lysate and incubated for 3 h at 4°C on a rocking platform. Beads were pelleted by 
centrifugation (20 s at 12,000xg), and supernatant was transferred into a fresh tube. Then, 
2 µg of rabbit anti-VWF (DAKO, Germany) were added to 1 ml lysate each and incubated for 
1 h at 4°C on a rocking platform. After addition of 50 µl protein G-agarose beads, incubation 
was continued overnight. Agarose-bead-antibody-antige  complexes were collected by 
centrifugation (20 s at 12,000xg), and the supernatant was discarded. Beads were washed for 
10 min in washing buffer 1 [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 % Nonidet 
P40 (v/v), 0.5 % sodium deoxycholate (w/v) supplemented with Complete Protein Inhibitor 
cocktail (Roche, Penzberg, Germany)] at 4°C. Supernatant w s removed after centrifugation 
and the wash was repeated once with washing buffer 1, twice with washing buffer 2 [50 mM 
Tris-HCl (pH 7.5), 500 mM NaCl, 0.1 % Nonidet 40 (v/v), 0.05 % sodium deoxycholate 
(w/v)], and twice with washing buffer 3 [50 mM Tris-HCl (pH 7.5), 0.1 % Nonidet P40 (v/v), 
0.05 % sodium deoxycholate (w/v)]. Pelleted beads and 1 µg of input lysate were resuspended 
separately in SDS sample buffer, incubated 10 min at 95°C, separated by SDS-PAGE, and 
transferred onto a PVDF membrane using standard Western blotting techniques. PDI was 
detected by mouse anti-PDI antibody (Cell Signaling). The secondary goat anti-mouse 
antibody was conjugated with HRP (DAKO). 
 
Sample preparation for binding studies. PDI human (Genway Biotech. Inc, San Diego, 
CA) was labeled with Alexa Fluor 647 carboxylic acid, succinimidyl ester (Life Technologies 
GmbH, Darmstadt, Germany). Measurements were conducted in 5 mM Tris buffer containing 
500 mM NaCl and 2.5 mM CaCl2 at 21°C. A fixed concentration of labeled PDI (MST: 
25 nM, FCS: 3 nM) was titrated against varying rVWF, rVWF monomers (p.Cys2771Arg), 
and rVWF-CK-domain concentrations. Samples were incubated for 30 minutes at room 
temperature before measurement.  
 
Microscale Thermophoresis. Thermophoresis is the directed flow of molecules in a 
temperature gradient. This thermophoretic movement is opposed by mass diffusion resulting 
in a stationary spatial concentration distribution [17,18] 
))(exp( 00 TTSCC T −−=  
in the temperature rise ∆T = T-T0  at the respective spot. It is described by the Soret 
coefficient ST, a measure of the strength of the thermophoretic flow compared with ordinary 
diffusion, which depends on size, charge, solvation entropy and conformation of the 
molecules. MST detects this movement to analyze the interactions of proteins [19,20].  
Data analysis was conducted as described in detail elsewhere [19,20]. In short: The  
thermophoretic depletion, i.e. the fraction warm fluorescence FII/cold fluorescence FI, reports 
the fraction of bound receptor molecules. The binding of ligands to a specific receptor is 
described by the dissociation constant KD, a measure for the affinity of the binding reaction 
under equilibrium conditions. To obtain the dissociation constant from the MST data, the 
binding curves were fitted by a function derived from the law of mass action: 
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with the total concentration of receptor CB0 (PDI), the total amount of added ligand at each 
point CL0 (VWF binding sites), and the concentration of bound receptor molecules CBL (PDI 
bound to VWF). 
For MST experiments, a Monolith NT.115 system (NanoTemp r Technologies, Munich, 
Germany) was used. 15% IR-laser and 20% LED power were applied for generating local 
temperature gradients and illumination, respectively. Laser on and off times were set at 60 s 
and 10 s. Cold fluorescence was averages over 5 s before the temperature jump while the 
warm fluorescence signal was averaged over 30 s starting 5 s after the temperature jump. 
About 5 µl sample volumes were filled into standard teated capillaries (Nanotemper 
Technologies) for measurements.  
 
Fluorescence Correlation Spectroscopy. Fluorescence Correlation Spectroscopy (FCS) 
measures the dynamics of fluorescently labeled molecules diffusing in and out of a confocal 
volume due to Brownian motion. It analyzes the time-dependent fluctuations of the 
fluorescence intensity [21-25] using the autocorrelation function G(τ) of the intensities I(t): 
 
where  denotes the time average. For molecules diffusing freely in a Gaussian-shaped 
probe volume with radial dimension ωr and axial dimension ωz, G(τ) is derived analytically 
to [22]: 
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with the average number of molecules in the confocal volume N and the diffusion time τD, the 
time a molecule requires crossing the focal width. Tis analysis allows for calculation of the 
characteristic diffusion coefficient D = ωr2/τD.  
Data analysis: In a system composed of multiples of distinct species, the autocorrelation 
function can be generalized by summing the autocorrelation functions gi(τ) of all species: 
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with brightness qi and particle number Ni of species i. Binding events can be analyzed 
assuming a two component mixture of free and bound fluorescent receptor molecules. If 
binding does not change the brightness of the receptor molecule, i.e. qbound = qfree, this 
equation can be simplified to:  
[ ])()()1(1)( boundfree gfgfNG τττ ⋅+⋅−=  
where f denotes the fraction of bound receptor molecules and N the total number of receptor 
molecules [26,27]. This equation is used to analyze binding of PDI to VWF-p.Cys2771Arg 
and rVWF CK domain, which possess a constant number of binding sites. In the case of PDI 
binding to rVWF, the number of rVWF binding sites scales with the number of monomers, 
i.e., the rVWF size. Therefore, the brightness qi of a PDI-rVWF complex depends on the 
number of PDI molecules bound to the rVWF molecule. This number scales both with the 
fraction bound and with the size of the rVWF molecule qi = fiN(i) with the VWF size 
distribution N(i)=(p-1)pi-1 that was published recently [28]. As shown in Lippok et al., 2013, 
FCS analysis of the VWF size distribution can be simplified using single component analysis 
approach with the average diffusion time and for the brightness the average VWF size i . 
With this, equation () can be written in its normalized form as: 
)()()1()( 3 boundfree gifgfG τττ +−=  
which was used for fitting binding of PDI to rVWF. 
FCS experiments were performed on an Axiovert 200 microscope with a ConfoCor 2 unit 
(Carl Zeiss, Jena, Germany) equipped with an 40x (NA=1.2) water immersion appochromat 
objective (Carl Zeiss Jena). For sample illuminations a HeNe-laser 633 laser was used. 
Samples were measured in eight well LabTek I chamber slides (Nunc, Rochester, NY) three 
times for 10x180 s. 
 
 
  
RESULTS 
PDI binds to VWF exclusively within its CK-domain. In multiple publications, the co-
localization of VWF and PDI has merely been used to illustrate ER localization of VWF 
[29,30] but the physiological relevance of this potential interaction has not been elucidated 
yet. Since co-localization per se does not prove dir ct interaction of two proteins, we 
performed extensive binding studies employing three ind pendent approaches to determine if 
PDI actually binds to VWF. Co-immunoprecipitation of PDI and wtVWF (Figure 1A, wt) 
showed that both proteins are part of the same protein complex. To further prove a direct 
interaction of VWF and PDI, we performed Microscale Thermophoresis (MST) and 
Fluorescence Correlation Spectroscopy (FCS) using recombinant fluorescently-labeled PDI 
and recombinant wtVWF (Figure 1B-G). The dissociation c stants were determined to be 
KD = 236 ± 66 nM and KD = 282 ± 123 nM by MST and FCS, respectively. Therefore, the KD 
values measured by these two methods were in agreement to each other and prove direct 
binding of PDI to VWF.  
VWF is a glycoprotein rich in cysteine residues that de ermine the tertiary structure of the 
VWF A1, A3 and C domains by formation of disulfide bonds. In the C-terminal CK-domain, 
cysteines are not only bonded to form structural intramolecular disulfide bonds but also to 
dimerize monomers through intermolecular disulfide bonds [5]. To investigate whether PDI is 
involved in protein folding - which would require binding to all VWF domains - or 
specifically in dimerization of the CK-domains, we further performed MST of PDI and the 
CK-domain only. Binding to the isolated CK-domain results in a KD of 258 ± 104 nM (MST) 
(Figure 1D). Since the interaction of PDI with both the isolated CK domain and full-length 
VWF exhibit similar KD values, our data indicate that PDI exclusively binds to the CK-
domain of VWF.  
Effect of CK-domain mutations on PDI-VWF-interaction. The recently solved crystal 
structure of the VWF CK-domain revealed that the three disulfide bonds Cys2771-2773’, 
Cys2771’-2773 and Cys2811-2811’ are formed to dimerize two VWF monomers [5], but the 
enzyme essential for this bond formations has not been determined yet. To gain a more 
detailed insight into the mechanism of dimerization and its mutation-induced inhibition, we 
investigated the effect of dimerization inhibiting mutations on VWF-PDI-interaction.  
In VWD type 2A/IID patients carrying the heterozygous mutation p.Cys2771Arg, the 
formation of odd-numbered multimers due to N-terminal disulfide bonding to wt multimers 
was observed [31]. Homozygous expression yields N-terminally connected dimers only, 
showing a complete inhibition of the C-terminal dimerization in the CK-domain. To 
investigate the mechanism of the inhibitory effect of this mutation in dimerization, we 
performed co-localization and binding studies with the recombinant mutant. Compared to 
wtVWF (Figure 2A), mutant p.Cys2771Arg showed normal co-loca ization with PDI (Figure 
2B). The dissociation constants of p.Cys2771Arg binding to PDI, determined by both MST 
and FCS, exhibited KD values comparable to those of wtVWF-PDI-binding 
(KD = 235 ± 92 nM (MST) and KD = 350 ± 75 nM (FCS)). This shows that binding of PDI to 
VWF is not affected by this mutation.  
The insertion of an additional cysteine residue at position 2775 surprisingly has a strong 
inhibitory effect on dimerization. Although all three of the cysteines required for dimerization 
are present, mutant p.Ser2775Cys only yields dimers and some tetramers. When we 
investigated the intracellular localization of this mutant, we found a markedly reduced co-
localization with PDI compared to wtVWF (Figures 2A,C and 3A,C), indicating a disturbed 
binding of PDI to p.Ser2775Cys.  
Normal co-localization of PDI and a VWF mutant that exhibits a frameshift after amino acid 
2772 (p.Cys2773Alafs*76) (Figure 2D, 3D) further points to an initial binding event between 
PDI and a binding domain within VWF N-terminally of Cys2773.  
Effect of CK-domain mutations on protein folding. To determine whether decreased 
binding of PDI to p.Ser2775Cys is caused by misfolding, we investigated co-localization of 
this mutant with the ER-localized oxidoreductase ERp57 that is involved in repair of 
glycoprotein folding. As shown in Figure 4, we found co-localization of wtVWF as 
previously described [10] (Figure 4A). Mutants p.Cys2771Arg (Figure 4B) and p.Ser2775Cys 
(Figure 4C) showed the same week co-localization with ERp57 as wtVWF. In the latter case, 
an increase in ERp57 staining was observed that points to an increased expression of ERp57 
when p.Ser2775Cys is expressed. These data indicate th t p.Ser2775Cys undergoes more 
extensive refolding mediated by ERp57 than wtVWF and p.Cys2771Arg.  
 
DISCUSSION 
Here, we investigated the (patho)-physiological role of PDI in VWF processing. Employing 
different methods, we found independent evidence that PDI binds to VWF with a strong 
affinity in the nM regime. Moreover, we localized the CK-domain as the only PDI binding 
domain within VWF. These data revealed that PDI is involved in the dimerization of VWF in 
the ER.  
Our co-localization studies of VWD-associated VWF mutants might offer insights into the 
detailed VWF dimerization process. We hypothesize that dimerization starts with initial 
binding of PDI to VWF N-terminally of Cys2773 because th binding characteristics did not 
change for mutant p.Cys2771Arg. Additionally, a frameshift mutant that possesses only 
Cys2771 out of the three cysteines necessary for dimerization and an altered amino acid 
composition C-terminally of residue 2772 still co-localizes with PDI. This proves that, the 
dimerization defect of p.Cys2771Arg originates from the missing cysteine in contrast to a 
missing interaction with PDI. Cys2771 is the most N-terminal cysteine that is involved in two 
of the three disulfide bonds that are formed to connect VWF monomers. It has previously 
been described that mutant p.Cys2773Arg, which  is also s ociated with VWF 2A/IID leads 
to odd-numbered multimers in heterozygous patients [32]. However, homozygous expression 
reduces only formation of high molecular weight multimers showing merely a partial 
dimerization defect. The intracellular localization a d co-localization with PDI was found to 
be normal. Therefore, PDI seems to be able to at leas use Cys2771 and Cys2811 to form 
residual dimers. No pathological mutations have been id tified to far that show missense 
mutations of Cys2811, which further promotes the hypothesis that PDI needs to recognize 
Cys2771 to initiate dimerization. In case of mutant p.Ser2775Cys, all cysteines required for 
dimerization are present but an additional cysteine residue has been introduced. The fact that 
this mutant shows decreased co-localization with PDI and additionally increases expression of 
ERp57, points to misfolding of the protein that inhibits initial binding of PDI. Altogether, the 
inability of PDI to perform proper VWF dimerization in CK-domain mutants has 
pathophysiological consequences manifesting in VWD. 
On further physiological relevance of the PDI-VWF-interaction could be speculated in the 
context of tissue factor (TF) activation. TF is involved in secondary hemostasis through 
complex formation with coagulation factor VIIa. It was found recently, that PDI is associated 
with TF and implicated in the regulation of TF activity [33-35]. In particular, Langer et al. 
showed that TF decryption requires oxidation of cellsurface PDI [33]. However, how PDI is 
delivered to the surface of endothelial cells remains an open question [36]. Our findings lead 
to the suspicion that VWF might be an anchor for PDI on the surface of endothelial cells 
where VWF strings are exposed upon endothelial cell ativation. This would not only offer a 
regulatory system for PDI exposition on endothelial cells, but moreover depict an indirect 
involvement of VWF in secondary hemostasis.  
Furthermore, it has been shown that PDI is localized n close proximity to the GP1b receptor 
on the plasma membrane of platelets and that VWF binding to platelets decreases by addition 
of anti-PDI antibody [37]. Two possible explanations may be suggested to explain these 
findings: 1) PDI modifies the conformation of GPIb to expose VWF binding sites, 2) PDI 
enhances recruitment of VWF by additional binding events in the CK-domain. However, 
further measurements need to be performed to confirm these hypotheses. 
Summarizing, our data for the first time showed binding of VWF to PDI and shed light on the 
mechanism of VWF dimerization. Inhibition of either PDI binding or PDI-catalyzed disulfide 
bond formation was rationalized with studies of select d mutants that are known to result in 
hemostatic disorders. Additional physiological relevance of PDI in primary and secondary 
hemostasis has been proposed previously by other groups. Our finding that PDI interacts with 
VWF may help answering open questions in this context.  
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FIGURES 
 
 
 
Figure 1: PDI binds VWF. A HEK293 cell lysates of non-transfected cells (input), 
wtVWF (wt), and p.Cys2771Arg overexpressing cells were incubated with rabbit anti-
VWF antibody. Co-immunoprecipitating proteins were separated by SDS-
gelelectrophoresis and PDI was detected with a mouse anti-PDI antibody. In a control 
without anti-VWF antibody, no PDI was detected (control). B MST uses the movement 
of molecules in a temperature gradient to analyze the interaction of biomolecules. C
Binding of the fluorescently labeled PDI to VWF was detected as a decrease in 
thermophoretic depletion. D PDI binds to wtVWF, the isolated CK domain and 
p.Cys2771Arg with a very similar affinity (KD = 240 ± 100 nM). E FCS was applied 
complementary to MST. It detects the diffusive dynamics of molecules. F Binding results 
in prolonged diffusion times visualized by a shift o  the autocorrelation curve G(τ). G In 
agreement with the MST measurements, we detect similar affinities for wtVWF and 
mutant p.Cys2771Arg (KD = 300 ± 100 nM). 
  
 
 
Figure 2: ER localization of VWF and PDI. A wtVWF, B VWF mutant 
p.Cys2771Arg, C p.Ser2775Cys, and D p.Cys2773Alafs*76 were transiently expressed 
in HEK293 cells. 48 h after transfection cells were fixed and VWF proteins and PDI 
were detected by indirect immunofluorescence employing rabbit anti-VWF and mouse 
anti-PDI antibodies. VWF-PDI-co-localization appears yellow in the overlays. Scale bars 
represent 10 µm. 
  
 
 
Figure 3: Co-localization of VWF and PDI. Co-localization of wt or mutant VWF with 
PDI was visualized employing the co-localization plugin of ImageJ. Co-localization is 
shown in white for PDI and A wtVWF, B p.Cys2771Arg, C p.Ser2775Cys, and D 
p.Cys2773Alafs*76.   
 
  
 
 
Figure 4: Co-localization of VWF and ERp57. A wtVWF, B VWF mutant 
p.Cys2771Arg and C p.Ser2775Cys were  transiently expressed in HEK293 cells. 48 h 
after transfection, cells were fixed and VWF proteins and ERp57 were detected by 
indirect immunofluorescence employing rabbit anti-VWF and mouse anti-ERp57 
antibodies. VWF-ERp57-co-localization appears yellow in the overlays. White arrows 
point to transfected cells to highlight increase in ERp57 expression in p.Ser2775Cys 
overexpressing cells. Scale bars represent 10 µm. 
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FVIII Binding to PS Membranes and its Regulation by
Annexin A5
In this chapter, binding of FVIII to phosphatidylserine (PS)-containing membranes is investi-
gated, and the impact of annexin A5 on this interaction is shown. Binding of activated FVIIIa
to PS-expressing platelets is an essential process further downstream in the coagulation cas-
cade. It is required to avoid severe bleeding disorders and known to be influenced by many
cofactors. However, the exact binding mechanism had not been studied quantitatively, and it
remained an open question whether and how it is influenced by annexin A5, which has been
proposed to compete for PS-binding sites in the initiation of coagulation.
Using FCS and MST, we established a quantitative description of FVIII and FVIIIa binding
to PS-containing vesicles, which served as model platelets. Non-activated FVIII showed the
expected exponential increase in binding as a function of PS content of the vesicles. In con-
trast, FVIIIa exhibited a pronounced binding anomaly that consisted of a sharp peak in binding
affinity around the natural PS content of platelets (11%). We showed that annexin A5 strongly
influences the FVIIIa binding behavior, both reducing and increasing it, depending on whether
the relative PS content exceeds the maximum binding value. This behavior was reproduced by
an extended inhibition model, assuming that annexin A5 effectively reduces the PS content by
shielding PS lipids upon binding. This study exemplifies the important role of the PS content
as a regulatory signal within the blood coagulation cascade. The possible function of annexin
A5 as a passive regulator of the effective PS level in platelets suggests its use as a potential
drug for manipulation of the hemostatic function.
The experimental data and the resulting conclusions are presented in the following publication:
H. Engelke, S. Lippok, I. Dorn, R.R. Netz, J.O. Rädler. 2011. ”FVIII Binding to PS Mem-
branes Differs in its Activated and Non-Activated Form and can be Shielded by Annexin A5.”
J. Phys. Chem. B 115:12963-12970.
Reprinted with permission from ref. (83). Copyright 2011 American Chemical Society.
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’ INTRODUCTION
Factor VIII is a key cofactor in the blood coagulation cascade.
Its inherited deficiency in humans causes a severe dysfunction in
hemostasis, leading to the bleeding disorder known as hemophi-
lia A. A decisive event in the blood coagulation cascade is the
binding of activated FVIIIa to phosphatidylserine (PS)-exposing
platelets. FVIII is activated by thrombin, which releases FVIII
from its carrier, the von Willebrand factor by cleaving off its
B-domain. FVIIIa subsequently forms the tenase complex on the
surface of the platelet membrane with the enzyme factor IX.
Recently, it was found that activated FVIIIa exhibits enhanced
binding affinity to platelets, as compared to its inactive form.1
One important blood protein, that is believed to influence blood
coagulation, is annexin A5, which binds to PS-containing mem-
branes in a calcium dependent manner.25 Annexin A5 binds to
endothelial cells, leading to immediate effects on thrombin
formation.6 It was shown that antiphospholipid antibodies,
which inhibit annexin A5 binding to phospholipids, accelerate
plasma coagulation.7 Furthermore, the inhibitory effect of annex-
in A5 on the binding of FVIII to platelets seems to be specific to
activated FVIIIa and not significant for inactivated FVIII.8
Additional evidence has been reported regarding the anti-
coagulant effect of annexin A5, although the mechanism of this
effect remains unclear.2 It was proposed that the formation of a
two-dimensional annexin A5 crystal lattice leads to a reduction of
lateral movement of membrane-bound coagulation factors, and
hence a reduction of the kinetic rates in the membrane-based
coagulation pathway.9 Alternatively, annexin A5 is suggested to
compete with coagulation factors for binding sites on the platelet
membrane, thereby inhibiting their membrane-based interaction,
as schematically depicted in Figure 1.
Therefore, a quantitative understanding of FVIII and annexin-
A5 binding to platelet membranes and their possible interference
is important for quantitative modeling of the coagulation cas-
cade. Generally, a systems biology approach to hemostasis has
the potential to leverage medical and pharmaceutical research.10
However, the complexity of the biochemical network represents
a formidable challenge. Prerequisites for quantitative modeling
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ABSTRACT: Binding of Factor VIII to phosphatidylserine
(PS)-expressing platelets is a key process in the intravascular
pathway of the blood coagulation cascade. Activated by throm-
bin, FVIIIa acts as a cofactor on the surface of platelets. It is
under debate whether and how annexin A5 influences FVIIIa
binding to platelets. Here, we investigate FVIII binding to PS-
containing vesicles as model platelets and its interplay with
annexin A5 in buffer using fluorescence correlation spectrosco-
py (FCS). We find that activated FVIIIa, in contrast to
inactivated FVIII, exhibits a striking binding anomaly as a
function of PS content, marked by a sharp maximum of the
binding constant around 11% PS, which is close to the natural
PS content of platelets. Furthermore, we show that the addition
of annexin A5 can both increase or decrease this FVIIIa binding
depending on whether the relative PS content is lower or higher
than themaximumbinding value.We demonstrate in theory that the observed binding diagram supports the hypothesis that annexin
shields PS, indicating a possible indirect regulatory role of annexin A5 in blood coagulation. The overall PS- and annexin-dependent
binding behavior of activated FVIIIa is preserved in experiments in blood plasma, confirming the validity of our results under more
physiological conditions.
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are the knowledge of the binding constants and reaction rates.
Here, we focus on the lipid membrane related reactions of FVIII
in the blood coagulation cascade. For such proteinmembrane
interactions, lipid membrane composition and local lipid phase
segregation play a regulatory role. This kind of regulation by
spatial organization has been shown, for instance, for binding to
membranes containing the polyvalent acidic lipid phosphatidy-
linositol-4,5-bisphosphate (PIP2) and on T-cell membranes,
which form microdomains induced by protein binding.11,12,22
However, these parameters are not fully captured in the
current simulations and models. Binding of inactivated FVIII
to PS-model membranes occurs in a charge dependent manner
through a region in the C2 domain, which is enriched by four
basic and three hydrophobic residues.13,14 For activated FVIIIa,
however, binding and, particularly, its dependence on negative
charge, i.e., the PS content, has not yet been investigated.
Likewise, there is no support by quantitative data for the hypothesis
of competitive binding of FVIII and annexin to negatively
charged membranes.
In this Article, wemeasure the binding of FVIII and FVIIIa to
PS-containing membranes as well as investigate the mechanism
of how annexin influences FVIIIa binding to membranes, as
schematically shown in Figure 1. We use fluorescence correla-
tion spectroscopy (FCS) to study FVIII and FVIIIa interacting
with PS-containing vesicles as model membranes. FCS mea-
sures diffusion times and can discriminate freely diffusing from
vesicle-bound proteins based on the size dependence of diffu-
sion, as further explained in the Supporting Information.15,16
We measure binding isotherms of FVIII binding to vesicles in
consecutive titration experiments and study the binding char-
acteristics of FVIII and FVIIIa as a function of the PS content
of the membrane. For inactivated FVIII, we find a continuous
increase of the binding constant with increasing PS content. In
contrast, for activated FVIIIa, an anomaly in binding and an
extremely enhanced sensitivity to the PS content was observed
at the physiological PS content of activated platelets. The
underlying molecular mechanism can be explained by binding
of charged lipids to discrete protein binding sites and repulsion
from neutral protein sites. As we will show in this Article, the
binding anomaly of FVIIIa allows for an efficient regulatory
role of annexin A5, if annexin A5 competes for binding to PS
and hence changes the effective PS concentration sensed by
FVIIIa.
’EXPERIMENTAL PROCEDURES
Sample Preparation.Recombinant FVIII (Kogenate-FS) was
obtained from Bayer HealthCare and labeled using Alexa 488-
tagged ESH2 antibodies (American Diagnostica). (For addi-
tional information, see the Supporting Information.) This label-
ing method avoids aggregates that we found to be introduced by
direct labeling of FVIII, and it allows for flexible labeling without
direct chemical modification of the protein. Prior to labeling,
FVIII was activated through a 30 min incubation with human
thrombin at 37 C, as described in Ahmad et al.8 Antibody
binding tests (see the Supporting Information) showed that
activation was successful. FVIII and antibodies were diluted at
concentrations of 110 and 10 nM, respectively, in citrate buffer
(50 mM, pH 6.7, with 1 mM CaCl2, 40 μg/mL Tween 80).
100 nm unilamellar vesicles were prepared by the extrusion of
1-palmitoyl-2-oleoyl phosphatidylcholine (POPC) and 1-palmi-
toyl-2-oleoyl-sn-glycero-3-phosphatidylserine (POPS) (Avanti
Polar Lipids) in citrate buffer.
For experiments with annexin A5, annexin (Sigma Aldrich)
was mixed with vesicles in citrate buffer with CaCl2 added at a
concentration of 12.5 mM. Control experiments were per-
formed, which proved that FVIII binding does not change upon
addition of this amount of CaCl2. Annexin A5 (Sigma Aldrich)
was incubated with vesicles and CaCl2 for 2 min prior to the
addition of FVIII. Cross-correlation experiments were per-
formed with Alexa 647-labeled annexin A5 (Invitrogen) on
supported lipid bilayers, which were prepared using the sonica-
tion technique.21 FVIII-deficient plasma in citrate buffer
(American Diagnostica) was added to the buffer solution, yield-
ing a 1:1 buffer:plasmamixture. FXa inhibitor (Tenstop, American
diagnostica) was added to prevent possible tenase complex
formation on the vesicles.
Instrumentation. FCS measurements were performed on an
Axiovert 200 microscope equipped with a ConfoCor 2 unit (Carl
Zeiss, Jena, Germany). For excitation, an argon ion laser at
488 nmwith an average power of 15 μWon the sample was used.
Fluorescence emission was filtered from the excitation light using
a 525/25 bandpass filter. The objective used was a 40 (NA =
1.2) water immersion appochromat (Carl Zeiss Jena, Germany).
Samples were measured in eight well LabTek I chamber slides
(Nunc, Rochester, NY). For cross-correlation experiments with
Alexa 647-labeled annexin A5, aHeNe laser (633 nm) and a long-
pass 650 filter were added to the setup. Correlation and analysis
were performed using the ConfoCor 2 software. FCS data
analysis is in accordance with Rusu et al.,16 and is described in
greater detail in the Supporting Information.
’RESULTS
FVIII and FVIIIa Binding to PS Vesicles. We measured
binding of FVIII and FVIIIa to vesicles containing different PS
concentrations, as shown in Figure 2a. In FCS, fluorescence
intensity fluctuations are recorded from the diffusion of fluores-
cently labeled proteins through an open focal illumination volume.
The autocorrelation function of the fluorescence time series
exhibits a characteristic decay representing the average time the
molecules need to diffuse across the focal volume (Figure 2b).
For proteins binding to the 100 nm vesicles, which are larger than
the freely diffusing proteins, the diffusion time increases. This
leads to the evolution of the autocorrelation functions depicted
in Figure 2b. Each of the intermediate autocorrelation functions
Figure 1. Schematic illustration of FVIII activation and binding to a
phosphatidylserine (PS)-containing membrane. Annexin A5 is shown to
compete for PS binding sites.
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can be fitted by a sum of two autocorrelation functions corre-
sponding to the fraction of bound and unbound proteins.16
Consequently, the fraction of bound proteins can be obtained
from the measured correlation function using appropriate fits
(for details, refer to the Supporting Information). For FCS
measurements, the protein needs to be fluorescently labeled.
Here, FVIII was indirectly tagged using the fluorescently labeled
antibody ESH2, which binds to FVIII without obstructing the
capability of FVIII to bind PS-containing membranes.17 As a
control, we also used FVIII tagged with the antibody ESH8. We
measured the fraction of bound FVIII and FVIIIa as a function of
lipid concentration. Figure 3a shows an example of an isotherm
that was obtained from a measurement on FVIII binding to
vesicles of 10% PS content. These isotherms were recorded for
lipid compositions with varying amounts of PS. In each case, we
find binding isotherms described by
fboundðLÞ ¼ KðPSÞ 3 L1 þ KðPSÞ 3 L
ð1Þ
where K(PS) denotes the molar partition coefficient and L the
molar lipid concentration in solution. K(PS) describes the
distribution of free and bound FVIII, and hence its binding
constant to the lipid membrane as a function of its relative PS
content. Note that the binding isotherm is sometimes fitted with
reference to a bimolecular binding model, assuming a discrete
number of lipids per binding site.13 In the binding site descrip-
tion, the concentration of binding sites L* = L/n is related to the
lipid concentration through the number of lipids per binding site, n.
Consequently, the dissociation constant, KD, according to the
discrete binding model and K(PS) are related by n 3KD =
K1(PS). The PS content dependence of FVIII binding to
membranes is plotted on a semilog scale in Figure 3b. The molar
partition coefficient increases with increasing strength of binding,
showing that binding increases continuously with increasing PS
content for inactivated FVIII. For vesicles without PS, no
significant binding could be detected within the range of con-
centrations studied. The measured KFVIII(PS) values are in exact
agreement with the previously reported data by Gilbert et al. using
resonance energy transfer.13 The line represents a fit indicating
an exponential increase within the range of PS contents studied.
Interestingly, binding of activated FVIIIa notably deviates
from this behavior. Figure 3b shows the strongly peaked dependence
of FVIIIa binding on the membrane PS content. Binding sharply
increases up to KFVIIIa(PS) = 0.6 μM
1 at a relative PS
concentration of 11%, which exceeds the binding of inactivated
FVIII by 100%. Surprisingly, the binding constant of activated
FVIII decreases beyond this point, and reaches a minimum at
about 17% PS content (KFVIII(PS) = 0.1 μM
1). This behavior
must be considered anomalous, since the general understanding
implies that binding increases with PS content due to electro-
static interaction. In order to confirm this result, we have
measured the binding constant using optical thermophoresis as
an independent second technique and obtained agreement
within the experimental accuracy (see the Supporting In-
formation). It is remarkable that the observed anomaly falls
within the physiological range of PS content on the outer
membrane of activated platelets. A comparison of the molar
partition coefficients of inactivated and activated FVIII reveals
that activated FVIII shows weaker binding than inactivated FVIII
over most of the PS content range, except for this narrow region
of the peak between 8 and 14%.
Figure 3. (a) Binding isotherm of FVIII binding to vesicles of 10% PS
content. (b) The molar partition coefficient (binding constant), K(PS),
of activated (filled triangles) and nonactivated (open squares) FVIII.
The black round data points indicate control experiments with activated
FVIIIa labeled with ESH8 instead of ESH2. The range of physiological
mol percentage of PS in activated platelets is marked in red. The
region of the anomalous decrease in the binding constant with
increasing PS content is indicated by the gray region. Comparison
of the FVIII and FVIIIa data shows the strong deviation of FVIIIa from
common binding behavior.
Figure 2. (a) Fluorescence correlation spectroscopy (FCS) detects
FVIII binding to vesicles through the measurement of the diffusion time
of fluorescently labeled FVIII across an open illumination volume. (b)
Evolution of the time autocorrelation functions of FVIIIa as vesicles with
10% PS mol fraction are added. The fraction of vesicle-bound, slowly
diffusing FVIIIa to the freely diffusing FVIIIa increases with lipid
concentration from dark to light gray.
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Theoretical Modeling of FVIIIa Binding. The binding beha-
vior of FVIII differs remarkably depending upon whether it is
activated or not. In particular, the affinity of FVIIIa exhibits a
maximum as a function of PS content, which is unusual, as it
implies that beyond an optimal PS content the protein mem-
brane interaction, that has a significant attractive electrostatic
contribution, decreases despite the increasing surface charge of
the lipid membrane. In electrostatic theory, the interactions of
oppositely charged bodies, i.e., protein and membrane, increase
monotonously with increasing charge of either component.
This is indeed the case for the interaction of inactivated FVIII
with PS membranes.1,19 The existence of a maximum for FVIIIa
is hence a principal challenge to the mechanism of FVIII
binding to PS membranes. In the following, we present a simple
statistical model that describes this phenomenon. It is well-
known that the electrostatic interaction of the PS moiety in the
lipid membrane plays a key role in FVIII binding. First, crystal-
lography data show three residual positive charges on the
membrane facing side of the protein. Second, when the protein
binds to the membrane, its surface covers a distinct area of the
membrane, which can be estimated to correspond to about 25
lipids. A fraction Φ of the lipids are charged PS lipids, and it is
assumed that the binding energy is composed out of the binding
energy of these charged constituents. The situation is depicted
schematically in Figure S1 of the Supporting Information. We
now introduce the very assumption that discriminates the
activated and inactivated form in our model. In the nonacti-
vated form, we assume that the electrostatic charge of the
protein is equally distributed over the contact area and hence all
M = 25 lipid sites have the same chemical free energy for a PS
lipid. The reason for this could be that charges are buried by the
B-domain of the protein or that there is a water layer between
the protein and lipid bilayer. In contrast, in the case of activated
FVIII, we assume the existence of three discrete binding sites
for PS, as depicted in Figure S1 of the Supporting Information.
In both cases, the binding constant, K, of the protein is
determined from the statistical mean of the free energy, F,
considering all possible configurations of charged lipids under-
neath the protein.
K ¼ N expðF=kTÞ ¼ N 3Zðμ~Þ ¼ N 3 ∑
M
m¼ 1
PMðmÞemμ~ ð2Þ
where N is a constant normalization factor and Ζ(μ~) denotes
the partition function, with PM(m) being the probability that m
lipids in the contact area are charged and exp(mμ~) its statistical
weight (for the explicit presentation of PM(m), see the Support-
ing Information).
For the electrostatic binding of inactivated FVIII to mem-
branes, we assume that each charged lipid under the protein
contributes an equal amount of μ~kT to the binding energy.
Hence, binding increases with an increasing amount of charged
lipids underneath the protein. The fit in Figure S2 of the
Supporting Information with only the energy contribution per
lipid μ~ and the normalization factor N as free fit parameters
shows that this model reveals the PS dependence of the
inactivated FVIII well.
The discrete binding of activated FVIII is modeled by dis-
crimination of the energy contributions of charged lipids at
charge binding sites and those at neutral sites of the protein.
Negatively charged lipids at charge binding sites are attracted
and hence contribute a positive amount of μ~1kT to the binding
energy. Charged lipids, which are not at these sites, are repulsed
and their contribution μ~2kT to the binding energy is negative.
The reason for this could be the entropic confinement of the
counterions. The contribution of the charged lipids at charge
binding sites leads to an increase of binding with increasing
fraction of charged lipids at low PS concentrations up to a certain
value, beyond which the repulsion at neutral sites dominates,
resulting in a decrease of binding with increasing PS content of
the membrane. The discrimination of these two different energy
contributions leads to one additional parameter, μ~2, and the
probability function PM(m) splits into the probabilities PK(k) to
find k charged lipids at the K charge binding sites and PL(l) to
find l charged lipids at the L =MK neutral sites (for details, see
the Supporting Information). Figure S2 of the Supporting
Information shows that this discrete binding model reproduces
the peak in the PS dependence of activated FVIII with only one
additional parameter as compared to the model for inactivated
FVIII. However, it reveals only the peak and it fails to describe the
increase of the binding constant at high PS contents. This
increase signals cooperative effects, which we implement in the
model by addition of a quadratic term l2ε in the binding energy
per charged lipid at noncharge binding sites. The dashed line in
Figure S2 of the Supporting Information, which was obtained by
the model including this extension, reveals the increase of
binding at high PS contents. The experimental data for FVIIIa
are more sharply peaked around the maximum than the theore-
tical model. The agreement could be improved by including
higher order terms also for the PS lipids underneath charge sites,
which we did not pursue in this paper.
Annexin A5 Can Both Reduce and Increase Binding of
FVIIIa to PSMembranes.As annexin-A5 is supposed to affect the
binding of FVIII to platelets, we study its influence on the binding
of FVIII to membranes quantitatively by incubating the vesicles
with annexin-A5 prior to the binding experiments with FVIII. In
the case of inactivated FVIII, annexin-A5 had a weak but by trend
decreasing influence on the binding. In contrast, FVIIIa binding
was strongly influenced by the presence of annexin A5 even at
low annexin concentrations of 4 μM. In fact, the full binding
diagram as a function of both PS content and annexin concen-
tration revealed a multifaceted behavior, as shown in Figure 4a.
We note that the addition of annexin can both reduce and
increase the binding of FVIIIa, depending on the PS content of
the membrane. The binding of FVIIIa to vesicles containing 10%
PS is continuously reduced with increasing annexin concentra-
tion up to full inhibition (Figure 4b). When vesicles of a relative
PS content of 15% were used, however, the inhibition character-
istic disappears. In this case, preincubation of the vesicles with
annexin enhances binding up to a maximum value. At concen-
trations higher than this maximum, a reduction of FVIIIa binding
to the vesicles is again observed (Figure 4c). Separate experi-
ments on annexin binding to vesicles showed that this does not
lead to vesicle aggregation and hence does not lead to these
results by interfering with the FCS measurements.
Quantitative Model of Annexin Interaction. This change in
the FVIIIa binding behavior in the presence of annexin A5 can be
explained by an extended competetive inhibition model. It is
generally assumed that annexin competes with FVIII for binding
to PS lipid. We first demonstrate that, however, ordinary
competitive binding does not fully describe the data. Competi-
tive inhibition describes the interaction of a ligand and a receptor
in the presence of a second ligand competing for binding to the
same receptor. The competition for binding sites is based on
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mass action, and hence, in our case, the binding of annexin A5 to
PS reduces the absolute number of available PS binding sites for
FVIIIa. This leads to an effectively reduced lipid concentration,
Leff(A) = L LA, with LA being the number of lipids shielded by
annexin A5. Replacing L by Leff(A) in eq 1, we obtain the fraction
bound of FVIII for competitive inhibition. This model, however,
fails to describe the strong inhibition we measured for mem-
branes with 10% PS content quantitatively, as seen in Figure 4b,
where the blue dashed line represents a fit according to the
competitive inhibition model. Moreover, the standard inhibition
model can only explain the decrease in binding but not the
enhanced binding measured for membranes with 15% PS con-
tent (Figure 4c).
We introduce now an extended competitive inhibition model,
which assumes that annexin-A5 also modifies the binding constant
KFVIIIa(PS) due to the fact that PS lipid is shielded. The modified
binding constant KFVIIIa(PSeff(A)) is described by an effective PS
content, PSeff(A) = PS0 3 (1  αAb), where the amount of
annexin bound (Ab) is given by the binding constant, KA, of
annexin A5 to the membrane (see the Supporting Information).
In addition, the molar shielding efficiency, α, was introduced to
quantify the efficiency of relative PS content reduction per mol
annexin. A shielding efficiency of α = 0.1 μM1, for instance,
implies that 1 μM annexin reduces the relative PS content by
10%. Due to the sensitivity of FVIIIa binding to the PS content of
membranes described above, a reduction of the relative PS
content induces dramatic changes to the binding constant
KFVIIIA(PS), causing either the enhanced or reduced binding of
FVIIIa. A quantitative description of the fraction of bound FVIIIa
as a function of annexin A5 is given by
fboundðPS,AÞ ¼ KðPSef f ðAÞÞ 3 Lef f ðAÞ1 þ KðPSef f ðAÞÞ 3 Lef f ðAÞ
ð3Þ
Note that eq 3 contains only one unknown parameter, since we
can use both the measured dependence, KFVIIIA(PS), and the
measured binding constant of annexin, KA, which determine the
effective quantities (for more details, refer to the Supporting
Information). Equation 3 consistently describes the measured
concentration dependence of the bound fraction (solid lines,
Figure 4b and c). The strength of the model is the fact that only
one adjustable parameter, the shielding efficiency α, is required,
and has to be consistent with all measurements. The fact that both
10% PS and 15% PS data sets are well-described using the sameα
confirms the validity of the model. To further elaborate on the full
phase diagram of the binding behavior, we plotted the theoretical
landscape of binding as a function of PS and annexin A5 con-
centration (Figure 4d).The anomaly of thePSdependence of FVIIIa
binding to membranes allows for inhibition and enhancement of
binding, which occurs upon the reduction of the effective PS
Figure 4. (a) 3D plot of the measured fraction of membrane-bound FVIIIa as a function of PS mol fraction and annexin A5 concentration. Cross-
sectional plot of part a showing the influence of annexin A5 on FVIIIa binding to PSmembranes at a PS content of 10% (b) and 15% (c). The blue dashed
lines indicate a fit according to the simple competitive model, while the red full lines represent a fit following the extended shielding model. (d) Three-
dimensional binding plot showing shielding model simulations of the PS content and annexin A5 concentration dependence of FVIIIa binding to
membranes at a constant lipid concentration.
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content through the addition of annexin. The shielding model is
thus able to qualitatively and quantitatively explain the mechan-
ism of interaction of annexin and FVIIIa binding to membranes.
Cross-Correlation Experiments. A key component of the
inhibition model is the assumption that there is no direct
interaction between annexin and FVIIIa. All annexin interference
occurs indirectly via PS shielding, which then modulates the
binding affinity of the membrane to FVIII. In order to test this
hypothesis, we performed dual color cross-correlation experi-
ments on supported membranes, as schematically depicted in
Figure 5a. In this experiment, FVIIIa is labeled with green
fluorescent-tagged antibody, while annexin is labeled with a red
fluorescent-tagged antibody. Fluorescence cross-correlation,
through the two-color coincidence, can differentiate between
the diffusion of free proteins and correlated protein clusters
through the focal spot. Distinct autocorrelation curves are
obtained for both annexin and FVIIIa, yielding a diffusion
coefficient of about 10 μm2 s1. This is approximately equal to
the diffusion coefficient of lipids in the membrane (Figure 5b).
Nevertheless, the cross-correlation shows a flat time dependence,
indicating that the diffusion of annexin and of FVIIIa are not
correlated. Comparison of the diffusion coefficients of each
protein on a membrane in the presence and absence of the other
indicates that the diffusion of one is not influenced by the other.
Furthermore, the homogeneity of the intensity signal obtained in
these experiments shows the absence of aggregates and their
possible influence on the binding. Addition of calcium and
chelation of calcium with EDTA lead to a change of the ratio
of bound FVIIIa and bound annexin A5, whereas addition of
neither EDTA nor calcium changed the amount of bound FVIIIa
in the absence of annexin A5. This was used to fine-tune the
concentrations of bound FVIIIa and annexin A5 in the cross-
correlation experiments and is a further proof of the modulation
of FVIIIa binding by annexin A5.
Experiments in Plasma.To see if our experimental results are
valid under in vivo conditions, we repeated the experiments in
FVIII-deficient blood plasma. Since plasma is a strongly scatter-
ing, crowded medium, FCS measurements face an experimental
hurdle that needs to be addressed in the analysis. We have
recently described a procedure on the required corrections for
both the scattering and crowding effects in FCS data analysis.18
Taking these effects into account, we were able to measure FVIII
binding to vesicles containing 15% PS (see the Supporting
Information). The first satisfying finding is that the molar
partition coefficients of FVIIIa binding to LUVs (in the absence
of annexin A5) in plasma are consistent with those obtained in
buffer. Second, preincubation of the membranes with annexin A5
in plasma leads to the same characteristic enhancement and
inhibition behavior observed in buffer. However, the absolute
concentration of annexin A5 necessary to reach the same level of
inhibition differs in plasma and buffer by a factor of 4, as shown
by the rescaling of the theoretical prediction for the data in buffer
(solid line, Figure 6) by a factor of 4 (dashed line, Figure 6).
’DISCUSSION
We studied the binding of inactivated and activated FVIII to
PS-containing phospholipid model membranes. The molar par-
tition coefficient of inactivated FVIII is found to exhibit an
exponential increase as a function of mol percentage PS, which
is consistent with data from Gilbert et al.13 and Bardelle et al.19
This increase is caused by electrostatic interaction, which is
proportional to the mol percentage PS in cases where there is low
surface charge density.20 The molar partition coefficients for
FVIIIa, in contrast, were found to exhibit a pronounced binding
anomaly consisting of a peaked binding affinity in the region of
about 12% PS. This anomaly is reported for the first time, and a
possible molecular mechanism is presented employing binding
of charged lipids to a discrete number of protein binding sites.
Factor VIII is activated by thrombin through the site-specific
cleavage of both the heavy and light chains, resulting in the
separation of the A1 and A2 domains, as well as the release of the
B-domain. In vivo, these conformational changes lead to the
Figure 5. (a) Schematic diagram of the two-dimensional two-color cross-correlation FCSmeasurement on a supportedmembrane. (b) Autocorrelation
curves of activated FVIII (red line) and annexin A5 (green line) on a supported lipid bilayer. No cross-correlation (black line) between annexin A5 and
activated FVIII can be detected, indicating that these do not directly interact. The diffusion coefficient of activated FVIII is not influenced by annexin A5,
and is measured to be approximately 10 μm2 s1 for both.
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dissociation of FVIII from the von Willebrand factor.1 It is also
believed that FVIII undergoes a conformational change in the C2
membrane-binding domain. We assumed that the release of the
B-domain and possibly the associated conformational changes
lead to exposition of the charge binding sites to the membrane
and consequently to the observed enhancement of FVIIIa binding
to membranes with an approximate composition of 12% molar
content PS. It is noteworthy to mention that this binding
characteristic of FVIIIa is also observable in blood plasma. The
fact that binding of activated FVIII exceeds the binding of FVIII
only in a narrow region of PS content, which coincides with the
physiological PS content, might be important, since it allows for
the selective binding of FVIIIa when injury occurs.
The experimental data of FVIIIa binding in the presence of
annexin A5 seem to support an extended inhibition model
proposed here, which assumes that annexin effectively reduces
the PS content by shielding PS lipids upon binding. The partition
coefficient of FVIIIa is shifted according to the reduced PS
content, which, due to the unusual nature of the binding
isotherm, results in an increase or decrease in binding affinity,
depending on the actual PS concentration. The question arises if
the characteristic of FVIIIa binding to vesicles also holds true for
binding to platelets in circulation. Ahmad et al.8 measured FVIII
and FVIIIa binding to platelets corresponding to molar partition
coefficients of 0.56 and 0.8μM1, respectively, close to the values
reported here for liposomes having a PS content approximately
comparable to the physiological levels (10%). Our finding that
FVIIIa exhibits stronger binding compared to FVIII in the
physiological range is also consistent with results obtained for
platelet binding.1,8 Furthermore, FVIIIa binding to platelets is
inhibited by annexin A5, which is in accordance with the findings
from our model system. These results collectively confirm that
PS-containing vesicles serve as a suitable model system for
platelets, and that charge shielding, which reduces the effective
charge of the membrane for FVIIIa, could be amechanism for the
involvement of annexin A5 in blood coagulation. Such a shielding
mechanism explains the anticoagulant effect of annexin under
nonpathological physiological conditions, and predicts a possible
procoagulant effect for platelets exhibiting PS levels exceeding 12%.
We demonstrate that our competition model describes an
indirect influence of annexin A5 on the binding of FVIIIa via the
effective concentration of PS. It is likely that this scheme can be
extended to the interplay of many cofactors. Here, we presented
first indications that the effect of annexin A5 on FVIIIa binding to
model membranes is enhanced in the presence of blood plasma.
This enhancement might be due to other cofactors such as Factor
IX. Ahmad et al.,8 for example, reported an enhanced effect of
annexin on FVIIIa binding to platelets in the presence of EGR-
FIXa and FX. FCS allows for binding measurements in both
buffer and plasma, and hence serves as a powerful tool for
combinatorial binding studies. Such studies may ultimately allow
the multidimensional cofactor landscape mapping of the mem-
brane binding potential. This interplay of cofactor binding in
membrane-based biochemical networks would be an important
prerequisite to systems modeling of the blood coagulation
cascade.
In conclusion, we have shown that the interaction of FVIIIa
with PS membranes exhibits a highly unusual binding character-
istic, which can be modulated by the presence of annexin. The
binding of FVIII and FVIIIa is qualitatively described by a
statisticial binding model and in addition its modulation by
annexin by an extended competition inhibition model. Our study
thus exemplifies the importance of PS content as a regulatory
signal within the blood coagulation cascade and the possible role
of annexin as a passive regulator of the effective PS level in
platelets. Measurements of FVIIIa binding in blood plasma are
feasible using FCS and would allow the competitive or coopera-
tive binding of other cofactors to be studied. A complete and
quantitative description of the entirety of membrane-mediated
cofactor interdependencies will be the subject of further research.
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Conclusion and Outlook
For the underlying work, FCS was employed as a novel experimental approach for VWF re-
search. Until now, studies on polymeric VWF faced manifold challenges, which were difficult
to overcome: First of all, VWF is a blood plasma protein that is known to behave differently
in buffer than in blood plasma supposably due to hitherto unknown helper proteins in the
plasma. Thus, reliable quantitative data assessment requires experiments performed in blood
plasma. Moreover, most of VWF’s functions are known to be shear-dependent, because VWF
possesses structural elements that open under flow-induced tension. Therefore, defined flow
conditions have to be guaranteed in experiments. Finally, the multimer size is an important pa-
rameter for VWF’s shear-dependent functionality. Because the exact size distribution of VWF
was unknown, previously quantitative studies were virtually impossible with the full-length
protein.
The here presented application of FCS paves the way for quantitative assessment of VWF
properties. In this thesis, it was shown that FCS is well-suited to investigate VWF under blood
plasma conditions and it proved to be sensitive to characterize disease-related VWF mutants.
Moreover, the combination with a self-built microfluidic device allowed for studies of the full-
length protein under shear flow. Due to the complexity of FCS read-out, diverse issues were
successfully adressed, such as size distribution analysis, shear-induced cleavage, an enzyme
activity assay, and binding studies. All studies were performed with FCS. Additionally, the
different projects were complemented by alternative experimental approaches or computer
simulations.
Extent of polymerization as disease indicator
In a first study, VWF’s size distribution was quantified. Prior to this, commonly used assays
only qualitatively determined the total amount of VWF as well as the relative amount of large
VWF multimers. We showed that VWF has characteristic, exponentially distributed sizes and
can be described by a single parameter, the extent of polymerization. This parameter was
reduced for the disease related mutant VWF-IIC (VWF-C1099Y), and we proposed it as a
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Figure 9.1: VWF in inflammation. A Ruptures of the blood vessel induce inflammatory reactions
such as shifts of the pH and the Ca2+ concentration, and the secretion of cytokines. B The inflammatory
milieu might influence both ADAMTS13 activity and shear-dependent VWF unfolding. This may be
measured with the shear assay that was established in this work. (B modified from chapter 5)
potential disease indicator. There are various other VWF mutations that are known to result
in different multimer patterns, causing hemostatic disorders in patients. Application of the
presented assay to patient samples might help to quantify the disease-related shifts in VWF
sizes by proposing the extent of polymerization as a valuable indicator for diagnosis of VWF-
related diseases.
Model of shear-induced opening
In order to study VWF at defined shear rates, FCS was combined with a self-built shear cell.
With this setup, VWF cleavage was measured in blood plasma and under shear flow. The
assay enabled quantitative assessment of cleavage rates for VWF and VWF-G1629E mutant,
and the investigation of VWF degradation as a function of shear-dependent VWF unfolding.
Thereby, we found the unfolding transition and the opening of the A2 domain to be the crucial
parameters for VWF degradation.
While it is known that ADAMTS13 concentrations reduced to 10% of the physiological level
do not yet lead to critical symptoms, altered VWF unfolding transitions are likely to make a
much greater contribution to hemostatic dysfunctions. Single mutations in the A2 cleavage
domain can induce partly or even completely unfolded polymers. Thus, it would be of great
interest to predict the impact of VWF mutations on VWF unfolding and the contribution of
this unfolding transition to VWF proteolysis. Combining the here described approach, which
involves FCS and Brownian Hydrodynamics Simulation, with Molecular Dynamics Simula-
tions, might allow to construct such a complex model of shear-induced VWF opening. This
model could relate VWF mutations directly to hemostatic dysfunction, closing the gap be-
tween atomistic VWF domain models and the coarse-grained hydrodynamic model proposed
by us. This would not only lead to a more general understanding of VWF’s shear-dependence,
but moreover facilitate therapeutic VWF administration.
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Figure 9.2: VWF dimer conformation. VWF possesses a pH-regulated dimeric stem, which might
open after secretion to blood plasma at pH 7.4 (with courtesy of C. Baldauf, modified).
VWF proteolysis in inflammation
Interestingly, VWF proteolysis occurs not only under physiological conditions, as studied
here, but also under pathophysiological conditions (see Figure 9.1). This is due to the fact that
ruptures in the blood vessel simultaneously stimulate the initiation of the coagulation cascade
and evoke inflammatory reactions. The resulting inflammatory milieu with acidic pH and
altered Ca2+ concentrations might influence both ADAMTS13 activity and shear-dependent
VWF unfolding. However, studies on VWF degradation under inflammatory conditions are
lacking to date. Moreover, large amounts of VWF molecules are stored in intraendothelial
Weibel-Palade bodies (WPB). There, VWF is colocalised with several proinflammatory pro-
teins and chemokines, such as interleukin-8, P-selectin, and angiopoeitin-2. Upon endothelial
cell activation, caused for example by an injury, hypoxia, or inflammatory stimuli, the contents
of the WPBs are exposed to the blood flow. It is not known, whether the inflammatory proteins
affect VWF’s behavior, although there is the reasonable suspicion that VWF might work as
a carrier for angiopoeitin-2. Angiopoeitin-2 is involved with controlling microvascular per-
meability, vasodilation, and vasoconstriction by signaling smooth muscle cells surrounding
vessels. This poses the question whether and how VWF influences the regulation of vascular
permeability under flow conditions. Using our established shear setup and the introduced data
analysis, one could easily close these scientific gaps by solely modifying the surroundings,
thereby providing insight into VWF’s role and reactivity in inflammatory environments.
VWF stem conformation
We showed that VWF’s mechanosensitive conformation plays a crucial role in its degradation.
In addition to this, its flexible structure is essential for its overall functionality as it accounts
for its accessibility for binding partners. Current research mainly focused on opening of re-
combinant VWF A domains and unfolding of the full-length protein. However, the role of
the VWF C domains, the so called stem, has not been studied yet (see Figure 9.2). Recent
publications show first evidence of a pH-regulated dimeric bouquet in VWF’s structure and
indicate that the C domains might induce an opening of the stem structure (84). Nevertheless,
whether the dimers are in solution present with an open or closed stem remains an open ques-
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Figure 9.3: Formation of VWF-induced networks. A VWF (blue) self-assembles and binds to
thrombocytes (green) via two glycoprotein receptor complexes, namely GPIbα and GPIIb/IIIa. B Under
shear flow, VWF is streched and forms networks via crosslinking and binding to thrombocytes. C VWF
with C4 domain polymorphism F2561Y is related to increased network formation. The polymorphism
is located next to the GPIIb/IIIa binding site.
tion. Studying VWF’s dimer conformation in terms of hydrodynamic radii as a function of pH
and mutations might contribute to understanding the impact of VWF structure and flexibility
on its function.
C4-domain polymorphism and network formation
In this context, an interesting mutation was recently discovered by the group of Prof. Schnep-
penheim (UKE, Hamburg): Preliminary results indicate that a C4 domain polymorphism
(F2561Y) might be associated with an increased risk for myocardial infarction in young
women. The underlying mechanisms, however, are completely unknown. Still, it was shown,
that the polymorphism affects VWF-platelet network formation (see Figure 9.3 A,B). This
leads to the suspicion that the polymorphism facilitates both aggregation of VWF molecules
and binding to thrombocytes, resulting in higher order networks in the blood vessel, which
might induce myocardial infarcts. Thus, both an increased affinity to thrombocytes and fa-
vored VWF cross-linking are assumed for VWF-F2561Y. As the C4 domain might have an
impact on the stem formation, these properties are presumed to result from changes in stem
flexibility due to the polymorphism, especially since the GPIIb/IIIa binding site for platelets
on VWF is located next to the polymorphism site (see Figure 9.3 C). Thus, mutations in this
domain could heavily influence GPIIb/IIIa binding. This hypothesis may be proved by ex-
ploring the interaction of C4 domains both with each other and with full-length VWF wt and
mutant using FCS. In addition, binding affinities of VWF wt and mutants to GPIIb/IIIa may
be analyzed. Performing the experiments under flow conditions would allow to correlate the
binding affinities with the observation of collective network formation under shear flow and
finally lead to a description of the kinetics of the network formation for VWF wt and mutant
as a function of shear stress. This might elucidate the role of VWF in widespread conditions
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Figure 9.4: Pulsed Interleaved Excitation (PIE) - FCCS. A Two excitation sources are interleaved
so that the fluorescence emission generated from one pulse is completed before the next excitation
pulse arrives. B Due to different labels, FCS can distinguish between the time-resolved fluorescence
emission of binder and receptor molecule, while spectral crosstalk is eliminated. C Schematic of a
dual-color confocal microscope with pulsed interleaved excitation sources. In the diagram, APD refers
to avalanche photodiode, DCM to dichroic mirror, PM to polychroic mirror, and PH to pinhole.
such as stroke or cardiac infarction.
Binding studies under flow
In this thesis, an analysis routine was implemented for quantitative, FCS-based binding stu-
dies on full-length VWF. Binding of VWF-wt and -mutants to PDI showed that PDI is the en-
zyme that facilitates VWF dimerization in the endoplasmatic reticulum. Although this study
confirms that FCS is well suited for VWF binding studies under static conditions, the analysis
of binding under flow requires further enhancement of the FCS, which cannot be based on
determining diffusion times anymore. In 2005, Pulsed Interleaved Excitation (PIE) has been
introduced to meet this challenge (85). In PIE, multiple excitation sources are interleaved so
that the fluorescence emission generated from one pulse is completed before the next excita-
tion pulse arrives (see Figure 9.4). Hence, the excitation source for each detected photon is
known. Using PIE with FCS would allow to distinguish between the time-resolved fluores-
cence emission of binder and receptor molecule, if they were labeled with different colors;
cross correlation of both signals would designate the fraction of bound molecules. Thereby,
spectral crosstalk is eliminated, and the method is also sensitive for weak interactions. As
shear flow essentially influences VWF’s behavior, the establishment of a PIE-FCS would en-
able a whole slew of medically relevant and biophysically intriguing experiments.
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Conclusion
The multifaceted role of shear stress in the regulation of VWF function and mutation-related
dysfunction poses manifold experimental challenges and many open questions. In the here
presented work, we found PDI to assist with dimerization of VWF in the ER. We established
a model for the polymerization of these dimers based on the resulting size distribution. Follo-
wing the multimer size after secretion to the blood plasma, we helped to unravel the mecha-
nisms of shear-regulated activation of VWF cleavage and the influence of blood plasma con-
ditions and VWF mutations on these characteristics. Encouraged by this study, we developed
a highly sensitive assay to detect ADAMTS13 activity in patient samples. However, although
these studies unraveled many open questions, further research has to be done to establish a
coherent picture that relates the shear sensitive molecular structure to nano-mechanical pro-
perties of VWF and links dysfunction of VWF mechanistically to its outcome in clinical pre-
sentation. The realization of this picture represents a fascinating overlap of single molecule
studies with collective phenomena in a research area that is of paramount medical importance.
A
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S1: FCS data analysis 
FCS measures the dynamics of molecules in solution by analyzing the time-dependent 
fluctuations of the fluorescence intensity collected from a confocal detection volume 
(Figure S1A,B). The normalized autocorrelation function G() of the intensities I(t) is defined 
as: 
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where  denotes the time average. For free diffusion of molecules in a three-dimensional 
Gaussian probe volume with radial dimension r and axial dimensionz, G() is derived 
analytically to (1): 
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wherein N is the average number of particles in the focus and D, the diffusion time, the time 
the molecules need to cross the focal width. This single-component analysis allows for the 
determination of diffusion coefficient D=r2/4D and concentration N of molecules of the 
same species. For a perfectly spherical particle, the hydrodynamic radius is given by 
rhyd = kBT/6D with Boltzmann constant kB and viscosity .  
For a particle with cylindrical shape, the diffusion coefficient D is given by D = AkBT/3L 
with cylinder length L and correction factor A: A = ln(L/d)+0.312+0.565/(L/d)-0.1/(L/d)2  
with diameter d. According to (2,3), the dimer has a cylindrical shape. With this equations and 
the assumption that the VWF monomer can be described with the same diameter but half the 
length of the dimer, we get the length lD =  85.3 nm and the diameter aD = 3 nm for the VWF 
dimer (see Figure S1C). 
For measurements of an n-component mixture of noninteracting fluorescent particles, 
multicomponent analysis is applied based on the fact that the overall autocorrelation function 
is a weighted sum of the autocorrelation functions of all components (4): 
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where qi denotes the brightness, Ni the number and Di the diffusion time of molecules of 
species i. As VWF multimers are organized as long linear chains comprised of a certain 
number of dimers, VWF dimer serves as the building block of the distribution, and the 
multimer size is given in number of dimers i. To calculate the diffusion time Di of a VWF 
polymer that consists of i subunits, we use the simple Rouse model (5) that describes the 
conformational dynamics of an ideal chain by: i
DaDi
  with the diffusion time aD of the 
building block of the polymer. We choose this simple model as there is little known about the 
persistence length of the VWF polymer and its exact shape in the used buffer containing 
1.5 M urea. The diffusion time of the rVWF dimer is obtained from FCS measurements as 
aD = 447µs (see Figure 3A). The brightness qi scales with the number of dimers i as each 
VWF monomer is labeled with one eGFP molecule. Quenching is possible for dimers with 
respect to monomers due to binding of eGFP at the dimerization site but unexpected for 
multimers among each other as there is no label at the multimerization site. Since we measure 
in units of brightness per dimer, quenching is neglected (qi = i). If there was quenching among 
the multimers, we would expect it to be a constant resulting in a brightness qi =s*i with 
quenching factor s. In our fit formular, the brightness appears multiplied with the number of 
multimers Ni : qi*Ni = i*s*N1*p
i-1 where N1 denotes a constant fitting parameter. With the 
constant quenching factor s, a new fitting factor N1' = N1*s would be used and s would not 
affect fitting of the extent of polymerization. For this reason it would not alter our results. 
 
 
Fig. S1 Principles of Fluorescence Correlation Spectroscopy (FCS) and model of rVWF 
dimer. (A) FCS measures the dynamics of fluorescently labeled molecules diffusing in and 
out of a observation volume created by a confocal microscope. (B) Correlation analysis of the 
detected intensity trace provides information about particle size and concentration. (C) 
Cylindrical shape of the VWF dimer. 
  
S2: Step-growth polymerization model 
In 1936, Flory defined a step-growth polymerization model for polymers which have a 
functional group that reacts independently of the size of the molecule to which it is attached, 
and polymerize in an enclosed reactor as a linear chain (6). As VWF polymerizes in the Golgi 
Apparatus as a linear chain through the formation of disulfide bonds between the dimers, the 
exponential size distribution VWF shows can be explained by assuming the step-growth 
polymerization model presented by Flory.  
For better understanding, we present an abbreviated derivation based on Flory's Paper in the 
following:  
N0 is the total number of dimers, Npol is the number of polymerized segments, p=Npol/N0 is the 
extent of reaction, i.e. the fraction of the total number of segments that are polymerized 
(= extent of polymerization). A polymer is defined by containing two or more segments. An i-
mer is a polymer that exists of i segments (here: VWF dimers). 
For b being a possible polymerization site within a large group of partially polymerized 
segments, the probability that polymerization occurs at any particular b is p, and the 
probability that no polymerization takes place is 1-p. There are i possible configurations 
which fulfill the condition that a segment is part of an i-mer and each i-mer has i-1 
polymerized sites as well as 2 unreacted possible polymerization sites. Thus, the probability 
that any of the i configurations exists is i = i*pi-1*(1-p)2 = (i*Ni)/N0. i determines the 
fraction of segments which exist as component of i-mers. 
Therefore the number of i-mer molecules is given by: Ni = N0 p
i-1*(1-p)2. As we do not 
know the total number of dimers N0 that is present in the Golgi during polymerization, we 
define a constant fit parameter N1 = N0*(1-p)
2. This results in our fit formula: Ni = N1*p
i-1 
which fits the extent of polymerization p.  
The total number of molecules is given by N = N0*(1-p). Therefore the molar fraction of i-
mers containing i subunits is Ni/N = (p-1)p
i-1. 
 
 
 
 
  
S3: Size Distribution Analysis with TIRFM and rVWF dimer as a control 
For measuring the VWF size distribution, we monitor two-step photo bleaching of the rVWF 
molecules. We cannot simply use the overall intensity of molecules for our size distribution 
analysis, as the intensity of eGFP fluorescence depends on the orientation of the chromophore 
relative to the polarization of the exciting beam (7). In our experiment, the VWF-eGFP was 
immobilized via free amino groups on an epoxysilane (3-glycidyloxypropyltrimethoxysilan) 
coated glass slide. This binding of eGFP molecules on the surface restricts the rotational 
degrees of freedom of eGFP which influences the effective excitation and thus the intensity of 
the emitted light of the chromophore. Therefore, the steps in the intensity traces do not have 
the same height.  
There is the trend that the first step is larger than the last steps. For a constant excitation of a 
chromophore, the time until photo bleaching occurs (= emission time) follows an exponential 
distribution. An increase in the excitation intensity, which is correlated to the emission 
intensity, shifts this distribution to shorter emission times. High intensities are therefore by 
trend correlated to short emission times and vice versa. Thus, the first steps of the intensity-
time-traces, i.e. the photo bleaching events of chromophores with a short emission time, are 
more likely to come along with a high emission intensity. Therefore, early bleaching steps 
tend to be higher.  
To proof the ability of measuring rVWF size distribution by counting the bleaching steps of 
the rVWF molecules, we studied rVWF dimers that contain two eGFPs; one fused to each 
monomer (Figure S3). We detected one and two step events but no intensity trace with more 
than two bleaching steps. Therefore, a clear distinction can be made between the rVWF dimer 
and multimer sample.  
 
  
Fig. S3 TIRFM analysis of rVWF dimer sample. (A) TIRFM image of rVWF dimers. (B) 
Intensity-time traces were analyzed to count bleaching steps as indicators for the number of 
eGFP-tagged VWF monomers. In (C) the relative frequencies of the number of bleaching 
steps are shown for the dimer and the multimer sample. Whereas in the multimer sample 
multiple bleaching steps were detected, the dimer sample shows only one or two bleaching 
steps. 
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S1 Analysis of the VWF concentration using FCS 
FCS uses a confocal fluorescent microscope to analyze the diffusion of fluorescently labeled 
molecules by correlating the intensity fluctuations within the confocal volume over time [1-3]. 
For identical fluorescent particles undergoing Brownian motion in a three-dimensional 
Gaussian focus volume element with radial dimension ωr and axial dimension ωz, the 
autocorrelation curve can be described by [2]: 
 
The diffusion time τD, which states the time the molecules need to cross the focal width, is 
used to determine diffusion constants and hydrodynamic radii as described elsewhere [4,5]. In 
addition, the amplitude of the correlation curve at correlation time τ = 0 s is a measure for the 
molar particle concentration: the particle number N = 1/G(0) indicates the average number of 
fluorescent molecules within the confocal volume. Calibration of the confocal volume Vcon 
with a known substrate (e.g. eGFP) allows calculating the molar particle concentration
, with Avogadro constant NA. 
FCS can be used in crowded media such as blood plasma, thus enabling the investigation of 
blood proteins in their natural environment [6]. More ver, fast measurement times allow the 
online detection of kinetics processes that occur within the minute scale. 
 In this study, the molar particle concentration of VWF is determined using FCS. This is 
possible because the amplitude of the correlation curve at correlation time τ = 0 s, G(0), is a 
measure for the particle number N within the confocal volume: 1/G(0) = N [1-3]. To assure 
that this holds for the VWF distribution, we measured a serial dilution of rVWF in buffer 
(Figure S1A). This measurement validates that the particle number increases linearly with the 
rVWF concentration. 
However, FCS weigths the molecules according to their brightness. In our measurements, 
each monomer is labeled with one eGFP molecule. Therefor , the brightness qi of each VWF 
polymer scales with its size i. As a consequence, G(0) is given by 
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brightness qi = i and particle number Ni for a polymer with size i [7]. During cleavage, the 
VWF distribution changes its shape, shifting from longer to shorter polymer sizes. Before 
cleavage, Ni is exponentially distributed [5]: ∑ ∑ −−==
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. FCS experiments of complete cleavage, 
however, detected Nend/N0 = 2.9 (Figure S1B). Thus, the theoretical error due to the 
brightness-weighted particle numbers lies within the measurement accurancy and the used 
FCS analysis seems applicable.  
Nevertheless, to optimize our data analysis, we simulated VWF cleavage based on the 
assumption of random cleavage sites combined with an equal cleavage probability for all 
polymer sizes. These conditions are reasonable for cleavage in a denaturizing buffer [5]. The 
resulting particle number NSim was plotted versus the number of cleavage steps (Figure S1C). 
For each cleavage step, we calculated the FCS signal NFCS = 1/G(0) that would be generated 
by the corresponding size distribution. The percentaged deviation of the FCS signal NFCS and 
the simulated particle number NSim is depicted in the inlet. For the first three cleavage steps, 
which is the regime we use for the data evaluation, the error amounts to 37.02 ± 4.5 %. This 
means that there is a general underestimation of the VWF concentration, which we have to 
take into account to assess the absolute concentratio . As we can exactly calculate this 
underestimation for the uncleaved VWF distribution t  be %4.40
0
,00 =
−
N
NN FCS , we correct 
all CVWF values accordingly (red curves, S1C). In contrast, cleavage rates do not have to be 
corrected, as here the underestimation remains sufficiently constant within the relevant regime 
(S1C, inlet, red curve).  
 
For the VWF cleavage induced by shear flow, the cleavage sites in middle of the polymer 
might be slightly favored. In order to estimate thecase of the fastest possible size shift, we 
simulated the cleavage of the VWF distribution cutting each polymer in the middle 
(Figure S1D, black lines). For the resulting size distribution, the FCS output is calculated 
(Figure S1D, grey lines). This cleavage occurs faster; five cleavage steps are sufficient to 
cleave the physiological VWF distribution to dimers. Therefore, the FCS data equals the 
simulated particle number from cleavage step four onwards (Figure S1D, inlet). However, 
FCS data correction by adding the brightness-induce underestimation works very well for 
the first two cleavage steps. Because this is the regime, where maximal cleavage rates can be 
measured, we use it for our data analysis and correct th  VWF concentrations accordingly. 
 
Thus, we correct the systematic underestimation of 40.4 % for the VWF concentration in all 
analysis data. Although there is still a slight difference to the absolute concentration, the 
correction minimizes the error in the concentration detection. Moreover, a small shift in the 
VWF concentration has a negligible impact on our relevant fitting parameter, the Michaelis-
Menten constant. Therefore, using the corrected FCSdata, the precision of the Michaelis-
Menten constant is limited by the measurement accurncy only. For the measurements in 
blood plasma, we furthermore add the physiological VWF concentration of 3 nM to the 
measured concentration considering the unlabeled VWF within the plasma. 
 
With these corrections and the benefits of our approach, including avoidance of purification 
and immobilization, defined labeling with fluorescent proteins, and fast and easy data 
analysis, this method is a promising and sensible ass ssment of the VWF cleavage rates. 
 
 
 
 
 
S1 VWF concentration detection using FCS. A Dilution series of rVWF in buffer measured 
with FCS. B Changes in VWF concentration during complete rVWF proteolysis. 
C Comparison of the simulated particle number NSim (black) during random cleavage of VWF 
and the particle number 1/N = G(0) (grey) generated using FCS. Red curves show the particle 
number after correction of the FCS data. D Particle numbers originating from VWF cleavage 
that cuts the molecules in the middle. Data correction (red) shifts the FCS data (grey) towards 
the simulated particle numbers (black). Inlets: Percentaged error of the FCS data analysis 
with (red) and without (grey) correction. 
  
S2 VWF aggregation at high shear rates exceeds ADAMTS13 cleavage 
For high shear rates, ADAMTS13 cleavage seems to compete with VWF aggregation. For the 
physiological ADAMTS13 concentration (1 U/ml), we dtected VWF aggregation to appear 
at a shear rate γ&  = 7500/s (Figure S2A). After 30 minutes of shearing, aggregates with 
hydrodynamic radii of up to 1 µm formed. Within two and a half hours of shearing, the 
protease could not destroy these aggregates. However, aft r 135 minutes, the particle 
concentration recovered to 0.3 nM, corresponding to one twentieth of the initial concentration. 
At a tenfold higher ADAMTS13 concentration, aggregation was detected at γ&  = 10000/s 
(Figure S2B). After half an hour of shearing, the formed aggregates reached similar 
hydrodynamic radii of maximally 1µm but appeared at a significantly lower number. The 
particle concentration recovered to approximately one third of its origin within the next 105 
minutes of shearing, probably due to augmented proteolytic activity. 
 
 
S2 VWF aggregation at high shear rates. A Applying 1 U/ml ADAMTS13 and γ&  = 7500/s, 
VWF aggregates formed. Although, the number of aggre ates decreased over time, it stayed 
at high levels. B The tenfold protease concentration and a higher shear rate caused a 
significantly stronger increase in VWF concentration over time. Shearing time increases with 
diminishing brightness of the curves.  
S3 Brownian dynamic simulation 
Brownian hydrodynamics simulations were performed using the discretized Langevin 
equation 
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which describes the displacement of bead i at position ir
r
 after the time step ∆t. Note that all 
quantities used are made dimensionless by rescaling lengths arr /~=  by the monomer radius 
a, energies TkUU B/
~= by thermal energy, and times τ/~tt =  by the characteristic monomer 
diffusion time kTakTa /6/ 30
2 πηµτ == , where µ0 is the Stokes mobility and η the solvent 
viscosity. The first term in the Langevin equation represents a linear shear flow with rate 
τγγ ~&& = , and x̂  is the unit vector in x-direction. The second term accounts for the direct force 
acting on particle i itself as well as the hydrodynamic flow-field created by forces acting on 
all other particles ij ≠ . Hydrodynamic interactions are taken into account via the mobility 
matrix approximated by the Rotne-Prager tensor [9]: 
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is given by Gaussian random 
vectors with correlations according to the fluctuation-dissipation theorem 
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and vanishing mean. The simulation time step is typically chosen 
as ∆t = 10-4.  
The VWF is modeled as a homopolymer consisting of N beads, which interact via Lennard-
Jones potentials of depth 2.1/~ == TkBεε  and are connected in a linear chain by harmonic 
bonds with a rescaled spring constant ( ) 200/~ 2 == Takkk B ; the total potential reads 
( ) ( )( ) ( )∑ ∑
<
+ −+−=
ji i
iiijij r
k
rrU 21,
612 2
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Tensile forces acting along each bond, ( )21, −−= +iii rkf , are recorded during the course of 
simulation. In order to compare the dimensionless simulation values to physical units, we use 
for the dimer radius a = 45 nm, the viscosity η = 1.2x10-3 Pas, and temperature T = 310K and 
obtain a characteristic monomer diffusion time τ = 4.8x10-4s. The cohesive strength of the 
polymer is chosen as ε = 1.2 such that the polymer is collapsed in the absence of shear and the 
unfolding transition occurs at a shear rate comparable to the experimental value of 
 = 3000/s. 
 
The average tensile force profiles for three different chains length N=10,20,30 are shown in 
Figure S3. For low shear rate,  = 0.5, the polymers are collapsed and low tensile forces only 
stem from thermal fluctuations. The unfolding transition, which can be determined by the 
variance of the chain extension (data not shown), occurs around  = 1.5. Note that the value 
of this shear rate also depends on the chain length. The tension increases with increasing shear 
rate due to flow induced unfolding and exhibits a flattened profile with minimal forces at the 
chain ends. At high shear rates the maximal tensions along unfolded, long polymers does not 
strongly depend on their length. The standard deviation for  = 7.5 indicates a broad 
distribution of the tensile forces.  
 
Figure S3: Average tensile force as a function of bead position along the polymer. Different 
colored profiles correspond to different chain length N; tension increases for increasing 
rescaled shear rate  . The standard deviation σ(f) is shown on a separate scale as dashed lines 
for  = 7.5. 
 
From the tension distribution of a single bead, e.g. the middle bead i=N/2, we obtain the 
opening probability for a single cleavage site, defined by the probability Pi(f>fc) that the 
tension exceeds a critical value f
probability as the probability that at least one of the N cleavage sites is accessible
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FCS analysis 
The autocorrelation function of the measured intensity as a function of time is defined as: 
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For a solution containing a single species, the autocorrelation function is fitted with the 
equation for a Brownian particle in solution:  
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In solutions with fluorescently-labeled proteins that bind to unlabeled vesicles, the fraction of 
bound proteins, fbound, was determined from the autocorrelation function according to: 
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1)( +⋅−+=     Equation 3 
 
 
To enhance fit accuracy, the diffusion times τDfree and τDbound were determined in separate 
experiments and kept as fixed parameters. Note that Equation 3 is valid only if bound and 
unbound proteins display equal molecular intensity. This infers no quenching as well as the 
assumption that only one protein or less is bound to a vesicle on average. In our experiments, 
binding was not observed to affect intensity. Secondly the amplitude, i.e. the number of 
fluorescent proteins did not change significantly. Hence Equation 3 was used without 
restriction. For the general case of large number of proteins binding to vesicles the reader is 
referred to reference (S1). Using Equation 3 we determined the fraction of labeled FVIII and 
FVIIIa bound to PS vesicles for various lipid concentrations. These titrations yielded binding 
isotherms such as those shown in Figure 2(d). These were then used to determine the molar 
partition coefficient, i.e. the inverse of the equilibrium dissociation constant. The molar 
partition coefficient K is defined as: 
 
freefree
bound
PL
P
K =           Equation 4 
 
where Lfree is the concentration of free lipids, Pfree and Pbound are the concentrations of free and 
bound protein, respectively. It is related to the fraction of bound proteins fbound and the total 
lipid concentration, L, for excess lipid concentrations by the following equation:  
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Using these equations, the molar partition coefficient of inactivated and activated FVIII 
binding to PS-vesicles was determined for vesicles with various relative PS-content. 
 
For experiments in blood plasma, scattering and crowding effects have to be considered. 
Scattering leads to a distortion of the focus, while crowding slows down diffusion.  We 
accounted for possible scattering effects by performing additional calibration experiments in 
plasma. The slowdown in diffusion was taken into consideration by measuring the diffusion 
time of each component involved in the binding assay separately and in exactly the solution 
used for the binding measurements.  
 
For cross-correlation experiments, the sample was additionally illuminated with a 633 nm 
HeNe-laser. Alexa-647-labeled annexin A5was used. The red emission was separated from 
the green using a longpass 650 filter; fluorescence intensities were acquired for both red and 
green channels, and autocorrelation curves of intensities with respect to time were likewise 
calculated for each. Additionally, the cross-correlation of the two channels was determined 
using the following function:  
 
G(τ) =
Igreen (t)Ired (t + τ )
Igreen(t) Ired (t)         Equation 6
 
 
This cross-correlation function allows for the detection of correlated movements of red- and 
green-labeled particles. Correlated movement of red and green particles leads to a signal in 
the cross-correlation function, whereas independent movement will always result in a value of 
1 in the cross-correlation. 
 
 
 
 
 
 
Antibody labeling 
 
FVIII was indirectly labeled using Alexa-488 tagged ESH2 antibodies (American 
Diagnostica); antibodies were labeled using a labeling kit (Invitrogen) and were purified using 
spin-columns. Their purity was checked with FCS to be less than 10% free dye. ESH2 binds 
to the C2-domain of FVIII and FVIIIa, but does not inhibit binding to PS-containing 
membranes, allowing the easy, non-invasive labeling of FVIII. However, antibody binding 
might alter the protein conformation or change its binding behavior (e.g. through sterical 
hindrance). To exclude any effect of antibody binding, we performed experiments where 
ESH2 was replaced by ESH8, which binds to a different sequence on the C2-domain (in this 
case the von Willebrand-Factor binding-site).  As described in the main text, the same results 
are obtained for the two antibody tags. A negative control labeled using ESH4, an antibody 
that blocks the PS binding site of FVIII, and which consequently inhibits binding to PS 
membranes, did not exhibit any binding. From these findings, we can conclude that the 
anomaly in the PS-dependence of FVIIIa membrane binding is not caused by the antibody-
label. A further control on labeling as well as activation of FVIII was performed using 
antibodies binding to the B-domain of FVIII. They did not bind anymore upon activation 
showing, that activation (upon which the B-domain of FVIII is cleaved off) was successful.  
 
Control experiments using optical thermophoresis 
 
Thermophoresis is a technique that allows for binding experiments in solution independent of 
FCS measurements (S2). To confirm the FCS experiments and prove the existence of the 
unusual binding behavior of FVIIIa, we performed optical thermophoresis on our samples. 
These binding experiments are based on the change of the thermophoretic movement of a 
particle upon binding to a binding partner. Our experiments were carried out on the Monolith 
NT.015 (Nanotemper, Germany) thermophoresis instrument and for measurements samples 
were placed in borosilica glass capillaries (Nanotemper). Titration experiments and their 
analysis were performed as in the FCS experiments. The results are displayed in Fig. S4 and 
confirm the peak in the binding behavior of FVIIIa as measured by FCS.  
 
 
 
 
 
Model of FVIII binding 
 
We present a basic statistical model that derives the existence of a maximum from the 
assumption that FVIIIa displays discrete binding sites for PS lipid. It is well known that the 
electrostatic interaction of the PS moiety in the lipid membrane plays a key role in FVIII 
binding. Firstly, crystallography data show three residual positive charges on the membrane 
facing side of the protein. Secondly, when the protein binds to the membrane, its surface 
covers a distinct area of the membrane, which can be estimated to correspond to about 25 
lipids. A fraction Φ of the lipids are charged PS lipids and it is assumed that the binding 
energy is composed out of the binding energy of these charged constituents. The situation is 
depicted schematically in Fig. S1. We now introduce the very assumption that discriminates 
the activated and inactivated form in our model. In the inactivated form we assume that the 
electrostatic charge of the protein is equally distributed over the contact area and hence all 
M=25 lipid sites have the same chemical free energy for a PS lipid. Reason for this could be 
that charges are buried by the B-domain of the protein or that there is a water layer between 
protein and lipid bilayer. In contrast, in the case of activated FVIIIa we assume the existence 
of three discrete binding sites for PS, as depicted in Fig. S1. In both cases the binding 
constant, K, of the protein is determined from the statistical mean of the free energy, F, 
considering all possible configurations of charged lipids underneath the protein:  
 
Equation 7 
 
 
where N is a constant normalization factor and Ζ(µ) denotes the partition function with PM(m) 
being the probability that m lipids in the contact area are charged and exp(mµ) its statistical 
weight.  
To derive the partition function Ζ(µ)  and the binding probability PM(m), we assume, a protein 
that binds to the membrane covers M proteins. According to crystallography data M is known 
to be M=25. The membrane is composed of a fraction of Φ charged lipids and a fraction of (1-
Φ) uncharged lipids. Only charged lipids underneath the protein contribute to the binding. The 
probability P(m) that m out of the M lipids in the contact area of a protein are charged lipids is 
given by the Bernoulli-distribution: 
 
Equation 8 
 
Assuming that each of the m charged lipids contributes µkT to the binding energy, the 
weighted probability reads:  
 
Equation9 
 
The probability Ζ that a protein, which hits a membrane binds to it, is then given by the sum 
over the weighted probabilities of all possible configurations (i.e. amounts of charged lipids in 
the contact area): 
 
 
Equation 10 
 
The probability Ζ of a binding event is directly proportional to the binding constant K and its 
logarithm yields the free energy F of the interaction as given by Equation 7.  
 
This allows for description of the PS-dependence of the binding constant K(Φ) via Ζ(Φ) and a 
constant normalization factor N. 
 
For inactivated FVIII we assume all charged lipids contribute an equal amount of µkT per 
lipid to the binding energy. Hence, we use Ζ(Φ) as given in equation 9 to fit the data with 
only µ and the normalization factor N as free fit parameters. As shown in Fig. S2, K(Φ) of 
inactivated FVIII can be described well by this model (with µ= 0.4, N = 0.1).  
 
For activated FVIIIa we distinguish between two sorts of lipid positions in the contact region. 
We assume that K out of the M lipid positions underneath the protein coincide with charge 
binding sites of the protein. According to crystallography data, FVIII has 3 exposed positively 
charged sites. These K=3 sites serve as charge binding sites and charged lipids at such sites 
are attracted and thus contribute a positive amount of µ1kT to the binding energy. Charged 
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lipids at the L=M-K sites, which do not correspond to charge binding sites of the protein, 
contribute a different amount µ2kT to the binding energy. This contribution is negative since 
the charged lipids are repulsed from the neutral sites and attracted by the charged binding sites 
of the protein. Reason for this could be the entropic confinement of the counterions. The 
contribution of the charged lipids at charge binding sites leads to an increase of binding with 
increasing fraction of charged lipids at low PS-concentrations up to a certain value, beyond 
which the repulsion at neutral sites dominates resulting in a decrease of binding with 
increasing PS-content of the membrane. The discrimination of these two different energy 
contributions leads to one additional parameter, µ2 , and the probability function PM(m) splits 
into the probabilities PK(k) to find k charged lipids at the K charge binding sites and PL(l) to 
find l charged lipids at the L=M-K neutral sites. The binding probability is determined by the 
probability, that k charged lipids occupy one of the K charge binding sites and that at the 
same time l charged lipids are positioned at one of the L neutral sites. Consequently, the 
binding probability Ζ reads: 
 
 
Equation 11 
 
Fig. S2 shows that this discrete binding model reproduces the peak in the PS-dependence of 
activated FVIIIa with only one additional parameter as compared to the model for inactivated 
FVIII  (with µ1 = 7.6, µ2 = -19.8, N = 7.8E-7). However, it reveals only the peak and it fails to 
describe the increase of the binding constant at high PS-contents. This increase signals 
cooperative effects, which we implement in the model by addition of a quadratic term l
2ε in 
the binding energy per charged lipid at non-charge binding sites. The dashed line in Fig. S2, 
which was obtained by the model including this extension, reveals the increase of binding at 
high PS-contents. The experimental data for FVIIIa are more sharply peaked around the 
maximum than the theoretical model. The agreement could be improved by including higher 
order terms also for the PS lipids underneath charge sites, which we did not pursue in this 
paper.  
 
 
Terms accounting for cooperative effects involving charged lipids at neutral protein sites can 
be introduced by addition of nonlinear terms in the binding energy per lipid. In principle 
arbitrary functions u1(k) and u2(l) can be used for the binding energies per lipid, but in 
practice u1(k)= µ1k+ε1k
2
 and u2(l)= µ2l+ε2l
2
 is sufficient. In the case of unspecific binding of 
the charged lipids at neutral sites, for instance, the binding probability Ζ is expanded by an 
energy term quadratic in l: 
 
  Equation 12 
 
 
With a positive energy contribution ε, this kind of cooperativity leads to an increase of 
binding at high fractions Φ of charged lipids as measured for activated FVIIIa.  
 
So far, all cases were calculated explicitly. Although, the system is quite small, we can apply 
the thermodynamic limit. In this case, we use the Stirling approximation to calculate the free 
energy F, which is the logarithm of P (M, m, µ). Determination of the fraction of charged 
lipids x=m/M per contact area with minimal free energy leads to: 
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   Equation 13 
 
Calculation of the exponent of the free energy at this value yields the binding constant in the 
thermodynamic limit: 
))(exp( xFNK −⋅=          Equation 14 
 
Fig. S3 compares the result in the thermodynamic limit with the exact result. Although the 
numbers M, K, and L, which characterize the system size, are quite small, the thermodynamic 
limit reveals the binding behavior well.  
 
 
Quantitative modeling of annexin regulation 
 
Competitive inhibition model: 
 
In the competitive inhibition model, two species, annexin A5 and FVIIIa compete for binding 
sites on a third species, the membrane. A key parameter for this kind of inhibition is the 
absolute number of binding sites that each species can occupy. Assuming that annexin A5 
exhibits a stronger affinity for membranes than FVIIIa, annexin A5 molecules bound to the 
membrane reduce the number of free binding sites for FVIIIa, whereas annexin A5 binding is 
not affected by bound FVIIIa. The effective number of binding sites, Leff, for FVIIIa is then 
defined by the number of binding sites on the membrane in the absence of annexin A5, L0, 
from which the amount of annexin A5-bound lipids, La, is subtracted: 
           Equation 15 
  
In the case of excess lipid (i.e. the total lipid concentration is much larger than the number of 
FVIIIa-bound lipids), the number of bound FVIIIa, fbound, can be calculated as a function of 
the annexin A5 concentration: 
 
           Equation 16 
 
 
with K being the binding constant of FVIIIa in the absence of annexin A5. The assumption 
that annexin A5 binding to membranes is not influenced by FVIIIa binding allows the direct 
determination of La from the binding isotherm of annexin A5. Considering the high 
concentrations of annexin A5 used, the limit of excess lipid does not hold true for annexin A5, 
and La has to be calculated explicitly: 
 
           Equation 17 
 
 
where cA is the annexin A5 concentration and KA, the binding constant of annexin A5.  
 
This yields the equation for the fraction of bound FVIIIa used in generating the curves in 
Figure 4 (a) and (b) in the main text.  
 
 
Shielding model: 
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The shielding model assumes that annexin A5 binding to the membrane shields the charges of 
the membrane, reducing the relative number of PS detected by FVIIIa, and thus changing the 
PS content-dependent binding energy of FVIIIa. The fraction of bound FVIIIa, fbound, can then 
be described by the binding isotherm using a binding constant, K(PSeff(A)), as a function of 
PS content, which, in turn depends on the annexin A5 concentration: 
 
           Equation 18 
 
 
 
To quantify this, the PS-dependence of the molar partition coefficient of FVIIIa binding to 
membranes, K, is described by a phenomenological fit function applied to the experimental 
data, K(PS). Next, the shielding of PS by annexin A5 is modeled. The shielding is assumed to 
be linear with the concentration of bound annexin A5, Annexinbound: 
 
           Equation 19 
 
Here, PSeff is the effective PS content; PS0, the PS-content of the membrane; and α, the molar 
shielding efficiency. The concentration of bound annexin A5 depends on the total lipid 
concentration. Since the approximation for excess lipid (Ltot>>Lbound) does not hold for the 
annexin A5 concentrations used, the concentration of bound annexin A5 has to be explicitly 
calculated from the binding isotherm: 
 
 
 
           Equation 20 
 
with cAnnexin being the concentration of annexin A5 and KAnnexin the molar partition coefficient 
of annexin A5. KAnnexin was determined to be 0.5µM
-1
 under the experimental conditions used 
in a separate experiment. Incorporating the phenomenological fit function for the PS-content 
dependence of FVIIIa binding (where the effective PS-content is annexin A5 dependent) into 
the equation of the binding isotherm yields the fraction of bound FVIIIa; this fraction is 
defined as a function of the annexin A5 concentration, according to the shielding model. The 
function contains one fit parameter, namely the shielding parameter, and was successfully 
used in describing the data of the interaction between annexin A5 and FVIIIa, as shown in 
figure 4 (a) and (b). The function was also used to calculate the full 3-D phase diagram shown 
in figure 4 (c).  
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Fig S1 
Fig. S1: Schematic drawing of FVIII binding to membranes. (a) Inactivated FVIII is assumed 
to exhibit an electrostatic charge equally distributed over the contact area of the membrane. 
The diagram of the potential µ below shows, that the contribution of a PS lipid to the total 
binding energy is equal on all positions under the protein. (b) Activated FVIIIa exposes three 
distinct charge binding sites, which attract negatively charged lipids, to the membrane. Hence, 
the diagram of the potential µ shows an attractive contribution on specific sites under the 
protein and it is repulsive on all other sites under the protein. 
 
 
 
 
 
Fig. S2 
 
Fig. S2: Theoretical model and experimental data of the PS-dependence of inactivated and 
activated FVIII binding. The FVIII binding to membranes (triangles) is well described 
assuming equal electrostatic interaction of the protein with charged lipids at any position of 
the contact area (full line, µ= 0.4, N = 0.1). The anomalous peak in the PS-dependence of 
FVIIIa binding to membranes (full circles) is reproduced by a discrete binding model (dotted 
line, µ1 = 7.6, µ2 = -19.8, N = 7.8E-7) assuming three discrete binding sites within the area of 
about 25 lipids underneath the protein. Here only one additional parameter that discriminates 
the discretely bound charged lipids from those at unspecific contact sites is introduced. 
Addition of a non-linear binding term allows for description of the increase in binding at high 
PS-contents (dashed line, µ1 = 6.4563, µ2 = -10.0321, ε = 0.4989, N = 2.0495E-5).  
 
Fig. S3 
 
 
Fig. S3: Comparison of the exact binding model with the thermodynamic limit. (a) 
Inactivated FVIII binding fitted according to the exact model (red line, Equation 9) and in the 
thermodynamic limit (green line, Equation 14). In this case, the two models do not deviate 
significantly. (b) Activated FVIIIa binding fitted according to the exact model (red line, 
Equation 11) and in the thermodynamic limit (green line). Both models reproduce the peak in 
the PS-dependence of the binding constant.  
 
 
 
 
 
Fig. S4 
Fig. S4: Results of the thermophoresis experiments on the binding of FVIIIa to PS-vesicles. 
The data from experiments using thermophoresis (black squares) reveal the same peak in the 
binding behavior of FVIIIa as the experiments using FCS (grey circles). For comparison, the 
binding coefficients of inactivated FVIII measured with FCS are shown as well (grey 
triangles).  
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interleaved excitation. Biophysical journal, 89(5):3508–3522, 2005.

Full List of Publications
S. Lippok, C. Aponte-Santamarı́a, T. Obser, R. Schneppenheim, C. Baldauf, F. Gräter, U.
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Rädler. 2013. ”Exponential Size Distribution of von Willebrand Factor.” Biophysical Journal
105:1208-1216.
S. Lippok, S.A.I. Seidel, S. Duhr, K. Uhland, H.-P. Holthoff, D. Jenne, D. Braun. 2012.
”Direct Detection of Antibody Concentration and Affinity in Human Serum Using Microscale
Thermophoresis.” Anal. Chem. 84:3523-3530.
H. Engelke, S. Lippok, I. Dorn, R.R. Netz, J.O. Rädler. 2011. ”FVIII Binding to PS Mem-
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damit verbundenen Freiheiten und dein manchmal fast schon beängstigendes Vertrauen.
Ich danke allen SHENCs, inbesondere Reinhard Schneppenheim, Ulrich Budde, Martin
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